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1.  Introduction 
 
Stratified medicine (SM) is an innovative treatment concept using genetic or other molecular 
information to select the best therapeutic strategy in order to improve medical outcomes for the 
patient and the health care system.1 Targeting the right patient population with the right drug 
using stratification tools such as diagnostic testing offers the potential to enhance patient care 
with safer and more effective drug treatments. This has been illustrated in several well-known 
examples (Herceptin®, Glivec®, Vectibix®, Erbitux®, Xalkori®, Zelboraf®), particularly in 
oncology. For the industry, the SM approach provides an opportunity to improve efficiency and 
productivity in the research and development (R&D) process and to demonstrate a differential 
therapeutic profile to be successful and rewarding in an increasingly competitive and cost-
contained market environment. At the same time, the SM approach is changing and adding to 
many standard models of R&D and health care delivery, forcing many stakeholders involved 
in the development, acceptance and uptake of SM to grapple with new levels of uncertainty, 
costs and complexity associated with such concepts. For example, adding a test element to a 
pharmaceutical technology will increase treatment complexity and complicates value 
assessment of treatment interventions then also including the test characteristics. Moreover, 
regulatory and reimbursement processes show ambiguity on evaluating the ultimate value of 
test information and challenges exist to determine the clinical and economic value of more 
complex stand-alone or companion diagnostics.  
  
While the SM approach has drawn major attention in the medical community and the industry, 
the implementation and adoption of such approaches in clinical practice has been slower than 
many proponents have hoped or predicted. Industry is hesitant to use biomarkers and 
companion diagnostics in routine clinical practice despite scientific advances and increasing 
investment in the biomarker-related research and development.2,3 The reasons for the delays in 
widespread clinical adoption include the complexity of the underlying science, operational and 
organizational barriers as well as concerns about the economic viability of the SM business 
case, due to possible market size limitations.4,5 
In the meantime, the processes of drug discovery and development have become increasingly 
expensive and inefficient, with fewer new drugs being approved and increasing concerns on the 
safety of market drugs.6,7 Furthermore, health care costs are rising dramatically within the 
health care systems in light of the aging population and the development of new innovative 
medicines. Hence, many stakeholders are embracing the principle of SM to guide improvement 
of efficiency and effectiveness in health care and to offer a potential solution to address these 
economic challenges. Stratified medicine promises significant benefits to improve health 
outcomes and cost-effectiveness in the health care system. 
The evolving field of test-treatment combinations continues to generate complex economic 
issues for manufactures, payers, providers and the whole healthcare system. Decision makers 
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at all levels want value for money and require economic evaluations on the opportunity costs 
before implementing such approaches into clinical practice. This thesis attempts to tackle some 
important economic questions that are central when embracing SM into clinical practice and 
research.   
1.1 Background and Motivation 
 
1.1.1 The concept of Stratified Medicine 
 
SM as opposed to empirical medicine is the concept of using biomarkers or diagnostic tests to 
guide the choice of therapeutic treatments.8 In the SM concept, subgroups of responders are 
selected or identified/screened based on risk of disease or response to therapy, with the notion 
to improve treatment outcomes in these subgroups by increasing efficacy and/or reducing 
toxicity. This stratification of the population by using diagnostic tests or techniques is intended 
to reduce the use of ineffective or unsafe drugs, which should translate into improved health 
outcomes for patients and more efficient use of health care resources. Although patient 
treatment has always been personalized by clinicians based upon individual circumstance and 
medical history, the decade since the completion of the sequencing of the human genome 
(HUGO 2003) has witnessed significant advances in science which have resulted in major 
developments in molecular biology.9 This has led to the emergence of a new approach of 
healthcare, labeled SM and leveraging to create better diagnostic tools and targeted 
therapeutics.  
The terms ´stratified medicine´, ´personalized medicine´ and ´precision medicine´ are often 
used interchangeably in the literature. Personalized medicine is by all means the most widely 
used term, but often interpreted in different ways.10 People mean different things when they use 
the term and there is a certain concern that the expression ´personalized medicine´ might be 
misunderstood, leading the public to believe that there are unique treatments for each 
individual. Obviously, this is only very rarely the case, with scarce illustrations, for example, 
only in personalized oncological vaccines. In contrast, the term ´stratified medicine´ as well as 
´precision medicine´ emphasizes the classification of “strata“ and “groups of patients” as the 
target for the R&D and clinical efforts rather than the individual patients.11 Both of these terms 
underline the aim to find the appropriate treatments for those patient groups or subpopulations 
that will benefit, and to avoid treating those who will not benefit or even be harmed. 
 
In clinical practice, SM involves an additional clinical biomarker-assessment step to link a 
patient with a specific therapy, which will increase the complexity of treatment patterns. 
Moreover, a reliable diagnostic test for the biomarker may act as a gatekeeper to the individuals 
through which subsequent therapies must pass. Such tests can be based on gene expression 
patterns, individual proteins, proteomic patterns, metabolomics, histology, imaging, 
physicians´ clinical observations and even self-reported patient surveys. Obviously, all these 
different ways of testing have pros and cons and strengths and weaknesses. In this sense, 
Trusheim et al8 define a clinical biomarker not by its technology or biological basis, but rather 
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by its reliable and predictive correlation to differential patient responses. With a potential initial 
thought regarding genetics, it should however be stressed that a large part of variability in 
treatment response cannot be explained by genetic variations alone. Patient characteristics (such 
as age, gender), gene-environment interactions, and patient compliance may also play an 
important role and should not be underestimated.12   
 
SM potentially holds the promise to be of benefit to multiple stakeholders, including patients 
receiving more targeted treatments with increased confidence that these will offer best positive 
therapeutic effects. As for the clinicians, they will be able to prescribe tailored therapies 
avoiding poor efficacy or excessive toxicity, and ensuring better clinical outcomes. SM also 
promises attractive health economics for the payers who will be able to optimize the allocation 
of resources in relation to the improvement in health outcomes. And, more generally, the whole 
healthcare system will benefit as this new approach will render data on precise usage and 
outcomes, guiding further investments in drug development and clinical practice.13 Multiple 
studies have shown that most drugs prescribed in various diseases have high failure rates and 
are effective in fewer than 60% of treated patients (e.g., oncology only 25-30%) outlining the 
potential to realize efficiency gains for healthcare systems.14,15 
 
SM is practiced in several contexts within the healthcare industry and a shift from “one-size-
fits-all” to a tailored approach is increasingly impacting the development of new products. 
Pharmaceutical and biopharmaceutical industries use biomarkers as predictors of efficacy and 
safety to discover new targets and to achieve differential patient responses to therapies, helping 
to improve the efficiency of compounds’ attrition and R&D productivity over time. The 
investments of this industry in biomarker research increased between 2006 and 2010 by a mean 
of 75%, with an additional increase of 53% predicted by 2015 (21 leading companies in US and 
EU assessed).16 In some cases, industry is developing these markers as companion diagnostic 
tests to identify patient sub-populations most likely to benefit from a particular therapy. This is 
sometimes been done in co-development with a diagnostic company. The most recent examples 
here are the oncology drugs Zykadia®, Gilotrif®, Zelboraf® and Xalkori® which have been 
shown to be clinically effective and achieved rapid product approval; older examples include 
the now decade-old blockbuster stories of trastuzumab (Herceptin®) and imatinib (Glivec®). 
In other cases, stratified medicine tests are being developed post hoc by diagnostic companies 
as a way of stratifying an existing drug (for example, Ziagen® in HIV/AIDS and warfarin in 
anticoagulation) or as stand-alone tests (for example, Oncotype DX®) for diagnostic or 
prognostic purposes. 
 
1.1.2 Economic challenges and opportunities 
 
The uptake of SM in clinical practice depends very much on the use of appropriate value 
assessment methods and the economic viability of such approaches in the healthcare settings. 
Like any healthcare intervention, SM interventions have costs and consequences that require 
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considerations by third party payers and reimbursement authorities that seek to derive 
maximum value from limited resources. Economic evaluation provides healthcare decision 
makers with a powerful tool for resource allocation decisions because it offers a framework for 
comparing costs and benefits of competing interventions or options.17 For example, cost-
effectiveness analyses have become a central part of HTAs´ assessments in several EU 
countries to support a `value for money` argument, examining the incremental costs and health 
gain of various health care choices given limited resources.18 Yet, measuring ´value´ might 
differ from payer to consumer and to societal perspectives. In light of the importance of 
demonstrating an added value for SM interventions in clinical practice, economic evaluations 
are increasingly conducted for this new treatment concept to inform on optimal resource 
allocations underpinning decisions by third party payers. 
 
However, methodological challenges can arise in specific interventions or disease states. For 
example, by definition, SM leads to restricted populations due to stratification, and questions 
arise as to whether current approaches to economic evaluation are adequate for SM 
interventions. Of specific concern is whether current guidance for economic evaluation is 
specific enough to avoid inconsistent evaluation and contradictory findings. This, in turn, may 
lead to inconsistent decisions and may also lower decision-makers’ confidence in the usefulness 
of economic evaluations to support decision making or confidence in stratified approaches 
overall.19 
Several studies have identified the need for methodological scrutiny in the economic assessment 
of SM. Actual economic assessment of SM are fraught with challenges and Annemans et al 
explicitly outlined potential measurement issues for traditional cost-effectiveness analysis 
(CEA) when adding a diagnostic test to pharmaceutical technology.20 There is an ongoing 
discussion on evidence requirements and what level and nature of evidence is needed to 
establish clinical utility of tests and the overlay of related economic considerations. Obviously, 
the lack of sufficient evidence linking test use to patient management and health outcomes 
remains a fundamental challenge for reimbursement decisions.21 While there is a clear trend in 
the payer community for evidence-based approaches, development is requested of applicable 
evaluation methods which appropriately take into account clinical and economic uncertainties 
in the value assessment process in SM. This underscores that the assessment of the added value 
of SM interventions depends on many interdisciplinary factors associated with the testing 
component and might be more complex than traditional ones. 
From a manufacturer’s perspective, economic considerations play an important role in decisions 
on whether or not to pursue an SM approach and to invest in diagnostic development and 
diffusion. Drug development decisions are based in part on the expected rate of return to 
investments in R&D, which, in turn, is determined largely by expected revenues versus 
development costs. Because SM involves a number of changes in the conventional way of drug 
development and health care delivery, the economics of developing SM might be significantly 
different from developing an empiric medicine. There is anticipation that diagnostic testing may 
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enhance the efficiency of clinical trials of new drugs and allow smaller and cheaper studies 
which can significantly shorten development time and reduce costs. Yet, the introduction of a 
diagnostic test is likely to involve additional costs and complexity due to the inherently risky 
process of drug development and diffusion. Also, there is the fact, that a more targeted patient 
population may lead to a smaller set of eligible patients and thus limit the market size. In this 
case, additional value will need to be captured in terms of premium pricing, faster adoption and 
longer effective patent life for the targeted drug to offset the reduction in potential revenuers 
from market stratification as compared to full marketing.17 All these aspects and more, have 
triggered ongoing discussions on the financial viability of SM in industry. 
 
Several investigations have uncovered a number of factors and issues that are likely to influence 
the expected returns and hence, the incentive to invest in new pharmaceutical R&D in tandem 
with the development of a diagnostic test.[22-24] For instance, the Massachusetts Institute of 
Technology´s (MIT) Center for Biomedical Innovation has established a research program to 
investigate the economics of SM.25 Mark Trusheim et al performed an economic assessment of 
SM approaches in oncology as part of this research program using NPV (net present value) 
analysis and outlined the often rather limited financial viability of SM interventions given the 
current US health care environment.26 This underlines, that the commercial impact of using a 
diagnostic-guided strategy must be considered carefully in direct relation with patient access, 
clinical benefits and company interests. Investigating and understanding of certain scenarios is 
critical for the industry as several factors – from development to reimbursement and market 
adoption – will affect the potential clinical and commercial success of an SM-approach.  
 
The demand for more efficiency and effectiveness in healthcare is a key priority for healthcare 
systems and industry. In many respects both types of economic evaluations – those that  focus 
on value assessment to inform resource allocation decisions, as well as those supporting 
industry R&D decision making are based on similar sets of assumptions around that a likely 
differential therapeutic profile of responders in a subpopulation may allow for highly clinically 
and economically viable applications.  
 
1.1.3 Regulatory, reimbursement and clinical adoption challenges  
 
The regulatory and reimbursement systems are key factors in the development of new 
medicines and can significantly influence the economics of SM in several ways. From a 
regulatory perspective, adoption of a stratified approach to therapy relies on the development 
of effective tools for stratification and drugs tailored to the stratified groups. The appropriate 
selection of patient populations for clinical trials has the potential to reduce development times 
and lead to earlier regulatory submissions and approvals. Hence, scientifically selected, well-
defined sub-populations enriched for responders should result in more compelling overall 
product risk/benefit versus current therapies, and better odds for approval.27 This has been 
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demonstrated for several product launches (such as, Zykadia® and Xalkori®), having 
experienced accelerated approval procedures by FDA and EMA on a case-by case basis.  
However, the integration of diagnostic tests and drugs poses special regulatory challenges 
because it requires that historically separate regulatory pathways will need to be brought 
together. The regulatory frameworks that underpin the approval of therapeutic and diagnostic 
products vary between the two, from region to region and from country to country. The levels 
and types of evidence required are different, making global development of products more 
challenging.28 In addition, the regulatory processes for biomarker developments are quite 
different from traditional drug development. Notably, with regulatory frameworks for drugs 
differing geographically, this is even more the case for diagnostics. Additionally, such 
frameworks are much more vaguely defined and protocolled for diagnostics as they are for 
drugs. 
The FDA and EMA have issued a number of guidance documents and regulations that seek to 
clarify requirements for SM products.29,30 There is consensus, that the timelines for drug 
development are too slow, however, more clarification and guidance are requested by industry 
towards a more dynamic trial environment - inclusive Bayesian adaptive trial designs - and to 
address the required level and timing of clinical evidence for registration and reimbursement of 
SM products. For instance, it is not yet clear for either the FDA or EMA whether “marker-
negative” patients need to be included into Phase 3 clinical trials which, if required, would 
eliminate potential cost savings or reductions in development time for a company.31 Clear 
requirements for joint testing of diagnostics and therapeutics will also influence the design and 
cost of clinical trials as well as the business relationship between the test and therapy 
manufacturers. Driving a joint clinical trial design for diagnostics and drug requires careful 
coordination among regulatory divisions to ensure timely approval for both.  
SM also challenges current reimbursement approaches in many markets. Market access of SM 
is highly dependent on the assessment process, in particular health technology assessment 
(HTA) and pricing and reimbursement (P&R) decisions. As a current rule, diagnostics and 
pharmaceuticals are considered under separated appraisal and payment processes. Third party 
payers in various healthcare systems have been rather resistant to paying for costly stratification 
diagnostics unless the diagnostic companies can demonstrate clinical utility and /or cost-
effectiveness without endangering the various healthcare budgets. There is concern among 
payers that the use of potentially expensive tests for large populations or a higher price for 
diagnostic-based treatments will wipe out any potential savings from targeting therapeutic 
interventions. While P&R of pharmaceuticals in many EU countries and the US can be 
characterized as somewhat “value-based”, the reimbursement of diagnostics is often resource 
or cost-based, with potentially low reimbursement rates. Many analysts have emphasized the 
need for more flexible pricing and reimbursement schemes to encourage innovation in SM and 
accelerate its adoption.32 Garrison and Towse see value-based, flexible reimbursement systems 
for innovative, patent-protected diagnostics being critical to create stronger economic 
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incentives for the development of test-treatment combinations.33 However, limited intellectual 
property protections for diagnostics for the moment represent a barrier to market entry in the 
diagnostic arena. 
 
In addition, there is a general absence of implemented procedures, criteria and standards in 
assessing diagnostics/tests in SM.34 In many markets, HTA of diagnostics remains nascent but 
slowly evolving. Yet, also in general most diagnostics/ tests are reviewed at local and regional 
levels for reimbursement purposes. Hence, variability and inconsistency in value evaluations of 
stand-alone tests and test-treatment combinations has been noted in many EU markets.35 In this 
respect, questions remain about specific methodologies and appropriate economic 
measurements tailored to the specificities of SM approaches in order to facilitate a broader 
market access of SM interventions.  
Eventually, realising the benefits of SM approaches is very much dependent on whether 
diagnostic testing will diffuse appropriately into clinical practice. The development, adoption 
and the use of medical diagnostics will be influenced by healthcare provider competence in 
using these technologies. Efforts to educate physicians, pharmacists, patients and the public are 
critical for the proper use of new testing technologies. Moreover, various research work36 is 
claiming the importance of effective diffusion of diagnostic testing into clinical practices as a 
key factor to ensure economic viability of targeted therapies from a manufacturer´s perspective. 
If clinicians and patients adhere to targeted treatments with greater confidence in new 
technologies, a more rapid adoptions rate and greater market penetration can be expected. 
Another factor influencing development and diffusion of SM interventions relates to an 
adequate information technology infrastructure capable of storing and sharing complex medical 
information in a secure environment.37 Developing standards in electronic medical records and 
tissue storage (for example, bio-banking) as well as dealing with the privacy and ethical issues 












1.2 Aims and outline of this thesis 
 
This thesis investigates the economic challenges and opportunities in adopting SM approaches 
into clinical practice. The thesis can be categorized into three parts. 
Part I considers the new challenges SM is providing for the value assessment process, in 
particular HTA and P&R decisions. In this context, reimbursement issues of SM approaches in 
several EU countries and the US are addressed, outlining new incentive structures to overcome 
existing reimbursement barriers for SM and to enhance timely access for patients to cost-
effective treatment strategies. Today, HTA data requirements and methodologies, but also P&R 
systems for diagnostic testing are not necessarily structured to reward the added value of using 
tests to improve health outcomes within the context of SM. Furthermore, the main 
methodological issues in the health economic (HE) field of SM are discussed. Although best 
practices and key principles exist for performing economic evaluations and HTA in general, 
there are no commonly accepted standards for applying these methods to SM interventions. In 
addition, the applicability of HE data to support market access within and across European 
countries is addressed in this section. Gaining an understanding of methodological issues in the 
economic assessment of SM and how HE data can best help improve decision making and 
support market access for patient-beneficial approaches is increasingly of interest within many 
health care systems as more SM interventions reach the markets in the next years.  
Part II addresses two economic assessments in which the potential added value of SM 
interventions in clinical practice is examined. The first study in depression illustrates specific 
modeling issues associated with the concept of SM. Adding a testing element to pharmaceutical 
technologies will increase treatment complexity and complicates value assessment. A more 
complex model structure as well as issues on test performance (specificity and sensitivity) and 
potential data gaps will increase the level of uncertainties in SM modeling. The second study 
in fertility assesses the cost-effectiveness of fertility treatments associated with an embryo 
diagnostics element. This work goes beyond traditional economic evaluations studies and 
considers value-based pricing aspects when introducing non-invasive embryo diagnostics into 
in-vitro fertilization (IVF) standard treatment practices.  
Part III considers the economic viability of SM concepts from a manufacturer´s/investor´s 
perspective. In recent years, research to investigate the opportunity for SM has been on the rise 
as technology improves and costs increase. It became evident, that investigating and 
understanding of certain scenarios is critical for the industry as a unique set of factors from 
development to reimbursement and market adoption will influence the expected returns of SM 
interventions and, hence, the incentive to invest in new R&D in tandem with diagnostic 
development. Specifically, this investigation seeks to address the economic attractiveness of 
different SM development options in a cost-contained healthcare environment. For this purpose, 
a decision tree model was created to identify key economic drivers and conditions affecting 
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Stratified Medicine (SM) has the potential to target patient populations who will most benefit 
from a therapy while reducing unnecessary health interventions associated with side effects. 
The link between clinical biomarkers/diagnostics and therapies provides new opportunities for 
value creation, to strengthen the value proposition to pricing and reimbursement (P&R) 
authorities. However, the introduction of SM challenges current reimbursement schemes in 
many EU countries and the US as different P&R policies have been adopted for drugs and 
diagnostics. Also, there is a lack of consistent process for value assessment of more complex 
diagnostics in these markets. New, innovative approaches and more flexible P&R systems are 
needed to reflect the added value of diagnostic tests and to stimulate investments in new 
technologies. Yet, the framework for access of diagnostic–based therapies still requires further 
development while setting the right incentives and appropriately align stakeholders’ interests 
when realizing long- term patient benefits. This article addresses the reimbursement challenges 
of SM approaches in several EU countries and the US outlining some options to overcome 




















Stratified Medicine (SM) represents a novel approach to increase pharmaceutical and 
biopharmaceutical R&D efficiency and to provide improved medical outcomes for the patient 
and the health care system. Matching therapies to patient populations using clinical 
biomarker/diagnostics based stratified medicine offers the prospect to enhance patient care with 
safer and more effective drugs, delivered with a greater probability of treatment success. The 
link between clinical biomarkers and preventive or curative therapies provides new 
opportunities for value creation, offers the potential to change well-established clinical practices 
and to strengthen the value proposition to pricing and reimbursement (P&R) authorities.  
While the SM approach has drawn great attention in the medical community and the industry, 
there have been only a few clinical and public health applications in SM to date. [1-3] Often 
named examples are: HER2/neu – Herceptin, KRAS/EGFR –Vectibix and Erbitux, predictive 
for efficacy; UGT1A1/Irinotecan, HLA-5701/Ziagen (HIV), predictive for safety; Oncotype 
DX and MammaPrint prognostic for adjuvant chemotherapy. Industry is moving slowly to use 
biomarkers and companion diagnostics in routine clinical practice despite scientific advances 
and increasing investments in the biomarker-related research and development.4,5 Scientific 
barriers, concerns about the economic viability of the SM business case and difficulties in 
securing coverage and adequate reimbursement in various markets are main reasons mentioned. 
Although there is a push from health care authorities (FDA6, EMA7) and payers towards 
stratification, the application of biomarkers and companion diagnostics to drug development 
and commercialization is occurring in a complex legal, regulatory and reimbursement 
environment. Diagnostics and pharmaceuticals are evaluated by different decision makers 
within the health authorities, whereas a holistic approach is required in order to assess the full 
health- and economic value of SM. Third party payers in various healthcare systems have been 
rather resistant to paying for costly stratification diagnostics unless the diagnostic companies 
can demonstrate clinical utility and cost-effectiveness without endangering the various health 
care budgets. At the same time, third party coverage and adequate reimbursement are essential 
to providing beneficiary access to patient care and to encouraging continued investments in SM 
interventions.  
This paper will discuss the reimbursement challenges of SM approaches in several EU countries 
and the US. Required changes and options to overcome existing reimbursement barriers for SM 
will be outlined. 
2. Concept Stratified Medicine & Reimbursement Challenges  
2.1 Concept Stratified Medicine 
Stratified Medicine as opposed to empirical medicine is the practice of using biomarkers or 
diagnostic tests to guide the choice of therapeutic treatments.8 In the SM case, a predictive 
diagnostic test stratifies the patient population to responders and non-responders for a certain 
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treatment, whereas by contrast, in empirical medicine all patients would receive the same 
treatment.9 This approach of proactively testing and selecting populations for specific 
treatments aims at ensuring increased efficacy and/or reduce toxicity, but at the same time it 
reduces the eligible patient population. Advances in understanding the mechanisms underlying 
diseases, as well as drug response, create opportunities to match patients with therapies that are 
more likely to be effective and safe. At the extreme of patient matching are ‘individualized’ 
medicines, which vary inherently for each patient such as cancer vaccines that are based on a 
particular patient’s tumour, representing one end of a continuum (Figure 1).  
 
Figure1. Stratified medicine diagram (adopted from: Trusheim et al., 2007 The patient 
therapeutic continuum)                           
                                               Empirical medicine Stratified medicine Individualized medicine 
 
                 Vaccines                     Gleevec                             Cancer vaccine 
                           NSAIDs                    Herceptin                             (Oncophage)  
                           PPIs                                             Erbitux/Vectibix 
                      Ziagen               
 
Empirical medicine is at the other end of this continuum where some agents, such as non-
steroidal anti-inflammatory drugs (NSAIDs) work for a large group of patients. In between lies 
the field of SM, in which a patient can be found to be similar to a cohort that has historically 
shown a differential therapeutic response to a particular therapy using a clinical biomarker. For 
example, the anticancer drug trastuzumab (Herceptin) shows superior efficacy in breast cancer 
patients with HER2/neu-positive cancer (expressed in 25-30% of breast cancer patients). 
Stratified medicine adds a further step to traditional clinical practice in which a clinical 
biomarker is evaluated to associate a patient with a specific therapy. The identification of 
clinical biomarkers or diagnostics linked to the gene expression profile of individual or sub-
populations of patients is an essential feature of SM. Trusheim et al8 consider clinical 
biomarkers to include any diagnostic test or clinical observation that indicates a preferred or 
contraindicated treatment for a specific patient subpopulation. Such tests can be based on gene 
expression patterns, individual proteins, proteomic patterns, metabolomics, histology, imaging, 
physicians´ clinical observations and even self-reported patient surveys. In other words, they 
define a clinical biomarker not by its technology or biological basis, but rather by its reliable, 
predictive correlation to differential patient responses. However, the identification of valid, 
reproducible associations between genetics, disease progression and /or treatment response is 
challenging in the clinical R&D process and implies a good understanding of the molecular 
mechanisms which causes the disease as well as appropriate studies to identify genetic variants 
correlated with drug response.  
 
Today, some therapeutic areas include SM approaches and others do not, as at least three 
specific criteria10 will be necessary for the emergence of a clinical relevant patient subclass and 
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consequent SM. These criteria include the presence of: differential biological mechanisms, 
different treatment options, and a biological marker or diagnostic.  
 
Stratified medicine is practiced in several contexts within the healthcare industry and a shift 
from “one-size-fits-all” to a tailored approach is already impacting the development of new 
products. Pharmaceutical and biopharmaceutical industry is using biomarkers as predictors of 
efficacy and safety to discover new targets and to achieve a differential patient response to 
therapy helping to improve the efficiency of compound attrition and R&D productivity over 
time. Today between 12 and 50% of current clinical pipelines of leading pharmaceutical and 
biotechnology companies (21 assessed) involves SM, and between 2006 and 2010, the 
investment of this industry in SM/biomarker research increased by a mean of 75%, with and 
additional increase of 53% predicted by 2015.4 In some cases, industry is developing these 
markers as companion diagnostic test (e.g., co-developed with a diagnostic company) to 
identify patient sub-populations most likely to benefit from a particular therapy. For instance, 
trastuzumab (Herceptin) used a HER2 overexpression test as a predictive marker to increase 
efficacy in the responder patient population and has achieved blockbusters status. Also, 
cetuximab (Erbitux) and paminumab (Vectibix) have benefitted from KRAS companion 
diagnostic test predictive for efficacy in colorectal cancer patients and KRAS testing became 
mandatory for certain EGFR-kinase-target therapies. HLA-B*5701genetic testing predicts 
hypersensitivity to abacavir (Ziagen) and found widespread acceptance in the HIV/AIDS 
treatment to be responsible for the resurgence of this drug in the market. In other cases, SM 
tests being developed post hoc by diagnostic companies as a way of personalizing an existing 
drug (e.g., metabolic potential of Warfarin to guide dosing) or as stand-alone tests (e.g., 
Oncotype DX) for diagnostic or prognostic purposes. 
 
2.2 Stratified Medicine challenges current reimbursement schemes in EU and the US 
Third party payers in public and private health care systems in EU and the US have adopted 
different pricing & reimbursement policies for drugs and diagnostics. While pricing & 
reimbursement of pharmaceuticals in many EU countries and the US can be characterized as 
somewhat “value-based”, the reimbursement of diagnostics is resource or cost-based.11 For 
instance, laboratory-based in vitro diagnostic tests have traditionally been treated as low-margin 
commodity items in many markets with rather low reimbursement rates which are solely based 
on the method of test (e.g., immunoassay) and not according to the value the tests brings to the 
patient.  
Reimbursement agencies across Europe have compiled lists of devices and procedures which 
are generally based on the diagnostic-related group (DRG) system (e.g., in Germany G-DRG; 
France/GHS code). In this system, similar and related medical procedures are grouped together. 
Each group is then coded and given a monetary value, which is the set amount of money that 
will be reimbursed for each procedure. In the US, all in vitro diagnostic must be assigned to 
Current Procedural Terminology (CPT) code in order to be reimbursed. 
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Major payers and other health authorities will make an effort to link new diagnostic to the 
existing reimbursement level of older tests involving similar effort and cost. This means, that 
payments must come from an existing budget set for procedure based inpatient DRG’s or linked 
to out-patients codes set.  
 
To command higher prices for a more complex diagnostic outside the global caps of these 
procedures will be both challenging and time-consuming in various countries. Currently, there 
is no clear or consistent process for value assessment of more complex diagnostics established 
in the EU and the US. Standards and mechanisms such as with AMCP Format in the US and 
health technology assessment (HTA) with NICE in the UK do not exist in the same way for 
diagnostics in Western EU countries and the US. Instead, reimbursement of diagnostics in these 
markets is set on a case-by-case basis where diagnostic tests in most EU countries are reviewed 
at the local or regional level, and in the US, for example with Medicare, as a combination of 
national and local jurisdictions. 
Only in few examples of companion diagnostic tests, there have been HTA´s in some EU 
countries (e.g., NICE for HER2, EGFR, and KRAS testing) often followed by cumbersome 
reimbursement negotiations and resulting in a cost-based funding of the test.12 Moreover, in 
some countries (UK, Spain) market access for these diagnostic based therapies have been 
achieved only through subsidizations for the diagnostic tests (lower test prices / or free test) by 
pharmaceutical manufactures.   
There are challenges to determine the clinical and economic value of more complex stand-alone 
or companion diagnostics. Often there are scientific barriers, such as lack of data that links 
interventions to health outcomes and costs and that provides comparison to alternative 
approaches. For a diagnostic test to be useful in clinical practice, it must provide reliable, 
actionable, and predictive information to a clinician´s treatment recommendation.13 However, 
in clinical practice, the strength of evidence from simple diagnostic test to rather complex 
molecular diagnostic test varies widely across types of diagnostics technology. Often, tests are 
developed to prove clinical validity (sensitivity and specificity of the test) without evaluating 
clinical utility. Also, case-control, observational and patient cohort studies are used to 
determine the clinical value of biomarker based diagnostic when randomized control trials 
(RCT) are not feasible or too expensive.14 Furthermore, different payers (regional, budget 
holder) have different evidence requirements (prospective, retrospective) for what is sufficient 
to determine the clinical utility of a diagnostic test.  
There is a significant need to clarify the evidentiary framework of the payers concerning 
specific characteristics from simple versus complex molecular test for separate development 
versus co-development. Organizations such as the Center for Medical Technology Policy 
(CMTP) and the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) in 
the US as well as the European Personalized Medicine Diagnostics Association are working to 
explore evidentiary criteria for reimbursement to increase transparency on coverage decisions 
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and to provide industry some guidance when making their decisions to develop innovative 
diagnostic products.15 In addition, there are on-going projects from the European Commission 
such as IT-Future of Medicine (ITFoM) to build a ´personalized patient model´ and regional 
initiatives (e.g., DEMOTEK from Basque country) aimed at helping to facilitate the 
introduction of innovative technologies developed by the local industry. 
Directly linked to the quality of clinical evidence there are challenges in determining the 
economic value of SM interventions. Although many observers have discussed the potential 
economic value of SM approaches there is currently limited empirical evidence available 
supporting such claims.16  To date, a few cost-effectiveness analyses exist for SM interventions 
with inconclusive results as the evidence for effectiveness is frequently preliminary or 
hypothetical. A recent review by Wong et al.17 which examined the economic literature for 
pharmacogenomics, found 34 economic evaluations where only for two biomarkers there was 
sufficient evidence supporting both clinical validity and utility, allowing a true cost-
effectiveness analysis. The lack of reliable information was also reinforced by a former 
systematic review of pharmacogenetic and genomic interventions by Vegter et al.18 which may 
explain why currently such cost-effectiveness analyses have little influence on reimbursement 
decisions in many markets. 
To realize the promise of SM approaches there is a need to perform economic evaluations which 
take into consideration the full impact of using such an intervention on the whole treatment 
pathway of patients including disease prevention. But in contrast, in many health care systems 
in Western EU countries and the US there is no longitudinal accounting which would enable 
payers to capture long-term cost savings from near-term testing. However, anticipated health 
care costs savings from targeting drug therapy will remain theoretical until a more holistic 
perspective on healthcare may be followed.13  
Many observers have emphasized the need for more flexible P&R systems which stimulate and 
reward innovations and reflect the added value of diagnostic tests. Garrison and Austin see 
value-based, flexible reimbursement systems for innovative, patent-protected diagnostic being 
critical to create stronger economic incentives for the development of SM approaches. Seiguer19 
also concluded that there is hardly any incentive for industry to invest in companion diagnostics 
unless diagnostics can capture adequate value of diagnostics. Several government 
commissioned reports have recommended a re-evaluation of reimbursement rates for 
diagnostics20 by pursuing changes in diagnostic coding and payment systems to better reflect 
the value of diagnostic tests. However, changing standard coverage principles and/or to 
establish new coding systems is a rather long-term process in many EU countries and the US. 
In the meantime, novel payment approaches, risk sharing and conditional reimbursement 
agreements with third party payers are explored to overcome the tension between funding new 
but expensive technologies and obtaining value for money where traditional reimbursement is 
not deemed appropriate. These arrangements between a manufacturer and payer/provider can 
use a variety of mechanisms (e.g., pay-for-performance, value-based purchasing) to address 
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uncertainty about the real performance of technologies in daily practise enabling certain market 
access. They can help to enhance the value of SM on a case-by-case basis and may provide 
incentives for the Diagnostic industry to generate high quality clinical and health economic 
evidence. However, in practice there are many organizational and implementation challenges 
to overcome to ensure effectiveness of such agreements including the need for a strong 
collaboration between Pharmaceutical/Biotech and the Diagnostic industry by addressing value 
sharing issues for companion diagnostic in particular. 
Finally, reimbursement authorities are concerned not only with the performance characteristics 
of new medical diagnostics but also in its feasibility to implement it in a service setting.21 Beside 
of the availability of appropriate infrastructure, the development, adoption and the use of 
medical diagnostics will be influenced by health care provider competence in using these 
technologies.  
 
3. Conclusion & future perspective 
Stratified medicine can offer the potential to target patient populations who will most benefit 
from a therapy while reducing unnecessary health interventions associated with side effects and 
thus, may demonstrate a differential value proposition in order to gain substantial market 
access. Multiple studies have shown that most drugs prescribed in various diseases are effective 
in fewer than 60% of treated patients (e.g., oncology only 25-30%) outlining the potential to 
realize efficiency gains for healthcare systems.22 
Medical diagnostics is fundamentally about identifying the subgroups of patients, however, in 
clinical practice, many of the available tests do not demonstrate clinical utility which makes it 
difficult to demonstrate the value of diagnostics.  
Market Access of SM approaches depends much on the assessment process, in particular HTA 
and P&R decisions. Today, fragmentation of HTA data requirements and methodology but also 
of P&R systems for diagnostic testing which are primarily cost/procedure based are not 
necessarily structured to reward the added-value of using tests to improve health outcomes. 
Novel payment approaches and risk sharing agreement may help to enhance the value of SM 
interventions on a case-by-case basis provided that clinical and health economics outcomes are 
transparent.  
Generating high quality clinical and health economic evidence will provide the confidence that 
enables payers more rapidly to adopt tests. At the same time, payer decision making may need 
to become flexible enough to allow for short-term inefficiencies in order to understand and 
benefit from long-term value. While the need for market access of diagnostic-based therapies 
is not questioned, the framework for access while setting the right incentives and appropriate 




Fostering broader coverage of SM approaches within the healthcare systems will require a more 
centralized, holistic and consistent process for conducting HTA´s in Europe and the US. 
Commonly accepted standards and procedures on how to evaluate stand-alone diagnostics and 
test treatment combinations may provide industry with a clear-cut pathway to market access 
and reimbursement for population-wide use.23 At the same time, a more holistic approach to 
health care funding is required in order to realize the full clinical and health economic benefits 
of SM interventions. Because of silo mentality in many health care systems, national authorities 
may need to develop a central financial system specifically applied for SM interventions.  
Recent emerging policy trends and health care financing reform initiatives towards a more 
value-based healthcare will help to enhance the value of SM approaches in clinical practice. 
There is a need to take this further and ensure that core SM measures are incorporated into the 
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Background: Stratified Medicine (SM) is becoming a practical reality with the targeting of 
medicines by using a biomarker or genetic-based diagnostic to identify the eligible patient sub-
population. Like any healthcare intervention, SM interventions have costs and consequences 
that must be considered by reimbursement authorities with limited resources. Methodological 
standards and guidelines exist for economic evaluations in clinical pharmacology and are an 
important component for health technology assessments (HTAs) in many countries. However, 
these guidelines have initially been developed for traditional pharmaceuticals and not for 
complex interventions with multiple components. This raises the issue as to whether these 
guidelines are adequate to SM interventions or whether new specific guidance and methodology 
is needed to avoid inconsistencies and contradictory findings when assessing economic value 
in SM. 
Objective: This article describes specific methodological challenges when conducting health 
economic (HE) evaluations for SM interventions and outlines potential modifications necessary 
to existing evaluation guidelines / principles that would promote consistent economic 
evaluations for SM. 
Results/Conclusions: Specific methodological aspects for SM comprise considerations on the 
choice of comparator, measuring effectiveness and outcomes, appropriate modelling structure 
and the scope of sensitivity analyses. Although current HE methodology can be applied for SM, 















1.  Introduction 
The concept of ´Stratified Medicine`(SM) is becoming a practical reality with the targeting of 
medicines by using a biomarker or genetic-based diagnostic to identify the eligible patient sub-
population.1 The quantity of biomarkers, prognostic and diagnostic tests available for patients 
has increased significantly over the last decade and SM interventions are increasingly being 
developed and used in clinical care. In the SM concept, subgroups of responders are selected or 
identified based on risk of disease or response to therapy, with the notion to improve treatment 
outcomes in these subgroups by increasing efficacy and/or reducing toxicity. This stratification 
of the population by using diagnostic tests or techniques is intended to reduce the use of 
ineffective or unsafe drugs, which should translate into improved health outcomes for patients 
and more efficient use of health care resources. However, there is much debate and uncertainty 
on which SM tests provide economic value and how to balance the need for innovative new 
technologies with affordability. Decision makers and stakeholders need information on which 
tests provide added value in order to make appropriate decisions about where to invest efforts 
in development and adoption.2 A number of analysts have observed that the promise of SM is 
yet to be realized, partly due to the lack of sufficiently robust clinical and economic evidence 
based to support the widespread use in clinical practice.[2-6] Several published systematic 
reviews had suggested there are limitations in the quantity and quality of economic evaluations 
of examples of targeted therapies, imposed by weak clinical and economic evidence base.[7-9] 
Annemans et al as well as Buchanan et al explored methodological challenges of conducting 
economic evaluations of targeted interventions, and outlined new measurement issues for 
traditional cost-effectiveness analysis (CEA) when adding a test or sequence of tests into the 
clinical car pathway.10,11 Furthermore, there is uncertainty in methods to be used with testing 
of multiple biomarkers or clinical applications based on whole exome or genome sequencings. 
In addition, challenges arise if the economic evaluation of SM interventions is understood as 
an evaluation of the benefits, harms and cost-effectiveness at the individual patient preference 
level;12,6 it should rather be conceived as applying to subpopulations as a whole. 
Methodological standards and guidelines exist for economic evaluations in clinical 
pharmacology and are an important component of programs for health technology assessment 
(HTAs) in many countries. However, these guidelines have initially been developed for 
traditional pharmaceuticals and not for complex interventions with multiple components. This 
raises the issue as to whether these standards and guidelines are adequate to address more 
targeted approaches to therapy or whether new specific guidance and methodology is needed 
to avoid inconsistencies and contradictory findings when assessing economic value in SM. 
This article addresses key methodological issues and challenges when conducting health 
economic evaluations for SM interventions and outlines potential modifications necessary to 
existing evaluation guidelines and principles that would promote consistent economic 
evaluations for decision making in SM. Utilizing a set of criteria represented by the guidelines 
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for cost-effectiveness (such as, ISPOR, NICE)[101,102] we identified various aspects of the 
criteria/guidelines which require specific attention/modification for SM interventions.  
 
2. Specific methodological aspects in SM 
While the basic framework for economic evaluations of SM interventions is similar to 
traditional clinical pharmacology some specific issues and challenges can be identified and 
assessed based on economic evaluation checklists102,13 (see Table 1). 
Perspective and target audience 
Health Economic evaluations can be performed from the perspective of the society and the 
national third party payer according to country-specific economic guidelines in health 
technology assessments. From a methodological point of view, the societal perspective should 
be preferred over the national third party payer perspective, especially for SM, which requires 
a more system wide (holistic) approach to perceive the full health- and economic value taking 
into considerations costs and long-term benefits having less adverse therapies target towards 
those who benefit most. However, in practice most economic analyses of SM interventions are 
performed from a third party perspective, since there is no longitudinal accounting in many 
healthcare systems in EU and the US which would enable payers to capture long-term cost 
savings from near-term testing. In addition, pharmaceuticals and diagnostics are considered 
under separate appraisal and payment processes in many healthcare systems. Only NICE (UK) 
has so far established a Diagnostic Assessment program (DAP) which carries out cost-
effectiveness assessments of selected diagnostics.14 Funding silos may lead to different payer 
perspectives, e.g. those who pay for drugs versus those pay for diagnostic requiring different 
questions. Hence, the defined perspective which determines the relevant cost and benefits 
relates much to the discussion on the target audience. For instance, in hospital setting, 
diagnostic testing is covered by the fee-based DRG system in several EU countries (e.g., 
Germany, France) or on budget-based systems (e.g., UK, Spain) where a global budget is 
allocated to local budget holders for payment processes. Further specification of what defines 
a third party payer, a clear understanding of target audience and broadening to societal 
perspectives will increase relevance of policy decision making and is useful to identify their 
evidence needs and incentives to adopt a new technology when proven valuable. 
 
Target population and comparators 
SM interventions may accelerate the evolution and development of clinical treatment pathways 
which makes the specification of target populations groups a challenge. Technological advances 
in genetic sequencing and identification of biomarkers have made it feasible to test multiple 
biomarkers to inform treatment choices, or use algorithms to target screening interval strategies. 
Also next generation sequencing and whole genome or exome sequencing may allow 
identifying mutations in multiple genes for multiple conditions in parallel. As a consequence, 
the number of pathways to include into a model-based economic evaluation may grow 
exponentially with the number of biomarkers used for stratification.6 A recent evaluation of a 
gene recurrence score assay enumerated 1,000 potential clinical strategies from 24 clinical 
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testing pathways and 12 unique risk categories based on two tests with two chemotherapeutic 
regimes.15  In this context it is important to consider that targeted subgroup-specific treatment 
strategies are clinically plausible and implementable. Identifying the exact place of a SM test 
within care pathways is crucial and may change the cost-effectiveness outcomes of the 
intervention (e.g., different results of HER2 testing of trastuzumab in breast cancer patients 
with adjuvant versus metastatic settings). This will guide the selection of a relevant comparator 
- which is usually current standard care in economic evaluations conducted for HTA´s -, and 
determines the appropriate clinical testing strategies to be modelled. Unlike traditional 
interventions, SM interventions should have at least two comparators: comparisons of the “test 
first with the new compound/drug” versus “ treat all with new compound/drug ” and versus  
“standard of care” are recommended although various published cost-effectiveness studies to 
date have used only the “treat all” strategy as a comparator and ignored the “standard of care 
(treat-none with new drug) option. From payers´ perspectives, comparisons of the SM approach 
with “standard care“ is often crucial.16 For example, a cost-effectiveness analysis of KRAS 
testing with cetuximab in colorectal cancer performed by Shiroiwas et al in Japan considered 
three treatment strategies and outlined that the test-first strategy with cetuximab was dominant 
vs treat-all-with cetuximab but perhaps not cost-effective versus the treat-none-with cetuximab 
strategy.17  
 
Measuring Effectiveness and Outcomes 
There is general acknowledgement that the quality of effectiveness data for SM interventions 
is often weak and challenging to incorporate into standard health economic analyses.18  
Effectiveness of SM intervention is a function of both the efficacy of drug and the accuracy of 
the test and includes considerations on false-positive and false-negative outcomes of testing. 
One reason why there are relatively few assessments of economic value is that many diagnostic 
tests do not have widely accepted evidence of clinical utility, i.e. linking test use to patient 
outcomes. The issues surrounding the definition and measurement of clinical utility are major 
areas of debate for all kinds of diagnostic testing technologies. Currently, regulators do not 
require proof of clinical efficacy for a test or even sensitivity/specificity specification which 
could be used to estimate model effectiveness. Furthermore, data on the effectiveness of 
laboratory-developed tests is often even more limited due to the ad hoc nature of their 
development.3  
There are differences in the evidence generation for the SM-development scenarios. For a test 
developed in association with a drug (co-development), the economic analysis might be based 
on randomized controlled trials (RCTs), where the diagnostic test was included in the clinical 
studies of the drug’s efficacy; i.e. sensitivity/specificity data of the test as well as efficacy data 
of the drug/diagnostic combination are included in the overall outcomes of the trial, which can 
produce direct evidence of the clinical utility of the test. For a stand-alone test, this is much 
harder to achieve as RCT´s are often not feasible because of ethical reasons, shift to multi-
therapeutic regimes, and lack of resources or small patient populations. Real-life data 
generation is increasingly needed in this case perhaps via prospective cohort studies, 
observational studies or chart review, as payers might seek additional post-market evidence for 
clinical utility. It is becoming increasingly apparent that new methods will have to evolve to 
ensure efficient evidence generation reflecting realistic expectations around evidence standards 
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(thresholds) aligned between stakeholders given the pace of genomic discovery and the 
associated costs. This implies that health economists and decision makers must be prepared to 
accept data that have come from different settings (case-control and observational) outside 
RCT´s. Potential alternative solutions may involve the use of novel trial designs, such as 
adaptive clinical trials. 
 
Furthermore it is to consider, that the overall effectiveness of the SM intervention doesn´t only 
rely on the development of new treatment modalities, but also on providers and patients 
behaviour when using diagnostic-based therapies. How patients are managed in practice is 
important and will influence the adoption of new technologies (e.g., examples warfarin PGx 
testing and TMPT testing for patient taking 6-mercaptopurine or allopurinol). SM underscores 
the need for additional information on patients and physicians response to diagnosis and will 
require post-approval data collection. Accounting for compliance and adherence (e.g. by use of 
local utilization pattern to improve behavioural assumptions) will reduce variability of findings 
and should be incorporated into sensitivity analyses. The recently drafted guidelines for 
preparing assessment reports for the Medical Services Advisory Committee- Service Type: 
Investigative (version 1.3) in Australia specifically request a supplementary analysis of the non-
health related impacts of diagnostic testing.103 
 
The impact of an intervention on health status (e.g., cost per QALY´s or life year saved) is the 
preferred outcome measure for several EU governmental advisory bodies (e.g., NICE, SMC, 
TLV or CRM) as recommended in the health economic guidelines. However, for third party 
payers such standard measures may have limited applicability in assessing SM interventions 
rather requesting cost-offsets and budget impact information to address affordability issues in 
various health care systems. Methodological issues regarding the valuation of health outcomes 
for SM, particular the quality-adjustment of utility component in QALYs, are similar to those 
faced by other health care intervention. There is an ongoing discussion in academia how 
standard value assessment metrics can be expanded by personal utility data, as current metrics 
is focussed on average population based preferences rather than individual patient preference 
valuation. Capturing information on personal utility may be important, because additional 
benefits may arise from a patient´s increased certainty about the likelihood of successful 
treatment – the ´value of knowing´ (although ultimately always to be aggregated to population 
levels). This might affect adherence and thereby patient outcomes. Yet, alternative metrics (e.g. 
personal utility) are underdeveloped or alternative approaches underused (e.g. state of choice, 
willingness to pay) in policy decision making.11 Further research in this area is required to 
provide guidance for quantifying and incorporating non-health outcomes in economic 
evaluations. 
 
Estimate resource use and cost 
The costing methodology is straightforward and there may not be methodological differences 
with the costing methodology in health economic evaluations for traditional pharmaceuticals. 
Cost calculations in economic evaluation require total average costs (including capital and 
allocated overhead costs) derived from resources consumed and unit cost measures based on 
economic (opportunity costs).19 Yet, establishing and projecting the additional costs due to 
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testing may provide challenges for analysts. A broad range of direct testing costs may include 
additional clinic visits, sample collection and testing, the cost of subsequent treatment and 
genetic counselling as well as re-testing considerations. However, the complete estimation of 
costs relates to the type of cost items and primarily not a methods issue, beyond the perspective 
chosen. 
Often, there are challenges to identify the unit cost of tests which may depend on number of 
tests performed or be part of platform diagnostics with multiple applications. Unlike 
pharmaceutical, there is no national list of available genomic or other tests, as often each 
laboratory is free to set their own price (or charge) to clinicians requesting the test and 
negotiations between suppliers and users often occur at local levels. Large variation in the unit 
cost of these tests can affect the findings of an economic evaluation and increase uncertainty in 
the estimated relative cost-effectiveness of a test. Sensitivity analysis should address robust cost 
estimates relevant to diagnostic testing, yet national price lists of diagnostic test costs would 
help avoid the currently reported variation in costs.20 One costing question is related to the 
perspective. If we assume that a test is performed in an inpatient setting, then from a payer 
perspective, only the diagnosed related group (DRG), including all inpatient resource 
utilization, needs to be applied and the hospital must take care of being able to finance the test 
within the DRG. However, from a societal perspective, the cost of the test should be added to 
the DRG assuming that the current DRG reflects an opportunity cost to the hospitalization. 
Therefore, micro-costing approach would be most appropriate in order to capture the real/true 
costs.  
 
Modelling and dealing with uncertainty 
The existing modelling techniques are appropriate and can be applied for cost-effectiveness 
models in SM, given that special issues are taken into consideration. The inclusion of 
sensitivity/specificity and especially false negatives and false positives, requires additional 
structural complexity in order to make the link between the test and the medication and the 
subsequent clinical and economic outcomes. Another issue is dealing with gaps in the evidence 
base, especially for stand-alone tests. Information on treatment patterns, its costs and outcomes, 
are often lacking, especially for false positive and false negative patients. There is a need to 
identify best practices for economic modelling including approaches which address these 
evidence gaps in a manner that is both acceptable to payers and feasible for test manufactures. 
Thus, extrapolation methods are required in order to extrapolate the short-term 
sensitivity/specificity data to long-term economic outcomes, as shown in a recent paper by 
Fugel et al.21 Given that health economists will increasingly be faced with poor quality 
effectiveness and cost data early modeling approaches will become more common in early 
development stages to better understand the HE value of new technologies. An iterative 
approach could then be employed that systematically and explicitly considers the need for 
further evidence to reduce decision uncertainty, and is consistent with an approach to HTAs 
known as constructive technology assessment.22,23 
 
Sensitivity analyses aim at providing information on the degree of uncertainty in economic 
evaluations and it is currently the most widely applied method of dealing with uncertainty in 
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economic evaluations.24 Because of the more complex structure, lack of data, and extrapolation, 
the uncertainty level in the SM model is higher than in a comparable model for traditional 
pharmaceuticals. In addition, the efficacy of the stand-alone test is often based on a small 
sample size leading to extra uncertainty, thus, extra sensitivity analyses are required for 
sensitivity/specificity and cost of the test. In SM, there are more gaps in information and the 
number of possible assumptions increases with the number of parameters added which may 
cause interpretation problems. A practical way to overcome this problem is the use of scenarios, 
in which several factors are set to reflect a specific situation, such as the best-case and worst-
case scenarios.25 Hence, for the SM approach, scenario analyses may be more important than 
sensitivity analyses, especially when considering test characteristics and potential evidence 
gaps, because there are rather issues on the quality of the data than the distribution of the 
variable. The structural uncertainty of the assumptions due to gaps in data is larger than the 
uncertainty due to statistical distribution. Specific scenario analyses in SM, which are not 
relevant in traditional pharmaceuticals, may be required for a range of estimates in turn, but it 
may also be possible to perform a “multi-scenario” analysis, where the effect of simultaneous 
changes in different assumptions is examined on the outcomes of the study. 
 
A probabilistic sensitivity analysis (PSA) permits the analyst to assign a range and distribution 
to input variables.26 The results of a PSA are presented in a cost-effectiveness acceptability 
curve, which displays the probability that a new treatment is the most cost-effective treatment 
considered in the analysis at a range of different threshold ICER values representing what 
society might be willing to pay to gain one e.g. QALY. However, the results of a PSA for SM 
may need to be considered with more prudence than with traditional pharmaceuticals. Gaps in 
information and subsequent assumptions cannot be captured by a statistical distribution and 
therefore this type of uncertainty cannot be included fully in a PSA. 
 
3. Conclusion and future research  
In general, we can conclude that current health economics methodology can be applied for SM, 
although various aspects of the guidelines require specific attention for stratified medicine 
approaches. These aspects comprise considerations on the choice of comparator, measuring 
effectiveness and outcomes, appropriate modelling structure and the scope of sensitivity 
analyses. Many of these aspects refer to a lack of evidence on testing heterogeneity and the 
quality of effectiveness data. Notably, the level of economic evidence for SM interventions may 
differ from what is generally experienced with traditional pharmaceuticals, thus stressing the 
need to identify best practice for economic modeling including approaches which address 
evidence gaps in a manner that is both acceptable for payers and feasible for test manufactures. 
This may involve the use of novel trial designs, such as adaptive clinical trials, evidence from 
observational studies, and the use of coverage-with-evidence development and real-world 
evidence collection for both drugs and diagnostics. However, the evaluations of both test-
treatment interventions (companion diagnostic) and stand-alone diagnostics is occurring in a 
complex legal, regulatory and reimbursement environment which does not currently fit with 
SM approaches. New incentive structures are needed to increase the efficiency of evidence 
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generation. Previous suggestions for economic incentives for evidence generation include 
value-based price flexibility, intellectual property protection from evidence generated and 
public investment to complement the effort of payers and manufactures.27 
SM underscores the need for additional information on patients and physicians response to 
diagnosis which is not readily available from clinical trials or administrative data sets. 
Accounting for compliance and adherence (e.g. by the use of local utilization pattern to improve 
behavioural assumptions) will provide insight into variability of findings and should be 
incorporated into sensitivity analyses. Health economist may need to take new accountabilities 
when using observational research methods to perform additional value from utilization data to 
payers. 
Incorporating complex genetic or genomic data into cost-effectiveness analyses is a challenge 
that will grow as next generation sequencing technologies enter clinical practice. While there 
is no need to develop completely new tools, there are requirements for some refinement by 
including sensitivity and specificity consideration of the test as well as to address consequences 
of false-negative and false- positive test results on the value proposition. This may require 
further methodology development to address the increased complexity and the need for 
additional analyses associated with the testing component. Further research should also 
consider examining other approaches to measuring values for SM interventions. The specific 
aspects outlined in this article suggest there may be opportunities to improve current guidelines 
























Table 1. Summary of methodological issues in economic evaluations of SM interventions 






Societal or third party Societal perspective is preferred 
(ideally), although third-party is 
most used.  Funding silos may 
lead to different payer 
perspectives, i.e., those paying for 
drugs versus those paying for 
diagnostics. 
 
Clear understanding of target 
audience and further 
specification of what defines a 
third-party-payer will increase 
relevance for decision-making. 
Target 
Population 
Clear description of 




Testing reveals heterogeneity and 
creates multiple subgroups & 
treatment pathways which may 
challenge specification of target 
population groups. Identifying the 
exact place of a test within care 
pathway is critical.  
Specification of target 
populations groups according 
testing rules will guide the 
selection of relevant 
comparator and may reduce 
variability of evaluation 
findings.  
 
Comparators Standard care being 




Multiple potential test designs 
may exist and makes defining 
testing interventions a challenge. 
The sequence of testing and the 
inclusion of a "no test” 
comparator is often variable and 
can lead to different coverage 
recommendations.  
An additional comparison 
should be considered by 
splitting the SM treatment.  A 
comparison of the “test first 
with the new 
compound/drug” vs. “treat all 
with new compound/drug” vs. 







world factors that 
modify effectiveness 
which also may 
include indirect 
comparisons.  
Estimates of effectiveness relies 
on various data sources and is 
more sensitive to adherence and 
compliance effects.  
Strict recommendations that 
compliance and adherence 






measures to value 
differences between 
the intervention and 
alternatives (e.g., 
OALY). 
Standard measures (e.g., QALY) 
have limited applicability and are 
focused on average population 
rather than individual/sub-
population outcomes. Yet 
alternative metrics (e.g., personal 
utility) are underdeveloped and 
alternative approaches (e.g., cost-
benefit analysis) are underused. 
Recommendation to 
incorporate local utilization 
patterns to improve 
behavioral assumptions. 
Further research is needed for 
quantifying non-health 




Measure and value 
resources that are 
relevant to study 
perspective. 
Establishing and projecting the 
additional costs due to testing is 
challenging 
 
National price lists of 
diagnostic test (unit) costs 
would help avoid reporting 







Inclusion of sensitivity/specificity 
and especially false-negative and 
false-positive considerations will 
increase structural complexity to 
establish the relationship 
between test results and 
treatment changes and outcomes. 
An iterative approach to 
evaluation is recommended 
(via early modeling) to identify 
the need for further evidence 
generation in alignment with 
HTA requirements. 
Uncertainty Sensitivity analyses Extra sensitivity analyses are 
required for sensitivity/specificity 
and cost of the test.  
Scenario analyses may be 
more important in SM; 
especially when considering 
test characteristics and 
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Background: Stratified Medicine (SM), as opposed to empirical medicine, is the practice of 
using biomarkers or diagnostic tests to guide the choice of therapeutic treatments. The link 
between the diagnostics and therapy provides new opportunities for value creation and may 
strengthen the value proposition to pricing and reimbursement authorities. However, SM 
provides new challenges for the value assessment process, in particular health technology 
assessment (HTA) and pricing and reimbursement (P&R) decisions. Although health 
economics (HE) should be relevant for all stakeholders, not all stakeholders are comfortable 
with analysis/interpretation of economic data relevant to SM interventions as this approach is 
still in an early/emergent stage in most markets. 
Objective: This article addresses how different stakeholders are using the health economic data 
in the overall value of information analysis to inform prioritization and reimbursement of SM 
interventions.  
Results: Findings of an expert discussion outlines key challenges affecting various stakeholders 


















Stratified Medicine (SM) as opposed to empirical medicine is the practice of using biomarkers 
or diagnostic tests to guide the choice of therapeutic treatments. The SM approach stratifies the 
patient population into responders and non-responders using a predictive diagnostic test and 
hence defines a cohort of patients that shows a differential therapeutic response for a certain 
treatment, and as a consequence reduces the eligible patient population. Matching  therapies to 
patient populations using diagnostic-based stratified medicine offers the prospect of enhancing 
patient care with safer and more effective drugs, delivered with a greater certainty of success to 
those in need. The link between the clinical biomarker and the therapy provides new 
opportunities for value creation, offers the potential to improve clinical practice and treatment 
pathways and to strengthen the value proposition to pricing and reimbursement authorities.1 
However, the application of biomarkers and companion diagnostics to drug development and 
commercialization is occurring in a complex legal, regulatory and reimbursement environment 
which does not currently fit with SM approaches. For example, diagnostics and pharmaceuticals 
are evaluated by different decision makers within the health authorities, whereas a holistic 
approach is required in order to assess the full health and economic value of stratified medicine 
from a health care system perspective. Third party payers in various healthcare systems have 
been rather resistant to paying for costly stratification diagnostics unless the diagnostic 
companies can demonstrate clinical utility and / or cost-effectiveness without endangering the 
various health care budgets. The concern regarding SM approaches among payers includes fears 
that the use of expensive tests for a large population and /or that the higher price for some 
biomarker-targeted treatments will wipe out any potential savings from targeting therapeutic 
interventions. However, in practice this depends on a number of factors including test cost, 
percentage of test responders anticipated in the target population, and the cost of the stratified 
treatment versus alternatives. 
Stratified Medicine provides new challenges for the value assessment process, in particular 
health technology assessment (HTA) and pricing and reimbursement (P&R) decisions. Adding 
a diagnostic or testing element to pharmaceutical technology will increase treatment complexity 
and can complicate value assessment, including uncertainties around evidence assessment, gaps 
in the evidence supporting clinical utility and differences in the quality of medical management 
with the tests. In addition, there is an absence of implemented procedures, criteria and standards 
in generally assessing diagnostics/tests in SM.2 In many markets, HTA of diagnostics remain 
nascent and evolving although in general most standalone tests are reviewed at local and 
regional level for reimbursement purposes) while globally HTA of diagnostics is highly 
heterogeneous with no clearly accepted standard. 
Although health economics (HE) should be relevant for all stakeholders, not all stakeholders 
are comfortable with analysis/-interpretation of economic data relevant to SM interventions as 
this approach is still in an early/emergent stage in most markets. In addition, some stakeholders 
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may consider the specific ethical issues related to SM more important than health economic 
benefits. They may be concerned about stratification of patients associated with possible false 
positive/negative results which may have severe consequences for the patient leaving to 
inappropriate treatment. Furthermore, physicians must take an active role in applying SM 
approaches for this concept to be successful, but may require education on ‘how to use’ new 
technologies and appropriate financing systems including incentives to support appropriate use 
of the test. As more SM interventions reach the markets in the next years, payers will be making 
more coverage and reimbursement decisions that take into account the cost and value of these 
technologies. 
This article will address how different stakeholders are using the health economic data in the 
overall value of information analysis to inform prioritization and reimbursement of SM 
interventions. Findings, derived from an expert discussion will outline key challenges affecting 
various stakeholders when applying health economic data in the health care decision making 
process for SM interventions.  
 
Expert meeting  
An expert meeting was organized (December 2011) with a panel of international experts in the 
field of both health economics and SM to discuss the main methodological issues in the health 
economic field of SM (manuscript of ‘Health Economic Assessments in SM’ is currently under 
review) as well as the application of these data in the healthcare decision making process of 
different stakeholders in EU countries and the US. The experts were sent before the meeting a 
set of published literature on health economics and stratified medicine as preparatory materials. 
The panel discussion was guided by statements drafted from key principles and best practices 
for health economics to address specifics of HE in SM. It was considered important to focus on 
SM in active disease populations, therefore SM as preventive tool in healthy people (e.g. 
screening for oncogenes) was not addressed. There was no specific disease focus during the 
discussions, however, the specialists participating in this meeting considered issues associated 
with conducting health economics research in SM for two scenarios: a) Diagnostic is used as a 
companion diagnostic test in a test-treatment combination (e.g. HER2/neu- Herceptin, 
KRAS/EGFR- Vectibix and Erbitux, predictive for efficacy); b) Diagnostic is developed as 
stand-alone test (e.g. Oncotype DX and MammaPrint prognostic tests for adjuvant 
chemotherapy).  
 
2. Use of HE-data for SM decision-making 
The following target users (stakeholders) have been identified as relevant for SM decision-
making: 
 Third party payers  
 Advisory bodies (e.g. NICE) 
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 Governmental central public policy makers (e.g. NHS) 
 Providing institutions / Hospitals 
 Health Care professionals 
 Employers (e.g. relevance to US settings)  
 
Different health economic data are relevant to different health decision makers in various 
markets.  Cost-effectiveness is relevant to some key health decision makers but is not the most 
useful form of economic information to others. To date, a few cost-effectiveness analyses 
(CEA) exist for SM interventions with inclusive results as the evidence for effectiveness is 
frequently preliminary at the time of product launch. Tests may lack conclusive evidence 
linking their clinical usefulness to health outcomes and without sufficient evidence addressing 
key dimensions of test value it is difficult to assess cost-effectiveness. The lack of reliable 
information to support SM cost-effectiveness has been reinforced by several systematic reviews 
on the topic.[3-5] For instance, some stand-alone diagnostics (e.g. CYP2C9 testing to inform 
warfarin dosing or CYP2C19 testing to identify clopidogrel (Plavix) responders) have not 
achieved broad payer acceptance because evidence of the links between testing, treatment and 
health outcomes has not been sufficiently established.6 Because of complexities in CEA of SM, 
budget impact information (BIA) may be more relevant and actionable for most target users, 
especially third party payers. There is an expectation by payers that applying a test will lead to 
cost savings (cost-offset) by limiting care to effective regimens, and decreasing resource use by 
lowering the frequency of treatment complications. However, many tests that are used to stratify 
patients are still “below the radar” of decision makers, because they are either cheap, or used 
on small scale, and individual tests may not be easily differentiated by existing payment 
mechanisms in many markets.  
Often, these tests are covered within the DRG (diagnosis related group) fee schedule in the 
inpatient (hospital) setting and a code-based fee schedule in the outpatient (ambulatory) setting, 
respectively, a technical procedural cost which does not consider clinical and economic value.7 
Moreover, nonspecific coding issues (i.e., “code stacking”) for molecular tests makes it difficult 
for payers to track outcomes associated with diagnostics. Health economics is not an issue in 
such circumstances, until the prevalence of the conditions becomes high, at which point there 
may be perceived ethical issues associated with test accuracy or possible budget consequences. 
Under these circumstances, the choice between a SM treatment approach and traditional 
treatment becomes relevant and requires the assessment of opportunity costs of decisions about 
which health care intervention to use. 
 
However, in many markets there is a lack of implemented procedures, criteria and standards in 
generically assessing tests in stratified medicine.2 For instance, stand-alone diagnostics follows 
a medical device technology evaluation process which has very different evidentiary 
requirements from medicines. Different types of test have different evidence requirements and 
diagnostic evidence assessment methods are still evolving in most major markets, although 
countries like the UK, France, Canada, Australia and the US have started to explicit developing 
criteria-/-guidelines for more appropriate diagnostic value assessments.8 Historically, in a 
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majority of markets diagnostic evidence has most frequently been submitted by test 
manufactures to individual budget holders assessing test performance and budget impact. While 
currently there is no consistent process for conducting HTA´s of companion diagnostic in EU 
and the US, payers are interested in evaluating the clinical utility (linking test use to change 
patient management) and economic impact of diagnostic testing (cost offsets throughout the 
test and treatment cascade) as part of coverage and reimbursement decisions. 
  
At present, payers often do not differentiate between stand-alone and co-developed companion 
diagnostic tests in terms of acceptance criteria (economic or clinical). This may be problematic 
for stand-alone tests if criteria associated with companion diagnostics (i.e., drug/diagnostic 
combinations) are applied to stand-alone tests that do not operate with the same market and 
economic freedoms as pharmaceuticals. For companion diagnostics developed in tandem with 
the drug, this is often not an issue since the evidence developed will be more “drug-like” in 
nature and will more clearly link test use to clinical utility and health/economic outcomes.  
 
Regardless of the criteria used in the actual decision-making, both CEA and BIA can be 
considered important in both companion and stand-alone diagnostic scenarios for the payer 
(including a wide variety of governmental and private organizations). An example is the 
Mammaprint test in The Netherlands, which shows that the evaluation depends on the type of 
stakeholder. The Dutch national health authorities are currently exploring the value of the 
Mammaprint test from a clinical and cost-effectiveness perspective (within a prospective 
clinical phase III trial - MINDACT1). However, payers (insurance companies) are already 
reimbursing this test, because the use of the test has demonstrated to realize cost savings and 
positively impact on the annual budget of the payers. This example shows that from a payer’s 
perspective, clinical utility and cost-effectiveness are not that important if budget impact and 
clinical consequences are clear.  
 
Inconsistent methodology for value assessments 
For central HTA bodies (e.g. NICE) incremental cost-effectiveness is an important health 
economic outcome in certain markets (e.g. UK, Sweden, Belgium and The Netherlands) 
although the cost-effectiveness estimates for recent SMs (e.g., HER2, EGFR and KRAS testing) 
have been highly variable among major HTA markets, suggesting that methods for 
incorporating test information into economic evaluations are inconsistent.6 Different evaluation 
approaches have been used within the EU to inform reimbursement and there is currently much 
ambiguity about whether SM interventions are or will be covered, by whom, and at what rates. 
For instance, while Herceptin (trastuzumab) in breast cancer and Erbitux (cetuximab) in colon 
cancer are widely reimbursed across the EU, reimbursement for the companion HER-2/neu 
testing and KRAS testing varies across Europe. In the UK, France, Germany and Italy both tests 
are publicly-funded and are reimbursed on cost-based formulae, hence not subject to a value-
based payment negotiated based on its relevance to clinical decision making. In other countries 
(e.g. Spain), local/ regional market access for these diagnostic based therapies have been 
achieved only through subsidizations for HER-2 and KRAS testing (lower test prices / or free 
test) by pharmaceutical manufacturers. However, decentralization of HTA reviews 
                                                     
1 MINDACT: (Microarray In Node-negative Disease may Avoid ChemoTherapy) 
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(regional/local) and lack of health technology assessment transparency makes a broad coverage 
of diagnostic tests within countries to a cumbersome and lengthy process. Questions remain 
about appropriate economic measurements and approaches towards more flexible 
reimbursement schemes, which would facilitate a broader market access of SM interventions. 
 
Increased complexity 
Assessment of the added value of SM interventions is complex and depends on many factors 
including the performance of the diagnostics, quality of labs and medical management 
practices. There are also relatively few mechanisms or incentives to assess economic value from 
a societal perspective because in many health care systems in EU and the US there is no 
longitudinal accounting to enable payers to capture long-term cost savings from near-term 
testing. However, anticipated health care costs savings from targeting drug therapy will remain 
theoretical until a more holistic perspective on healthcare may be followed.9 There is a need to 
clarify the evidentiary framework and to establish evaluations standards on how to evaluate 
diagnostic and test treatment combinations by leading HTA agency and payers. Organizations 
such as the Center for Medical Technology Policy (CMTP) and the Evaluation of Genomic 
Applications in Practice and Prevention (EGAPP) in the US as well as the European 
Personalized Medicine Diagnostics Association are working to explore evidentiary criteria for 
reimbursement of diagnostics and SM interventions. 
 
Ethical Aspects 
Governmental bodies (e.g. NHS/UK, Department of Health /US) will take a broader perspective 
beyond clinical and economic outcomes assessing SM intervention, including social values 
(equality) and ethical issues. The ethical issues are most closely related to the 
sensitivity/specificity of the diagnostic test in SM. On the one hand, SM is an improvement 
over empirical medicine, due to one treats only the right patient identified by the companion 
diagnostic instead of a broad population that includes also unknown non-responders. On the 
other hand, there is a risk to fail to treat the right patient because of the sensitivity of the test. 
For example, a number of patients will not receive the most optimal treatment after a false 
negative test, which may have severe consequences for the patient. Alternatively, following a 
false positive test, a cancer patient may not receive a SM treatment that will work and could die 
because alternative treatments were not used/ denied. Thus, if a SM program leads to a 
favourable incremental cost-effectiveness ratio, e.g. 20,000 Euro/QALY, but the 
sensitivity/specificity of the diagnostic test is only 50%, the SM program will probably not be 
accepted. The low sensitivity/specificity and its resulting ethical issues are unlikely to justify 
approval, despite the favourable cost-effectiveness. This example shows that balancing clinical, 
economic and ethical issues is key for SM interventions.  
 
The weight of ethical issues related to sensitivity/specificity of the test makes the assessment 
of SM much more a multi-criteria decision than traditional pharmaceuticals. However, the 
relevance of ethical issues compared to health economic issues will vary significant by market- 
and cultural perceptions and may become especially important for severe diseases, like multiple 
sclerosis. It is more challenging to evaluate a biomarker for such a disease due to the large 
number of patients and the test required to be highly accurate (i.e., as close to 100% sensitivity 
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and specificity as possible) given the severity of the disease and the risk of withholding an 
appropriate treatment from someone. Likewise, the principles of equality and access should be 
applied ensuring that new SM interventions are equitable available to patients recognizing its 
willingness to pay and the ability/ scope of patient co-payment.  
 
Within hospitals, the interest of health care providers is more towards budget impact data and 
financial savings related to more efficient use of healthcare resources than towards cost-
effectiveness data which is not different to traditional pharmaceuticals. Providers may judge 
SM approaches based on limited short-term sensitivity and specificity outcomes of the 
diagnostic test and may not include the long-term treatment associated outcomes. The 
performance of an additional test is often included in an existing diagnosis-related group (DRG 
tariff) where hospitals are paid a predetermined fixed payment rate per case according to 
historical cost patterns that do not reflect additional cost of using tests. So the additional tests 
can be viewed as an extra expenditure for the hospital, creating a disincentive for adoption 
unless cost-offsets in other budget centers justify use of the test or the payment system is 
updated to account for extra costs. However, changing existing payment system is cumbersome 
and requires the demonstration of sufficient cost and volume-data associated with a new 
technology. To bridge introduction of new technology temporary funding instruments such as 
NUB2 in Germany may be used and new flexible infrastructure is emerging across Europe 
which may allow clinic budget holders to enable possible patient access to such new technology 
via specific market access schemes including risk sharing with manufactures to address 
uncertainty about performance of technology and budget impact. At the same time, 
development, adoption and use of new diagnostic tests will be influenced by health care 
provider competence in using these technologies. Efforts to educate physicians and other 
providers are critical for proper use of these technologies in treatment decision making. 
 
Health care professionals are another important target user. The physician or health professional 
will mostly be interested in the clinical effectiveness of SM intervention rather than in the costs 
which is not different to traditional pharmaceuticals. Clinicians in Europe will think about 
whether it is good practice (also according to their clinical group) and if SM treatment is 
included in the clinical guidelines. However, considering the increasing pressure on health care 
budgets, physicians may well be willing to provide advice on possible economic benefits or 
even to contribute to net cost-savings (either immediate or in the future) of SM interventions 
provided robust and transparent economic outcomes are available and have been communicated 
to them. At the same time, physicians in many health care systems are not paid for applying 
test/diagnostic in daily practice and may require appropriate financing systems including 
incentives (e.g., fee by doing the test) to support SM approaches from the physician’s 
perspective. In the US, there are examples of Accountable Care Organization models where 
quality measures/clinical pathways may alter the incentive structure for selection of certain 
treatments which may support SM approaches in this context. 
 
For Health care professionals and providers, legal issues are also important to consider given 
potential for false positive/negative results, especially in the US, but also increasingly in 
                                                     
2 NUB: Neue Untersuchungs- und Behandlungsmethoden, a new Diagnostic and Treatment Method Regulation  
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Europe. Providers (hospitals) may still use the test to avoid malpractice lawsuit risk that may 
follow from withholding the test to patients. The hospitals will incorporate this test into the 
guidelines to make explicit when the test can or cannot be used, including to defray potential 
legal risks associated with SM.  
 
For employers in the US who subsidize employee health insurance, there may be a budget 
impact issue on the premium cost with the introduction of new SM technology. This is 
especially true for high prevalent disorders, where downstream costs in terms of the premiums 
will be based on excess costs of the prevalent group. For instance, the application of the Roche 
AmpliChip CYP450 test for depression could present an example for employers to be forced to 
increase premium cost, because of the high prevalence of depression in the professional 
population. 
 
3. New challenges for HTA and P&R schemes 
 
Stratified Medicine provides new challenges for the value assessment process, in particular 
health technology assessment (HTA) and pricing and reimbursement (P&R) decisions. Adding 
a diagnostic or testing element to pharmaceutical technology will increase treatment complexity 
and complicates value assessments. Furthermore, third party payers in public and private health 
care systems in EU and the US have adopted different pricing & reimbursement policies for 
drugs and diagnostics. While pricing & reimbursement of pharmaceuticals in many EU 
countries and the US can be characterized as somewhat “value-based”, the reimbursement of 
diagnostics is resource or cost-based.10  
 
Reimbursement agencies across Europe have compiled lists of devices and procedures 
established which are generally based on a version of the DRG system (e.g. in France/GHS 
code; UK/HRG).11 In this system, similar and related medical procedures are grouped together.  
Each group is then coded and given a monetary value, which is the set amount of money that 
will be reimbursed for each procedure, frequently including diagnostics and drugs, unless they 
are separately payable in the system. Often, these lists vary by country, between public and 
private healthcare provider, between hospital and outpatient care and sometimes by 
geographical region. For example, in the US, all in vitro diagnostics must be assigned to CPT 
(Current Procedural Terminology) code in order to be reimbursed. Major payers and other 
health authorities will make an effort to link new diagnostics to the existing reimbursement 
levels of older tests involving similar effort and cost. This means, that payments must come 
from an existing budget set for this procedure based on DRG or CPT codes and tests outside of 
the DRG system are separately payable. In the US, payment techniques such as “cross-walking” 
and “gap filling” are used for this purpose. Many observers have emphasized the need for more 
flexible pricing & reimbursement schemes which stimulate and reward innovations and reflect 
the added value of diagnostics tests.  Current reimbursement schemes for diagnostics do not 
reward value creation, which discourage diagnostic companies from investing in such research. 
Several government commissioned reports have recommended a re-evaluation of 
reimbursement rates for diagnostics12 by pursuing changes in diagnostic coding and payment 
systems to better reflect the value of diagnostic tests. However, changing standard coverage 
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principles and-/or to establish new coding systems is a rather long and uncertain process in 
many EU countries and the US. 
 
In the meantime, novel payment approaches, risk sharing and conditional reimbursement 
agreements with third party payers are being explored to overcome the tension between funding 
new but expensive technologies and obtaining value for money where traditional 
reimbursement is not deemed appropriate. These arrangements between a manufacturer and 
payer/provider can use a variety of mechanisms (e.g. pay-for-performance, value-based 
purchasing) to address uncertainty about the real performance of technologies in daily practice 
enabling certain market access. They present an opportunity to enhance the value of SM by 
measuring comprehensively both outcomes and cost over a full cycle of care (e.g. episode of 
care payment); thus may be more appropriate to align the incentives of various stakeholders 
involved in P&R decisions when realizing long-term patient benefits including associated 
funding. However, in practice such market access schemes present an administration burden 
and many organizational and implementation challenges need to overcome to ensure 
effectiveness of such agreements. There must be good research governance and such 
agreements may be difficult to negotiate, due to legal requirements and increased costs and 
bureaucracy. 
Coverage with evidence development (CED) provides another opportunity to move diagnostic 
testing forward within SM interventions. CED is used to generate data to inform clinical 
usefulness of tests while enabling earlier financial rewards to test developers, helping to 
maintain the return of investment. CED is currently under consideration in several jurisdictions 
in the US and in Europe.  
To foster a broader coverage of SM approaches within the healthcare systems will require a 
more centralized, holistic and consistent process for conducting HTA´s in Europe and the US. 
Given the general lack of the HTA-approach for SM interventions, commonly accepted 
standards and procedures on how to evaluate stand-alone diagnostics and test-treatment 
combinations need to be established in order to provide industry with a clear-cut pathway to 
market access and reimbursement for population-wide use.2 Although key principle and 
standards for HTA´s exist for traditional pharmaceuticals in general, there is a need for more 
specialized HTAs which take into account most reliable and available evidence and being 
tailored to the specificities of SM interventions. This involves a rather broad value definition 
including clinical, economic, ethical and social values when considering the full impact of using 
a SM approach on the whole treatment pathway of patients. At the same time, a more holistic 
approach to health care funding is required in order to realize the full clinical and health 
economic benefits of SM interventions. Because of silo mentality in many health care systems, 
national authorities may need to develop a central financial system specifically applied for SM 
interventions. Creative solutions, such as the approach to care integration through bundled 
payments in The Netherlands will need to be identified and tested. In this sense, there is an 
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opportunity for Europe with its primarily single payers systems to realize SM approaches in a 
more cohesive way compared to the rather segmented US system.  
4. Discussion 
  
In an area of cost-containment and limited health care resources there is a need to consider 
opportunity cost of decisions about which health care interventions to use. Health economic 
analyses represent a key factor to determine the uptake of SM into healthcare systems while 
third party payers must be apprised of the value-adding effects of stratified medicine 
interventions to better understand the benefits of using such technologies in establishing their 
payment and reimbursement plan. However, understanding of economics of SM is challenging 
because the available evidence is often inadequate to truly inform decision making at both the 
local and national levels. Adding a testing element to pharmaceutical technology will increase 
treatment complexity and complicates value assessment including uncertainties about evidence 
assessment, test performance and quality of labs or medical management. There is a clear need 
to clarify areas of uncertainties and to establish evaluations standards on how to evaluate 
diagnostic and test treatment combinations by leading HTA agency and payers. While cost-
effectiveness data may or may not be considered by payers in their rationale for paying for high-
value tests, for many payers in EU and the US the cost impact is influential, particularly if use 
of the test results in direct cost savings such as avoidance of inappropriate drug therapy. 
 
Market Access of stratified medicine approaches depends much on the assessment process, in 
particular HTA and P&R decisions. Today, fragmentation of HTA data requirements and 
methodology but also of P&R systems for diagnostic testing which are primarily cost 
/procedure based are not necessarily structured to reward the added-value of using tests to 
improve health outcomes. Novel payment approaches and risk sharing agreements may help to 
enhance the value of SM interventions on a case by-case basis provided that clinical and health 
economics outcomes are transparent. Moreover, such forms of market access schemes may be 
more appropriate to align the incentives of various stakeholders involved in P&R decisions 
when realizing long-term patient benefits including associated funding. Generating high quality 
clinical and health economic evidence will provide the confidence that enables third party 
payers more rapidly to adopt tests. At the same time, payer decision making may need to 
become flexible enough to allow for short-term inefficiencies in order to understand and benefit 
from long-term value. However, anticipated health care costs savings from targeting drug 
therapy will remain theoretical until a more holistic perspective on healthcare may be followed. 
Fostering broader coverage of SM approaches within the healthcare systems will require a more 
consistent process for conducting HTA´s in Europe and the US. Although best practices and 
key principle exist for HTA´s of traditional pharmaceuticals in general, there are no commonly 
accepted standards for applying these principles & measurements to SM approaches. However, 
recent attempts for HTA’s in stratified medicine are increasing in defining pathways and 
evidence criteria for SM technologies in some markets (e.g. UK/NICE’s Diagnostics 
Assessment Program). Moreover, further methodology development through an inclusive 
dialogue which reflects and balances input from key stakeholders including payer, patients, 






As more SM interventions reach the markets in the next years, payers will be making more 
coverage and reimbursement decisions that take into account the cost and value of these 
technologies. This article outlined key challenges affecting various stakeholders when applying 
health economic data in the health care decision making process for SM interventions. These 
challenges include methodological issues in the economic assessment of SM interventions and 
the need to clarify uncertainties regarding clinical and economic evidence requirements. 
Stratified medicine raises also new ethical issues in the market access evaluation, which do not 
exist for traditional pharmaceuticals. The weight of ethical issues related to 
sensitivity/specificity of the test makes the value assessment of SM much more a multi-criteria 
decision than traditional pharmaceuticals. HTA methodologies will have to evolve to address 
the multiple components of value that a diagnostic and therapy can provide. It is likely that 
different mechanisms of evaluation will be developed that are appropriate to each scenario (i.e. 
test-treatment combinations vs stand–alone diagnostic). In addition, coverage and payment 
pathways must be developed to adequately capture the value of diagnostic and test-treatment 
combinations to incentivize future investments in new technologies. Finally, early–stage cost-
effectiveness analyses models may be particularly useful in SM and can help manufactures to 
prioritize investment decisions, including whether or not to combine a test and a drug and to 
generate more evidence. Such approaches may play an increasingly important role in 
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Assessment of added value of stratified medicine (SM) interventions is complex and depends 
on many factors including the performance of the diagnostic test and the utility of the test for 
informing patient management. Modelling studies based on decision analysis is a well-
recognized method used for health technology assessments (HTA’s) of health care interventions 
to analyze the consequences of decisions that are made under uncertainty. In this study, we 
address specific modelling issues associated with SM interventions and used depression to 
scrutinize the modelling approach with SM in particular. The model includes the stratification 
of patients into poor, normal and rapid metabolizers. The analysis outlines the importance of 
addressing input parameters such as test sensitivity and specificity and especially false negative 
and false positive considerations of the diagnostic test. This requires additional structural model 
complexity to establish the link between the test results and the consecutive treatment changes 
and outcomes and lead to a higher degree of uncertainty in economic models for SM compared 
with traditional ones. In case of depression, CYP450 testing will aid the decision maker (e.g. 
GP) in dose adjustment of antidepressant treatments, and in minimizing factors (adverse events 





















Health care markets are becoming more complex and fragmented owing to the widening range 
of stakeholders involved. Third party payers in public and private health care systems are 
concerned about getting value for their money and demanding increased evidence of 
differentiation and proven value before granting market access of a new therapy. The 
reimbursement environment is becoming increasingly stringent and a range of initiatives are 
being implemented in the major geographical markets to drive down the cost of the drugs. At a 
central (reimbursement authority) level the demand for cost-effectiveness and budgetary impact 
data has been increasing, which already resulted in formal dossier requirements in most 
countries.1  
Stratified Medicine (SM) represents a novel approach to increase pharmaceutical and 
biopharmaceutical research and development (R&D) efficiency and to improve the health 
outcomes of individual patients. Utilizing a stratified approach and identifying groups of 
patients based on certain biologic characteristics or biomarkers has the potential to be more 
efficient and effective while reducing undesirable drug interactions and side effects.2 The link 
between clinical biomarkers and preventive or curative therapies provides new opportunities 
for value creation, offers the potential to change well-established clinical practices for physician 
and to strengthen the value proposition to pricing and reimbursement authorities.3  
 
At the same time, the SM approach is disrupting and confounding many standard models of 
R&D, forcing many stakeholders involved in the development, acceptance and uptake of SM 
to grapple with new levels of uncertainty, costs and complexity associated with such 
technologies. Especially, regulatory and reimbursement processes show  ambiguity about the 
ultimate value of test information and challenges to determine the clinical and economic value 
of more complex stand-alone or companion diagnostics. For instance, third party payers in 
various healthcare systems have been rather resistant to paying for costly stratification 
diagnostics unless the diagnostic companies can demonstrate clinical utility and cost-
effectiveness without endangering the various health care budgets. In an era of cost containment 
and limited health care resources there is a clear need to consider opportunity cost of decisions 
about which healthcare interventions to use by demonstrating the potential added value a new 
SM technology brings to the healthcare system. However, assessment of the added value of SM 
interventions is complex and depends on many factors including the performance of the 
diagnostics, handling of uncertainties, gaps in the evidence supporting clinical utility and 
quality of medical management. The uptake of SM in healthcare depends much on appropriate 
value assessment methods and the economic viability of such approaches in the healthcare 
settings.    
Health economic research identifies measures and compares the costs and clinical outcomes of 
different treatment strategies. Economic evaluation is widely supporting decision makers in 
health services for allocation of scarce health care resources, and guidelines for evaluations 
have been developed in most Western countries.4 While in practice it is not always possible to 
62 
 
derive health economic information from scientifically sound prospective studies, often 
decision-analytic models will be used to provide the necessary cost-effectiveness information 
using various existing data sources (direct and indirect evidence) for clinical and economic 
information. Modelling studies based on decision analysis is a well-recognized method for 
analyzing the consequences of decisions that are made under uncertainty.5  
As decision-making for reimbursement and formulary access of health care interventions is 
often based on health economic data derived from modelling studies, it is vital to address 
specific modelling issues associated with SM interventions. In this paper we use Depression as 
an example to scrutinize the modelling approach with SM in particular.    
 
2. Stratified Medicine and Depression 
 
Stratified Medicine as opposed to empirical medicine is the practice of using biomarkers or 
diagnostic tests to guide the choice of therapeutic treatments. By identifying groups of patients 
who will benefit from treatments SM is a step towards personalized medicine, where the 
treatments will be completely tailored to the individual patient. The SM approach stratifies the 
patient population to responders and non-responders using a predictive diagnostic test and 
hence defines a cohort of patients that shows a differential therapeutic response for a certain 
treatment (e.g. KRAS/EGFR – Vectibix and Erbitux, predictive for efficacy). In other cases, 
SM tests have been developed to allow for a patient stratification based on the optimal dosing 
strategy for each group of patients (e.g. genetic test to determine the variants in individual 
patients used for many classes of drugs including the antidepressants) or as stand-alone tests 
(e.g. Oncotype DX) for diagnostic or prognostic purposes. This stratification of the population 
on the basis of diagnostic testing is intended to reduce the use of ineffective or unsafe drugs, 
which should translate into improved health outcomes for patients and more efficient use of 
health care resources.  
 
Applying SM technology for depression, there is a need to identify characteristics of individuals 
that reliably predict differences in benefits and / or adverse effects of alternative depression 
treatments. These personalizing factors might include socio-demographic characteristics, 
clinical characteristics (such as symptom patterns or comorbidities), and biological markers 
(such as neuroimaging and genetic variation).6 In depression, response to specific treatments 
varies widely among individuals. More than a half of all patients with major depression will 
fail to respond adequately to the first antidepressant they are prescribed.7 Multiple 
antidepressant medications have demonstrated efficacy for treatment of major depressive 
disorder (MDD) and selective serotonin reuptake inhibitors (SSRIs) have become first-line 
treatment in the treatment of depression partly because of their better tolerability and relative 
safety in overdose compared with older tricyclic antidepressants.8 However, at the same time, 
many patients do not reach remission with initial antidepressant treatment, with consequences 
including greater functional dysimpairment, greater likelihood of discontinuing treatment 
prematurely, and substantially increase medical costs associated with more chronic illness. 
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Accurate selection of the best initial treatment or an improved understanding and predicting of 
treatment variations could have great benefits for people living with depression.9  
 
Recent studies haves suggested that common genetic variations are associated with 
antidepressant response and the development of pharmacogenetic predictors and tests of 
treatment response has become an active area of investigation.[10,11] The cytochrome P450 
(CYP450) enzymes –primarily CYP2D6, CYP2C19, and CYP2C9 – are involved in the 
metabolism of all of the SSRIs and several tests are now available to test for CYP450 
polymorphisms. The FDA-approved AmpliChip CYP450 test can detect many CYP2D6 and 
CYP2C19 polymorphisms and predict in the form of “predicted phenotypes” if a patient will 
be a poor, intermediate, extensive or ultra-rapid metabolizer of these two polymorphisms. 
Although CYP450 tests appear to be sensitive (99%) and accurate (100% specificity), there is 
currently a lack of convincing evidence to prove clinical utility for these tests12 emphazing a 
paucity of good-quality data addressing the evidence regarding the association between 
CYP450 genotypes and SSRI metabolisms outcomes. However, research is on-going to 
determine how drug metabolizing enzyme genotyping systems such as the AmpliChip test can 
increase chances of identifying effective and /or more tolerable medications in depression to be 
useful in medical, personal or public health decision making. 
 
3. Health Economic Modelling in Stratified Medicine 
 
According to recent research[13-15] the existing modelling techniques are appropriate and can be 
applied for cost-effectiveness models in SM, given that special issues are taken into 
consideration. The inclusion of sensitivity/specificity and especially false negatives and false 
positives considerations, requires additional structural complexity in order to make the link 
between the test and the medication and the subsequent clinical and economic outcomes. 
Another issue is the paucity of data available to be used to populate an economic model, 
especially for stand-alone tests. Information on treatment patterns, its costs and outcomes, are 
often lacking, especially for false positive and false negative patients. There is a need to identify 
best practices for economic modelling including approaches which address these evidence gaps 
in a manner that is both acceptable to payers and feasible for test manufactures. This means 
also, that extrapolation methods are required in order to extrapolate the short-term 
sensitivity/specificity data to long-term health economic outcomes.  
 
Sensitivity analyses aim at providing information on the degree of uncertainty in economic 
evaluations and it is currently the most widely applied method of dealing with uncertainty in 
economic evaluations.16 Because of the more complex structure, lack of data, and extrapolation, 
the uncertainty level in the SM model is higher than in a comparable model for traditional 
pharmaceuticals. In addition, the accuracy and predictive value of the stand-alone test is often 
based on a small sample size leading to extra uncertainty, thus, extra sensitivity analyses are 
required for sensitivity/specificity and cost of the test. Thus, in SM, there are more gaps in 
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information and the number of possible assumptions increases with the number of parameters 
added which may cause interpretation problems. A practical way to overcome this problem is 
the use of scenarios, in which several factors are set to reflect a specific situation, such as the 
best-case and worst-case scenarios.17 Hence, for the SM approach, scenario analyses may be 
more important than sensitivity analyses, especially when considering test characteristics and 
potential evidence gaps, because these are rather structural model assumptions and issues on 
the quality of the data than the distribution of the variable. Specific scenario analyses in SM, 
which are not relevant in traditional pharmaceuticals, may be required for a range of estimates 
in turn, but it may also be possible to perform a “multi-scenario” analysis, where the effect of 




4.1 Model Description 
A SM model was constructed using decision analytical techniques to perform a 
cost/effectiveness (C/E) analysis for a cohort of depressive patients using diagnostic testing. 
The SM model (Figure 1) is based on a previously described cost-effectiveness study in The 
Netherlands (Nuijten et al 2012)18 which evaluated the cost and the effectiveness of 
escitalopram compared with venlafaxine and citalopram. To illustrate the specific modelling 
issues associated with combining a test element to a specific antidepressant treatment here, the 
C/E model from The Netherlands (“standard C/E study”) is used and applied to the economic 
outcomes of a SM intervention as a relevant treatment choice. The specific antidepressant with 
a testing element is citalopram for purpose of illustration. 
The primary perspective of the standard C/E study was that of the society in The Netherlands 
in 2010. A secondary perspective was that of the health insurance. The data sources (Table 1) 
included published literature, clinical trials, official price/tariff lists and national population 
statistics. A Delphi panel was performed in order to collect data on resource utilization. The 
total time horizon of the model was 6.5 months, which includes the initial acute phase of 
treatment (8 weeks) followed by continuation treatment (18 weeks) after remission. In this 
model, patients initiate antidepressant therapy either with 10 mg escitalopram or 75 mg 
venlafaxine or 20 mg citalopram. During the second month of treatment, an adjustment in 
dosage may be required. Titration to escitalopram 20 mg, venlafaxine 150 mg and citalopram 
40 mg are then proposed. After 8 weeks of treatment, patients may achieve a remission or not. 
After remission, patients are supposed to be maintained under the same medication over the 
remaining 18 weeks and a proportion of the patients will experience a relapse. In case of non-
remission, after 8 weeks a change in therapeutic management is applied, either by switching to 
another medication, stopping prematurely the current medication or raising dosage of the initial 





The effectiveness outcome for the standard C/E model has been defined as quality-adjusted life-
year (QALYs); the economic outcomes were the direct medical costs and costs due to lost 
productivity. Discounting was not applied because the time horizon of the model was shorter 
than 1 year. The costs were incorporated in the model by means of treatment costs of depression 
and treatment costs of adverse events as well as the costs for consultations and laboratory tests. 
Indirect costs due to lost productivity were also included using the Friction method according 
to the Dutch health economic guidelines.  
 
4.2 Model adjustments for stratified medicine 
In this section, only the adjustments for the incorporation of a model for a stratified medicine 
are described; the remainder of the model design is similar. Figure 1 shows the structure of the 
model after the adaptation to stratified medicine. The new model includes 1) the stratification 
of patients into poor, normal and rapid metabolizers, and 2) the diagnostic test with sensitivity 
and specificity. There are various scenarios to use stratified medicine in the treatment 
guidelines, which will be explored using the model (note: to be defined later in this paper).  
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Figure 1: Model for depression after adaptation to stratified medicine. 
 
 
4.3 Treatment pathways based on stratified medicine 
The SM model starts with a diagnostic test for cytochrome P450 (CYP450) in order to assess 
if a patient is a poor metabolizer (PM), a normal metabolizer (NM), or an ultra metabolizer 
(UM) for citalopram. The model starts with the actual distribution of PM, NM and UM 
according to data from the literature. The subsequent structure of the model depends on the 
sensitivity and specificity of the diagnostic test and the treatment based on the outcomes of the 


























































































































The diagnostic test will classify true PM patients in: 
 True positive PM or false negative PM. The assumption is that treatment of a false 
negative PM corresponds with treatment of a NM, and not a UM.  
The diagnostic test will classify true NM patients in: 
 True positive NM or false negative NM. The assumption is that treatment of a false 
negative NM corresponds with either treatment of a PM or treatment of a UM.  
The diagnostic test will classify true UM patients in: 
 True positive UM or false negative UM. The assumption is that treatment of a false 
negative UM corresponds only with treatment of a NM, and not treatment of a PM.  
 
The following treatments are recommended based on the outcomes of the test:  
 PM patients: Use citalopram at half a lower dose. 
 NM patients: Use citalopram antidepressant at normal dose. 
 UM patients: Use citalopram at higher dose. 
 
The interest of the dose adjustment is that lowering dose may lead to lower drug costs with 
similar efficacy in PM, which may be balanced by higher drug costs because of higher dosage 
in UM. The initial lower dosing in PM will lead to lower discontinuation due to adverse events 
leading to a reduction on cost of treatment failure and consequently also a higher effectiveness 
and Quality of life. 
The initial higher dosing in UM will lead to a higher efficacy and a more rapid onset of response 
resulting in a reduction on cost of treatment failure and consequently also a higher effectiveness 
and Quality of life. The UM will have lower probability of discontinuation due to adverse 
events. 
 
4.4 Data sources 
 -  Probabilities  
The probabilities, which drive the difference in the health economic model are the probabilities 
related to efficacy and adverse events (AE). The assumption is that all probabilities (efficacy, 
adverse events) as well as treatment patterns are similar for subsequent line of therapy. As 
registration is based primarily on efficacy, the probabilities related to efficacy, are the most 
important drivers of the health economic model.  
The inclusion of incidence of adverse events is relevant because of the associated costs, the 
associated disutility and the impact on treatment patterns, e.g. switching.  
 
 -  Resource utilization 
The resource utilization in the SM model may be similar to the standard C/E model, except for 
the initial test and its following treatments. In case, when also reduction or increase of AE is 
expected, the resource utilization has been an adjusted based on a difference incidence of AE 





 -  Utilities 
The utilities in the SM model may be similar to the standard C/E model. However, when a 
reduction or increase of AE is expected, the related disutilities have been adjusted based on a 
difference incidence of AE and a corresponding change in disutilities. 
 
Table 1: Data for model (source Nuijten et al. 2012) 
Variable†   
Clinical probabilities and utilities Probability Utility 
Remission  35.92% 0.52 






diarrhoea 8.80% -0.044 
dry mouth 6.21% -0.085 
ejaculation disorder* 4.4% -0.049 
fatigue 3.30% -0.085 
headache 14.76% -0.115 
impotence 0.82% -0.049 
insomnia 7.25% -0.129 
nausea 12.47% -0.065 
somnolence 3.75% -0.085 
   
Treatment after  
no remission 
  
- stop 11.7% 0.47 
- switch 56.4% 0.52 
- increase dose 31.9% 0.48 
   
Economic data Unit price Dose 
Citalopram  € 0.0380 20 mg 
 
€ 0.0760 40 mg 
Consultation tariff - GP € 22.15  
Consultation tariff – psychiatrist € 96.50  
Hospital per diem  € 274.14  
Indirect costs       € 44.80 (per hour)  
 
4.5 Model assumptions and input 
 - Distribution 
Rau19 provided the following distribution.  
 PM: 29% 
 UM: 7%  




We consider in this model extensive metabolizers (EMs), and ultra-rapid metabolizers (UMs) 
as one category.  
 
 - Diagnostic test: Price, sensitivity and specificity 
The price of diagnostic test is assumed to be €300. The same study by Rau reports a sensitivity 
and specificity in the range of 94 to 100%. The base case is based on 94%, and sensitivity 
analysis is based on a range from 80 to 100%. 
 - Assumptions 
The patients are stratified in order to predict the subsequent treatment pathway following the 




The subsequent treatment pathways following the outcome of a diagnostic test are described 
below, which is based on dose adjustment and its subsequent outcomes, which depend on the 
sensitivity and specificity of the test. 
1) PM: 
 True positive PM:  
o Low dose citalopram is prescribed and therefore there is a lower probability 
(10%) of no response due to discontinuation due to adverse events. 
o Cost of adverse events is excluded.  
o Disutility of adverse events is excluded. 
 False negative PM - (patient is perceived as NM by physician and treated with normal 
dose citalopram):  
o There is a higher probability (10%) of no response due to discontinuation due to 
adverse events. 
o Cost of adverse events is included.  
o Disutility of adverse events is included. 
2) NM: 
 True NM: there is a normal probability of response. 
o Cost of adverse events is included.  
o Disutility of adverse events is included. 
 False NM - (patient is perceived as PM by physician and treated with lower dose 
citalopram):  
o Low dose citalopram: there is a higher probability (10%) of no response due to 
lack of efficacy. 
o Cost of adverse events is excluded.  
o Disutility of adverse events is excluded. 
 False NM - (patient is perceived as UM by physician and treated with high dose 
citalopram):  
o High dose citalopram: there is a higher probability of no response (10%) due to 
discontinuation due to adverse events. 
o Cost of adverse events is included.  







 True positive UM:  
o High dose citalopram is prescribed and therefore there is a lower probability of 
no response (10%) due to lack of efficacy. 
o Cost of adverse events is included.  
o Disutility of adverse events is included. 
 
 False negative UM - (patient is perceived as NM by physician and treated with normal 
dose citalopram):  
o There is a higher probability of no response (10%) due to lack of efficacy. 
o Cost of adverse events is excluded.  




5.1 Base case analysis 
The base case analysis indicates that the medical costs for the SM approach over a period 6.5 
months were €878 per patient, including €300 for the test, compared with €627 per patient for 
standard treatment (Table 2). The SM approach reduces the medical costs from €627 to €578, 
but these cost savings do not balance the additional cost of the test (payer perspective). The 
base case analysis shows that the total costs for the standard treatment over a period 6.5 months 
are €19,313 per patient, compared with €18,756 per patient for SM approach (Table 2), which 
leads to cost savings of €557. This means that the additional cost for the test is more than 
balanced, when all costs are included (society perspective). The SM approach resulted in 0.315 
QALYs compared with 0.307 QALYs for standard treatment. Subsequently, the SM approach 
costs €31,772 per QALY gained relative to standard treatment from the payer perspective. The 
SM approach is dominant for the society perspective, which means that the SM approach leads 
to a gain in effectiveness (QALYs) with no additional costs.  
 
Table 2: Results – base case analysis 
 Costs  QALYs ICER  
 Medical 
costs 
Total costs  Medical 
costs 
Total costs 
no SM  €627   €19,313  0.307   
SM  €878   €18,756  0.315   
difference  €251   -€557 0.008 €31,772 SM dominant 
 
5.2 Sensitivity analyses 
The sensitivity of the base-case results to a range of uncertain values of key parameters was 
measured (Table 3). The sensitivity and specificity of the test were varied from 80% to 100%. 
The other input variables of the model were varied plus and minus 20%.  
The sensitivity analyses showed that the model was most sensitive to: test sensitivity, 
improvement in remission resulting from SM, remission for standard treatment, costs due to 
switching (Table 3 and Tornado diagram in Figure 2 from a payers’ perspective). 
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   change vs. 
     base case   
 change vs.     
base case 
sensitivity        
min €249  -€747 0.007 €35,571 12.0% -€106,714 53.3% 
max €252  -€368 0.009 €28,000 11.9% -€40,889 41.3% 
specificity        
min €250  -€544 0.008 €31,250 1.6% -€68,000 2.3% 
max €251  -€572 0.008 €31,375 1.2% -€71,500 2.7% 
frequency PM        
min €257  -€551 0.008 €32,125 1.1% -€68,875 1.1% 
max €245  -€563 0.008 €30,625 3.6% -€70,375 1.1% 
frequency UM         
min €250  -€558 0.008 €32,692 2.9% -€69,890 0.4% 
max - 0.71 €250  -€558 0.008 €32,089 10% -€69,032 0.9% 
relapse         
min €251  -€564 0.008 €30,679 3.4% -€70,500 1.3% 
max €251  -€551 0.008 €33,571 5.7% -€68,875 1.1% 
improvement response       
min €268  €593  -0.002 -€134,000 -521.8% -€296,500 325.9% 
max €234  -€1,707 0.017 €13,765 56.7% -€100,412 44.2% 
disimprovement response       
min €254  -€431 0.006 €42,333 33.2% -€71,833 3.2% 
max €248  -€683 0.009 €27,556 13.3% -€75,889 9.0% 
remission        
min €253  -€392 0.007 €36,143 13.8% -€56,000 19.6% 
max €249  -€721 0.009 €27,667 12.9% -€80,111 15.1% 
switching        
min €252  -€557 0.008 €32,215 1.0% -€69,832 0.3% 
max €251  -€557 0.008 €32,089 1.0% -€69,527 0.1% 
stop        
min €251  -€557 0.008 €35,655 1.2% -€69,625 0.0% 
max €251  -€557 0.009 €27,889 12.2% -€61,889 11.1% 
cost-hospitalization        
min €252  -€556 0.008 €31,500 0.9% -€69,500 0.2% 
max €250  -€558 0.008 €31,250 1.6% -€69,750 0.2% 
cost due to stop        
min €251  -€534 0.008 €32,089 1.2% -€66,750 4.1% 
max €251  -€580 0.008 €31,375 1.2% -€72,500 4.1% 
cost due to switch        
min €252  -€445 0.008 €32,294 0.9% -€55,625 20.1% 
max €249  -€668 0.008 €31,125 1.4% -€83,500 19.9% 
cost due to failure        
min €251  -€566 0.008 €32,170 1.2% -€70,750 1.6% 












5.3 Scenario analyses 
While a sensitivity analysis is based on the modification of the basic clinical and economic 
estimates of input variables over a plausible range of values to judge the effect on study results 
of alternative assumptions, a scenario analysis is based on the modification of the underlying 
structural assumptions strategies of the model. Therefore we have performed various scenario 
analyses by changing the assumptions of the model. A number of scenarios were developed 
reflecting different approaches to those in the base-case analysis (e.g. different assumptions). 
The results of the scenario analyses are reported in Table 4. These results confirm the results of 
the sensitivity analysis. The improvement in true positive patients has a high impact on the 
outcomes of the model, if we assume that all of the patients are accurately diagnosed as PM, 
NM, or UM and subsequently obtain the appropriate dosing. 
The scenario analyses show that the 1-line drug cost and cost of treatment failure also have a 
high impact on the outcomes of the model. The high impact of drug costs results from the 
continuation of treatment after remission. 
Finally, the cost of the test has high impact on the outcomes, and may be a key driver in the 

































      
change vs. 




in true positive 
patients €132 -€8,992 0.074 €1,784 -€121,514 94.4% 74.5% 
freq PM = 
100% €171 -€677 0.011 €15,545 -€61,545 51.1% 11.6% 
freq NM = 
100% €282 -€526 0.007 €40,286 -€75,143 26.8% 7.9% 
freq UM = 
100% €284 -€525 0.007 €40,571 -€75,000 27.7% 7.7% 
cost-
hospitalization:  
€ 1,000 €203 -€605 0.008 €25,375 -€75,625 20.1% 8.6% 
cost AE: €1000 €110 -€698 0.008 €13,750 -€87,250 56.7% 25.3% 
drug costs 
€20,000/year €1,760 €952 0.008 €220,000 €119,000 592.4% 270.9% 
cost failure: 10 
times higher* €163 -€645 0.008 €20,375 -€80,625 35.9% 15.8% 
cost failure: 
100 times 
higher* -€719 -€1,527 0.008 -€89,875 -€190,875 382.9% 174.1% 
cost failure : 
1,000 times 
higher* -€9,540 -€10,348 0.008 -€1,192,500 -€1,293,500 3853.3% 1757.8% 
Test: € 1,000 €751 -€57 0.008 €93,875 -€7,125 195.5% 89.8% 





The assessment of the added value of SM interventions is complex and depends on many factors 
including the performance of the diagnostic test, handling of uncertainties and gaps in the 
evidence supporting clinical utility. In this paper we used depression as an example to scrutinize 
the modelling approach with SM in particular. The results show that the SM approach reduces 
the medical costs, although these cost savings do not balance the additional cost of the test 
considering a payer perspective. However, there is a cost saving, when the indirect costs are 
included. The SM approach costs €31,772 per QALY gained relative to standard treatment from 
the payer perspective. The SM approach is dominant compared with standard treatment from 
the society perspective. 
 
From a methodological point of view, the societal perspective may be preferred over the 
national third party payer perspective, especially for SM, which requires a more holistic and 
long-term approach than for traditional pharmaceuticals in order to realize the full clinical and 
health economic benefits of SM interventions. Because of silo mentality in many health care 
systems, national authorities may need to develop a central financial system specifically applied 
for SM interventions. However, as long the current reimbursement systems do not capture this 
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holistic approach for SM, the payer perspective may be more relevant at this moment. Although 
a cost per QALY of €31,772 is within the range of between €20,000 and €80,000 per QALY, 
as used in The Netherlands, payers may consider it too high, especially when considering the 
budget impact of the additional test. The annual incidence in men is 5/1,000 in women 8/1,000, 
which leads to average incidence of 7.5/1000 20. In The Netherlands (16.77 million people) this 
corresponds with 125,775 patients with episode of depression leading to extra cost of €37.7 
million for the test. This means, as long as there is silo mentality in the system, the budget 
impact consequences for the test will substantially slow down the implementation of SM.  
 
The correct reporting of sensitivity/specificity and especially false negative and false positive 
considerations of the diagnostic test requires additional scenario and structural sensitivity 
analyses to establish the relationship between test result and the consequent treatment changes 
and outcomes. These considerations lead to higher degree of uncertainty in health economic 
models for SM compared with traditional ones. To some extent, these problems can be 
overcome by performing scenario analysis based on the modification of the underlying 
assumptions or data sources of the model. The scenario analysis for our example showed that 
cost of treatment failure is an important driver for cost-effective use of SM. Other key variables 
are sensitivity of the test, cost of the test, and clinical improvement resulting from appropriate 
diagnosis by the test. In addition, the scenario analysis confirms the results of the sensitivity 
analysis. Perlis et al. (2009) performed a cost-utility study based on data from the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) trial. Costs and QALYs were 
compared for sequential antidepressant trials, with and without guidance from a 
pharmacogenetic test (5-HT2A polymorphism) for differential response to SSRIs. This US 
study found an incremental effectiveness ratio (ICER) of $US93,500  per QALY gained (with 
test cost of $500) and outlined that the cost of the test itself as well as the test performance 
(sensitivity/specificity) had a large effect on cost-effectiveness.21 This study confirms our 
findings that the use of SM in depression may be questioned from a health economic 
perspective, as the ICERs are quite high. 
 
Some guidelines recommend the use of probabilistic sensitivity analysis (PSA). This type of 
sensitivity analysis is characterized by the use of probability distribution for the included 
parameters, as an alternative for a predetermined uncertainty range. The results of a PSA are 
presented in a cost-effectiveness acceptability curve. However, the results of a PSA should be 
considered with more prudence in the SM case than with traditional pharmaceuticals, because 
there is more uncertainty which can’t be quantified into a distribution. Gaps in information and 
subsequent assumptions cannot be captured by a statistical distribution and therefore this type 
of uncertainty cannot be included in a PSA. As a consequence, the PSA would underestimate 
the true uncertainty. Therefore, mainly scenario analyses in addition to the standard one-way 
sensitivity analyses were used in order to test the structural uncertainty resulting from the 
inclusion of SM elements in the model. Furthermore, it could be argued, that PSA analyses may 




The SM model described here for depression to scrutinize the modelling approach with SM has 
certain limitations. The current SM model is based on one type pharmacogenetic (PG) test (e.g. 
cytochrome P450 / CYP2D6) in order to avoid unnecessary complexity to illustrate the main 
issues in health economic modelling in SM. Future PG tests for antidepressant response will 
almost certainly incorporate multiple markers drawn from genome-wide associated studies, but 
the basic principle of our model can be applied regardless of the type or scale, or number of the 





Existing modelling techniques are appropriate and can be applied for C/E model in SM given 
that specific issues are taken into considerations. These issues comprise considerations on the 
study perspective, uncertainties related to evidence gaps of diagnostic testing, appropriate 
modelling structure and the scope of sensitivity analyses. The inclusion of sensitivity/specificity 
and especially false negatives and false positives of test results requires additional structural 
complexity in order to make the link between the test and the medication. 
 
In case of depression, the lack of biomarkers or clinically validated diagnostic tests makes it 
difficult for the decision maker to predict antidepressant efficacy and to make appropriate drug 
selection. However, the availability of genotyping tests concerning genetic control of drug 
metabolism and associated toxicity will aid the decision maker (e.g. GP) in selection of a safe 
antidepressant for a patient, and in minimizing factors that may influence patient’s 
compliance.22 Hence, the main impact of CYP450 testing is likely to be in reducing the time to 
find the optimal SSRI (dose optimization) based on genetic information, thereby potentially 
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Background: New techniques in assessing oocytes and embryo quality are currently explored 
to improve pregnancy and delivery rates per embryo transfer. While a better understanding of 
embryo quality could help optimize the existing "in vitro fertilization" (IVF) therapy schemes, 
it is essential to address the economic viability of such technologies in the healthcare setting. 
Methods: An Embryo-Dx economic model was constructed to assess the cost-effectiveness of 
3 different IVF strategies from a payer's perspective; it compares Embryo-Dx with single 
embryo transfer (SET) to elective single embryo transfer (eSET) and to double embryo transfer 
(DET) treatment practices. 
Results: The introduction of a new non-invasive embryo technology (Embryo-Dx) associated 
with a cost up to €460 is cost-effective compared to eSET and DET based on the cost per live 
birth. The model assumed that Embryo-Dx will improve ongoing pregnancy rate / realize an 
absolute improvement in live births of 9% in this case. 
Conclusions: This study shows that improved embryo diagnosis combined with SET may have 
the potential to reduce the cost per live birth per couple treated in IVF treatment practices. The 
results of this study are likely more sensitive to changes in the ongoing pregnancy rate and 
consequently the live birth rate than the diagnosis costs. The introduction of a validated 
Embryo-Dx technology will further support a move towards increased eSET procedures in IVF 
















1.  Introduction 
Increasing the efficiency of the “in vitro fertilization” (IVF) procedure by improving 
pregnancy/implantation rates and at the same time lowering (or avoiding) the risks of multiple 
gestations are the primary goals of the current assisted reproductive technology.1 These goals 
require a substantially improved gamete/embryo testing and selection procedure which cannot 
be achieved by the traditional evaluation method based on morphological assessment. New 
techniques in assessing oocytes and embryo quality are currently explored to improve 
pregnancy and delivery rates per embryo transfer. For instance, ´ Omics´ technologies, including 
transcriptomics, proteomics, and metabolomics have begun providing evidence that viable 
oocytes/embryos possess unique molecular profiles with potential biomarkers that can be used 
for the developmental and/or viability selection.2 Dynamic assessment of embryonic 
development by time-lapse imaging based on morphological grading as well as providing 
kinetic parameter presents another opportunity for optimizing embryo selection. A number of 
new non-invasive embryo viability diagnostic tests are under development to allow a rapid 
objective ranking of a patient’s cohort of embryos for transfer in order to improve clinical 
pregnancy and delivery rates per embryo transfer, thus encouraging greater uptake of single-
embryo transfer (SET).  
 
While a better understanding of embryo quality could help optimize the existing therapy 
schemes, it is essential to address economic viability of such technologies in the healthcare 
setting. As oocyte/embryo diagnostic (Embryo-Dx) procedures prepare to enter the market, 
health care decision makers (payers) will assess whether increases in efficacy (i.e. live births) 
are significant enough to justify the additional costs of the diagnostic procedure. If improved 
diagnostic success prevents patients from requiring additional fresh or frozen cycles it might be 
possible to realize a budget neutral scenario or potentially cost-savings. 
 
The objective of this study was to assess the clinical and economic outcomes associated with 
non-invasive embryo diagnostics (Embry-Dx) introduction into IVF standard treatment 
practices. For this purpose, the cost-effectiveness of different IVF strategies (with and without 
Embryo-Dx) has been compared from a payer’s perspective. 
 
 
2.  Value of non-invasive embryo technologies 
 
The current research on non-invasive oocytes and embryo technologies comprises both 
morphometric and biomarker assessments. Morphometric assessment is focused on the 
automatization and standardization of current morphological grading procedures; i.e. an 
incubator plus a camera providing time-lapse images of embryo. A dynamic assessment of 
embryonic development (cleavage kinetics) using automated time-lapse imaging systems may 
have the potential to improve oocytes/embryo selection.3 Biomarker assessment is trying to 
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identify predictive biomarkers of oocyte /embryo viability via gene expression profiling of 
cumulus cells surrounding the oocyte, and proteomic and metabolic approaches in embryo 
culture media using quantitative real-time Polymerase Chain Reaction (PCR)-based assays 
microarray technologies or mass spectrometry. The development of accurate and validated tests 
for embryo ranking including endometrial receptivity may significantly improve non-invasive 
embryo quality assessment. There are expectations with these new approaches to improve on-
going pregnancy rates between 5-15% (absolute increase) dependent on the methodology4, but 
all of the new approaches still need to prove clinical utility through prospective randomized 
clinical trials. Although, considerable challenges lay ahead as effective classification systems 
for ranking embryos continue to be developed, there is a clear need for a reliable and non-
invasive method of embryo selection to ensure that only embryos with the highest development 
potential are chosen for transfer thus reducing the need for multiple transfers and consequent 
risk of multiple births. This would support policies on elective single embryo transfer (eSET) 
in many countries (e.g. HEFAi policy in the UK). Elective single-embryo transfer has been 
proposed as a strategy to reduce the risk of multiple births, which are associated with increased 
maternal and neonatal complications as well as increased costs to the health service. However, 
such eSET policies can only be applied successfully in combination with high quality embryo 
selection and good cryopreservation programs.5 
 
While a better understanding of embryo quality could help optimize the existing therapy 
schemes, it is essential to address economic viability of such technologies in the healthcare 
setting. Given the current health care environment and limited health care resources there is a 
need to consider the opportunity cost of decisions and to evaluate efficacy and economic 
consequences of different IVF strategies with and without embryo diagnostics, and hence to 
assess Embryo-DX technology in the health economic context. Health economic evaluations 
are increasingly used to support policies on reimbursement and pricing for new innovative 
healthcare technology, as well as to evaluate and advise on its use in clinical practice.6 A health 
economic evaluation (e.g. cost-effectiveness analysis) is defined as a comparative analysis of 
both the cost and the health effects of two or more alternative health interventions.7 Such an 
analysis makes it possible to examine whether the money that would be invested in a new 
intervention for a particular condition would actually be used efficiently. The net costs can be 
balanced with the net health effects, often expressed in quality-adjusted life-years (QALYs) 











3.  Methodology 
3.1 Model design 
A decision analytical Markov model (Embryo-Dx model - see Figure 1) was constructed to 
assess the economic consequences of 3 different IVF strategies. The Embryo-Dx model:  
 
a) Compares Embryo-Dx with single embryo transfer (Embryo-Dx/SET) to eSET and to 
double embryo transfer (DET) treatment practices and 
b) Considers a maximum of one fresh and one frozen cycle in the comparison of the 
different strategies regarding their costs and life birth rates. 
 
The strategies were selected for clinical relevance. Elective single-embryo transfer has been 
proposed in many health care systems as a strategy to reduce the risk of multiple births, which 
are associated with increased maternal and neonatal complications as well as increased costs to 
the health service. For instance, in The Netherlands the current policy is to offer SET in good 
prognosis patients (i.e. young patients with a good quality embryos). On the other hand, the 
DET strategy of transferring two embryos into the uterus is still customary in the majority of 
women receiving IVF treatment, particularly in older women.9 
 
There have been many studies comparing the economic consequences of SET vs DET in various 
health care systems.[10-12] Also, several cost-effectiveness studies have shown that transferring 
one fresh embryo and then, if needed, using one frozen and thawed embryo may dramatically 
reduce the number of twin pregnancies while achieving similar cumulative pregnancy rates 
compared to DET in good prognosis patients.13 A cost-effectiveness study by Fiddelers et al14 
(2009) in The Netherlands compared seven embryo transfer strategies varying eSET, DET and 
standard treatment procedure. In this study clinical outcomes data came from a randomized 
clinical trial (RCT) performed at the University Hospital of Maastricht (Montfoort et al15) where 
308 couple were randomized between eSET and DET, irrespective of female age and embryo 
quality. The cost data were based on the Dutch healthcare system. The Embryo-DX model uses 
the same data sources in The Netherlands because it provided detailed data on cost and efficacy 
parameters including treatment costs in relation to treatment success, embryo fertilization, 
frozen cycles, embryo production and pregnancy rates as well as a broad range of multiple 
pregnancy and post –delivery cost. The results discussed here are broadly applicable to other 










Figure 1. Embryo-Dx model 
 
Embryo-DX technology  
Several technologies are currently being developed to improve embryo selection with the aim 
of improving live birth rates and reducing multiple pregnancy rates. For the purposes of the 
analysis described here we consider embryo diagnostic testing from a theoretical perspective. 
Therefore, the efficacy improvements discussed here are not based on any specific technology 
and are only used for purpose of illustration and clinical development. From an economic 
perspective we can assess the anticipated benefits with respect to the expected costs in order to 
inform decision-making.  
85 
 
3.2 Data Sources 
- Treatment assumptions and probabilities 
The following assumptions have been used in constructing the model: 
1. Patients with frozen embryos would progress to frozen embryo transfers in the second cycle. 
2. Embryo diagnostics testing would not be performed in patients with only 1 viable embryo. This 
represents approximately 9% of patients treated in The Netherland16 
3. The benefits of embryo diagnostics are only observed in fresh treatment cycles. For patients 
undergoing embryo diagnosis and progressing to frozen cycles, embryo diagnosis would have 
no observable benefit in frozen cycles.  
4. The cost of the embryo diagnostic procedure has been included as a fixed cost irrespective of 
the number of embryos retrieved and evaluated.  
5. With the introduction of Embryo-Dx it was assumed that DET transfer policy would not be 
used. This was based on expert advice that Embryo-Dx would minimize the need for DET 
because of the improved efficacy and the use of DET would further increase risk of multiple 
pregnancy.  
6. Improved efficacy was accounted for by adjusting the ongoing pregnancy rate. 
 
These assumptions have been developed in conjunction with IVF experts (see 
acknowledgements). The probabilities for pregnancy rates are outlined in Table 1.  
Table 1: Probabilities used as input for the Embryo-Dx model 
Clinical data                                                                                                     Source 
Pregnancy rates  
 
          after eSET (%)                                     21.4                         RCT data (n= 308) Maastricht (Montfoort et al 2006) 
          
          after DET  (%)                                     40.3                         RCT data (n= 308) Maastricht (Montfoort et al 2006) 
          
          after DxSET                                         33.4                                               Expert opinion 
 
For more clinical parameter see Fiddelers et al supplementary data; RCT: randomized controlled trial 
- Technical note to Embryo-Dx probabilities 
In the Embryo-Dx model the on-going pregnancy rate for eSET and DET was 21.4% and 
40.3%, respectively. Within the model we assumed that embryo diagnostics improved the 
ongoing pregnancy rate with SET, and that this ultimately resulted in improved live birth rates. 
There are several reasons why adjustments were made to the “ongoing pregnancy” rate and not 
to the probability of “live birth” directly. Firstly, adjusting the ongoing pregnancy rate ensures 
that all upstream costs in the model are accounted for. For instance, monitoring visits that occur 
during the ongoing pregnancy have to be considered appropriately. Secondly, because the 
model uses a series of probabilities, it is constrained by the numbers of people progressing 
through various stages of the model. If adjustments were made only to the end probability, it 
would be constrained by the number of people in earlier Markov stages. Therefore, much larger 
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increases to the end probability would have been required to achieve the improved efficacy 
associated with Embryo-Dx in the model.   
 - Costs included in model 
The cost analysis was performed from a payer perspective and included direct medical costs 
within the health care sector. The costs were determined empirically for each couple starting 
IVF cycle up to 6 weeks after birth. The Embryo-Dx model included the following cost 
variables in the analysis: Cost of IVF treatment (hormonal stimulation, oocyte pickup, 
Laboratory, embryo transfer), costs of a singleton and twin pregnancy (complicated and non-
complicated pregnancy), costs of delivery of a singleton and twin and costs of the period from 
birth until 6 weeks after birth, for the mothers as well as the children (see Table 2). All costs 
were based on data from the Netherlands and were converted to the index year of 2013 
according to the consumer price index (CPI, 2013).  
 
Table 2: Mean costs IVF cycle until four weeks after delivery for all 308 patients included 
in the study 
Markov cycle Resources included in model Costs per couple3 (€) 
mean 
IVF treatment cycle Medication 
Hospital care 
Ovum pick-up (OPU) 
Laboratory 
Embryo transfer 
Hospital admission/Others (GP’s) 
          1570 
            325 
            586 
           1314 
             310 
             909     
Pregnancy singleton  
(5-40 weeks) 
Complications  
Hospital costs: consults, ultrasound 
No Complications 
Hospital costs: consults, ultrasound / Others 
 
           4605 
 
 
           1522 
Pregnancy twin  
(5-40 weeks) 
Complications  
Hospital costs: consults, ultrasound 
No Complications 
Hospital costs: consults, ultrasound / Others 
 
           4605 
 
 
           2062 
Delivery singleton up to 6 weeks post 
delivery 
Hospital admission and delivery 
Singleton complication costs 
Other health care costs 
         
         12438 
Delivery twin up to 6 weeks post 
delivery 
Hospital admission 
Twin complication costs 
Other health care costs 
 
         41844 
 
 - Base Case 
The model reflects a base set of assumptions for costs and efficacy associated with introducing 
embryo diagnosis into treatment practices. The base assumption on efficacy is an ongoing 
pregnancy rate of 33.4% with Embryo-Dx. This translates into an approximate 9% 
improvement in the live birth rate with Embryo-Dx. The cost of the Embryo-Dx included in the 
model was €400 per test regardless of the number of embryos that were harvested.  
                                                     
3Cost per couple = unit price * volumes of use 
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3.3 Model output 
The model estimates several parameters useful for medical decision-making. 
Firstly, the model generates the cost per couple treated. This does not include only the costs of 
fertility treatment, but also costs associated with the proportion of people with a live birth, costs 
of multiples, and associated medical costs up to 6 weeks post-delivery. It was necessary to 
incorporate a range of costs in order to reflect the advantages of embryo diagnostics on cost 
savings associated with multiple pregnancies. Therefore, the cost per couple does not reflect 
the cost per cycle as typically described in the literature.  
 
Secondly, the model calculates live birth rates based on one fresh IVF cycle and the cumulative 
live births following a second frozen cycle. The number of cycles was limited to one fresh and 
one frozen because of uncertainty regarding how embryo diagnosis would impact on treatment 
success beyond the first cycle. 
Thirdly, the model generates the “cost per live birth” and “incremental cost-effectiveness ratio 
(ICER)” for the three interventions compared. The ICER is the extra cost for a gain in one extra 
live birth, when two treatments are compared. The cost per live birth and the ICER are common 
metrics in cost-effectiveness studies in assisted reproductive technologies (ART) and are 
familiar to paying audiences.  
4.  Results 
For the base case the cost and live birth rates after a single fresh cycle followed consecutively 
by one frozen cycle for eSET, DET and Embry-Dx SET are described in the Table 3 below. 
The cost per live birth for Embryo-Dx SET is the lowest compared to the other strategies. The 
improved live birth rate with Embrxo-Dx is still lower than the success rates achieved with 
DET after two cycles. The cost of a new Embryo-Dx explored in the base example was €400. 
The ICER of Embryo-Dx SET compared to eSET versus DET compared to eSET is lower 
(€15,439 versus €25,509). The ICER for DET versus Embryo-Dx SET is €52,674.  
Table 3: Cumulative costs and live birth rates for one fresh and one frozen cycle transferring  
              SET, DET and Embryo-Dx SET (Base case) 
Strategy Cost†  Incremental Cost Live 
births 









eSET €14,896 - 0.314 €47,439   
Embryo-Dx SET €16,687 €1,791 0.43 €38,807 €15,439  
DET €18,952 €2,265 
€4,056‡ 
0.473 €40,068 €25,509 €52,674 
‡ Based on cost comparison with eSET 
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4.1 Sensitivity analyses 
Appropriate sensitivity analyses were performed to test how sensitive the results were to 
changes in model parameter values for costs and clinical probabilities. A sensitivity analysis is 
based on the modification of the basic clinical and economic estimates of input variables over 
a plausible range of values to judge the effect on study results of alternative assumptions for 
the range of potential values for uncertain variables. Sensitivity analyses have been performed 
for both the cost per live birth and the ICER. 
4.1.1 Embryo-Dx success sensitivity analysis 
As the benefit of embryo diagnostics are only observed in fresh treatment cycles the variation 
in costs and live birth rates are only assessed here for 1 fresh cycle of IVF. Transitions in the 
cost per live birth based on variations in the live birth rates with Embryo-Dx are illustrated in 
Figure 2. In this analysis the live birth rate is increased for Embryo-Dx SET patients while live 
birth rates for eSET and DET are held constant. When the ongoing pregnancy rate for Embryo-
Dx is between 0.210 – 0.225 this is the least cost-effective option. However, when the ongoing 
pregnancy rate for Embryo-Dx is between 0.23 – 0.33 this option is more cost-effective than 
eSET. When the ongoing pregnancy rate reaches 0.335 Embryo-Dx becomes more cost-
effective than DET (point where red line crosses green line).  
Figure 2. Variation in embryo diagnosis on cost per live birth  
 
4.1.2 Embryo-Dx cost sensitivity analysis 
Because price is an important component that influences reimbursement, a sensitivity analysis 
was conducted based on variations in the acquisition cost for a new Embryo-Dx. In this analysis 
the purchase price was varied from €200 - €600 while the base assumption for improved 
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ongoing pregnancy rate with Embryo-Dx was held constant at 33.4% as the price of the test 
was varied.  
The analysis shows that at a price of €200 - €460 the Embryo-Dx results in the lowest cost per 
live birth compared to eSET and DET. From €480 - €600 the cost per live birth with Embryo-
Dx SET is lower than eSET, and slightly higher than DET (Figure 3).  
Figure 3. Variation in cost of Embryo-Dx on cost per live birth 
 
In addition, we conducted extensive one-way sensitivity analyses on the ICER for key input 
parameters, which may have an impact on the outcome of the cost-effectiveness analysis when 
analysis is performed for 2 cycles. The variation of the values was based on plus and minus 
20% of the base case value. The sensitivity analyses (Table 4) show that pregnancy rate to DET, 
is most sensitivity clinical parameter with ICER ranging from €35,438 to €22,235 for 
comparison between DET versus eSET. The cost for embryo transfer is most sensitive 
economic parameter with ICER ranging from €50,314 to €54,736 for comparison DET versus 
Diagnostic eSET. 
The cost for diagnostic tests is not a very sensitive economic parameter with ICER ranging 
from €54,596 to €50,454 for comparison DET versus Diagnostic eSET. 
The results of the sensitivity analyses show that the outcomes of the model are robust to the 
uncertainty in the input parameters of the model. Therefore the concept, which has been 
presented, is not affected by huge uncertainty of the underlying model, and therefore the model 
suits for the purpose of illustration of the concept. 
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Table 4:  Sensitivity- Analysis 
Clinical probabilities Range     
p_Pregnancy_cSET (mean:0.091) Input value   ICER difference 
Diagnostic_eSET versus eSET 0.073 0.109 € 15,481 € 15,473 €8 
DET versus Diagnostic eSET   € 52,447 € 52,603 €156 
DET versus eSET    € 25,553 € 25,465 €88 
  
  
p_Pregnancy_DET (mean:0.406) Input value   ICER difference 
Diagnostic_eSET versus eSET 0.323 0.4843 € 15,477 € 15,477 €0 
DET versus Diagnostic eSET   Dominated** € 28,826  > € 28,826 
DET versus eSET   € 35,438 € 22,235 €13,202 
 
p_Pregnancy_eSET (mean:0.214) Input value   ICER difference 
Diagnostic_eSET versus eSET 0.1714 0.2572 € 17,995 € 20,750 €2,755 
DET versus Diagnostic eSET   € 39,559 € 39,559 €0 
DET versus eSET   € 24,256 € 29,352 €5,096 
 
Costs      
c_diagnostic tests (mean: €400) Input value   ICER difference Input value 
Diagnostic_eSET versus eSET 320 480 € 14,705 € 16,249 €1,544 
DET versus Diagnostic eSET   € 54,596 € 50,454 € 4,142 
DET versus eSET   € 25,509 € 25,509 €0 
 
c_IVF_Medication (mean: €1570) Input value   ICER difference 
Diagnostic_eSET versus eSET  €1,256   €1,884  € 15,705 € 15,249 €456 
DET versus Diagnostic eSET   € 52,966 € 52,085 €881 
DET versus eSET   € 25,792 € 25,220 €572 
       
c_IVF_HospCare (mean: €325) Input value   ICER difference 
Diagnostic_eSET versus eSET  €260   €390  € 15,524 € 15,430 €94 
DET versus Diagnostic eSET   € 52,616 € 52,434 €182 
DET versus eSET   € 25,566 € 25,447 €119 
      
c_IVF_Laboratory (mean:€1314) Input value   ICER difference 
Diagnostic_eSET versus eSET  €1,051   €1,577  € 15,596 € 15,358 €238 
DET versus Diagnostic eSET   € 52,328 € 52,723 €395 
DET versus eSET      € 25,541 € 25,478 €63 
      
c_IVF_EmbryoTransfer (mean:310) Input value   ICER difference 
Diagnostic_eSET versus eSET  €248   €372  € 15,522 € 15,432 €90 
DET versus Diagnostic eSET    € 50,314 € 54,736 €4,422 
DET versus eSET    € 24,943 € 26,075 €1,132 
      
*Range: probabilities: plus/minus 20% but between 0 and 1. 




5.  Discussion 
New techniques in assessing oocytes and embryo quality are currently explored to improve 
clinical pregnancy and delivery rates per embryo transfer. The identification of high-quality 
oocytes and embryos using objective non-invasive technologies could help optimize existing 
IVF therapy schemes, thus encouraging greater uptake of single-embryo transfer. However, 
translating new innovative techniques (both morphometric and biomarker assessments) into 
clinical practice awaits evidence of their clinical utility. Good - quality studies of these 
techniques are needed and results need to be validated in clinical settings to determine their 
potential clinical and economic application. In addition, successful embryo implantation will 
require endometrial receptivity and an adequate bi-directional communication between the 
blastocyst and endometrium.17  
The Embryo-Dx model showed that under a set of base assumptions the introduction of 
Embryo-Dx exam into IVF is cost-effective compared to eSET. Based on a price of €400 per 
embryo diagnosis, the cost per live birth for Embryo-Dx is the lowest (€38,807) compared to 
eSET and DET. The ICER of Embryo-Dx SET compared to eSET is €15,439 for an extra live 
birth. DET is more effective but also more costly compared to Embryo-Dx with an ICER around 
€52,000 for an extra live birth. This situation may be different if long-term cost aspects by 
avoiding of high cost multiple pregnancies triggered by DET will be considered from a broader 
societal perspective. However, it depends on payers´ willingness to pay whether such new 
technologies will be applied in clinical practice. Although no agreement exists on an appropriate 
ceiling ration for one extra live birth, as opposed to the ceilings ratio for a QALY, a ceiling 
ration of about €15,000 (vs eSET) for Embryo-Dx testing in this study seems low. Also, assisted 
reproductive treatments present difficulties for the QALY approach, as the main outcome of an 
IVF treatment is a live birth. While QALYs are intended to capture improvements in health 
among patients, they are not appropriate for placing a value on additional lives which is the 
intended purpose of assisted reproduction.18 Furthermore, a comprehensive economic value 
assessment of new technologies may also require a budget impact analysis (BIA) to estimate 
the impact of the new intervention on short- or longer-term annual healthcare budgets. 
Especially local budget holders are interested to evaluate the economic impact of using such 
new diagnostic testing with focus on budget impact to ensure getting sufficient value and cost 
offsets.  
Decision making between SET and DET depends not only on ongoing pregnancy rates and twin 
pregnancy rates, but also on several other factors such as age (prognostic indicator), patients´ 
preference and the health care system in a particular country.19 For instance, the extent of 
reimbursement/coverage of the cost of new technologies will influence the acceptance of 
Embryo-Dx in many markets. Current diagnostic reimbursement policies in the US and many 
EU countries do not necessarily support the development of high-value molecular tests, as 
reimbursement of these tests has typically been based on cost, not on value (or potential) 
value.20 Funding is restricted to hospital/clinical budget and third party payers in these markets 
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are not willing to cover higher priced molecular diagnostics outside the standard procedures 
/DRG´s (diagnostic related groups). Often, flexible innovative payment approaches outside 
existing reimbursement schemes are needed to realize the benefits of these technologies on a 
case-by case basis. 
The economic model presented in this analysis has some limitations. First, with respect to the 
scope of the Embryo-DX model the cost-effectiveness analysis only covers short-term (1-year) 
cost and health outcomes from a payers´ perspective not including the long-term costs 
associated with children born as a result of a multiple pregnancy. Currently, an on-going 
TwinSing study (Maastricht University Medical Centre) 21 is investigating the long-term costs 
and outcomes of IVF singletons and twins and it may be interesting to apply such a long-term 
perspective to an Embryo-diagnosis model. Second, adding Embryo-Dx to current IVF 
treatment practice will increase complexity and complicates value assessment, including 
uncertainties about diagnostic characteristics (e.g. test performance) as well as gaps in the 
evidence supporting clinical utility.  
 
6.  Conclusion 
Within the limitations of this model, the results of this study show that improved embryo 
diagnosis will likely reduce the cost per live births per couple treated in IVF treatment practices, 
although this conclusion is price sensitive. The cost per live birth for Embryo-Dx is the lowest 
(€38,807) compared to eSET and DET, offsetting assumed diagnosis cost of €400 in this 
analysis and reflecting an improved cumulative delivery rate. The results of this study are likely 
more sensitive to changes in the ongoing pregnancy rate and consequently the live birth rate 
than the diagnosis costs. The introduction of a validated Embryo-Dx technology will further 
support a move towards increased eSET procedures in IVF clinical practice and vice versa. It 
also may trigger healthcare coverage and reimbursement policies addressing appropriate 
DRG’s and value-based diagnostics assessment for assisted reproductive technologies (ART). 
Finally, this assessment may outline pricing opportunities / limits for the industry to develop 
certain embryo diagnostic testing products for commercialization. 
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Rationale: Stratified Medicine (SM) is becoming a natural result of advances in biomedical 
science and a promising path for the innovation-based biopharmaceutical industry to create new 
investment opportunities. While the use of biomarkers to improve R&D efficiency and 
productivity is very much acknowledged by the industry, much work remains to be done to 
understand the drivers and conditions that favour using a stratified approach to create economic 
viable products and to justify the investment in SM interventions as a stratification option.  
Concept: In this paper we apply a decision analytical methodology to address the economic 
attractiveness of different SM development options in a cost-contained healthcare environment. 
For this purpose, a hypothetical business case in the oncology market has been developed 
considering 4 feasible scenarios. 
Conclusions: This article outlines key R&D-related and commercial-related value drivers 
which could explain a favourable economics for SM interventions under specific conditions. If 
regulatory and reimbursement challenges can be solved, decreasing development time and 
enhancing early market penetration would most directly improve the economic incentives 
facing SM developers. Offering a better targeted and hence ultimately more cost-effective 
therapy at reimbursable prices will facilitate time to market access and allow increasing market 

























1.  Introduction 
 
As advances in science give the rise to increasingly precise tools for the diagnosis and treatment 
of disease, Stratified Medicine (SM) becomes a natural result of biomedical science and a 
promising path for the innovation-based biopharmaceutical industry to create new investment 
opportunities.1 SM has the potential to improve medical outcomes for the patients and economic 
outcomes for the health care system. Matching therapies to specific patient subpopulations 
using clinical biomarker/ diagnostic-based SM offers the prospect to enhance patient care with 
more effective and safe drugs, delivered with a greater probability of treatment success.2 For 
the industry, the SM approach provides an opportunity to improve efficiency and productivity 
in the research and development (R&D) process and to demonstrate a differential therapeutic 
profile to be successful and rewarding in an increasingly competitive and cost-contained market 
environment. There have been several examples where SM has created clinical success and 
achieved accelerated product approvals, particularly in oncology (Glivec®, Herceptin®, 
Xalkori® and Zelboraf®) which triggered increased investments in biomarker-based R&D by 
the industry in the recent years.3 However, the implementation and adoption of targeted 
therapies has been slower than many proponents have hoped or predicted, indicating possible 
concerns from investors on the economic viability of such approaches.4                                      
                                                                                                                                                                                                                                                                                                                                                                                                                 
While the use of biomarkers to improve R&D efficiency and productivity is very much 
acknowledged by the industry, less is understood about the drivers and conditions that favour 
using a stratified approach to create economic viable products and to justify the investment in 
SM interventions as a stratification option. The commercial impact of using a diagnostic-guided 
strategy must be considered carefully in direct relation with patient access and benefits. 
Arguments over segmenting the market and hence, the loss of potential revenues will be 
weighed against possible accelerated market and patient access with increasing market share 
gains within the target sub-population or faster market adoption.5 Investigating and 
understanding of certain scenarios is critical for the industry as several factors throughout drug 
development, reimbursement and market adoption affect the potential clinical and economic 
success of a stratified medicine approach.  
The differential therapeutic profile of SM could allow for more economic viable applications 
by addressing numerous offsetting factors which will influence the investment decisions within 
the pharmaceutical and diagnostics industries. The objective of this paper is to explore these 
factors by developing a straightforward economic analysis for SM comparing different strategic 
options to help decision making for future R&D investments in an increasingly cost-contained 
healthcare environment. For this purpose, several case studies will be addressed. 
2.  Economic Viability of Stratified Medicine 
2.1 Pre-approval economic considerations 
There is anticipation that SM does not only provide better value for money thanks to improving 
drug effectiveness and reducing toxicity, but it could also help reducing R&D costs. Notably, 
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diagnostic testing may enhance the efficiency of clinical trials of new compounds and allow 
smaller and cheaper studies, still adequately statistically powered. This may occur, if diagnostic 
testing information can identify a subgroup of patients most likely to respond to a given 
treatment and early enough reduce clinical trials sizes so that the drug development process can 
indeed become more efficient. Smaller and possibly shorter clinic trials are likely to reduce 
drug development costs and perhaps may allow earlier commercialization of targeted therapies.6 
However, it is equally plausible that project specific investments in discovering and validating 
of biomarkers and diagnostic tests will involve additional costs and complexity to the inherently 
risky drug development process. Sometimes, the use of stratified clinical trial populations will 
require comprehensive biomarker evaluation and validation steps including an appropriate 
biomarker assay development in order to identify and test predictive biomarkers. Also, more 
narrowly defined inclusion criteria may lead to lengthier recruiting, the need for additional sites, 
and higher costs. Hence, since SM is in its early stages, there is indication that potential 
efficiency gains in R&D may be achieved only in the long run.7 In addition, from an economic 
perspective, a more targeted patient population may lead to smaller groups of eligible patients 
while R&D and other investment to bring products to market remain similar or even increase. 
In this case, premium prices seem inevitable and difficult discussions with reimbursement 
authorities emerge. Also, faster adoption or longer effective patent life for an SM intervention 
could be argued to offset the reduction in potential revenues from patient stratification. Yet, SM 
may not only diminish groups of eligible patients, they also can enlarge them by redefining the 
disease space at the molecular level and across traditional disease boundaries (e.g. targeting 
solid tumors in oncology may be used for various cancer types) 8 or by extension of the target 
indication (move from 3rd line to 2nd or even 1st line) due to an increased cost-benefit ratio. All 
in all, if superior clinical performance is adequately evidenced, actual revenues might increase 
because SM enjoys faster and wider adoption.9   
In addition, diagnostic testing may improve a company’s abilities to better identify promising 
drug candidates (assets) leading to higher probability of success of R&D projects due to lower 
attrition rates in the R&D portfolio and lower sunk costs of failed R&D projects. Especially, it 
has been shown that reducing phase II and III attrition are the strongest levers for improving 
R&D efficiency and reducing the costs per New Molecular Entity (NME).10   Yet, to fully 
leverage this impact on R&D budgets there must be a significant number of targeted therapies 
with improved cost-benefit ratios as part of a company´s development portfolio.11 
2.2 Time to product approval and commercialization 
Especially, the “time to market” is a key factor influencing the economic profile of a new 
compound and the future cash-flows, which determine the economic value of a product. If an 
SM approach can shorten development time because diagnostic testing has streamlined the 
clinical trial program, cash inflows will be shifted to earlier time periods which increase the net 
present value of this compound. In addition, a compound reaching the market earlier can 
leverage longer periods of patent protections, which also increase expected economic returns.6 
Recently, Zelboraf® (vemurafenib) and Xalkori® (crizotinib) achieved accelerated approvals 
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(both approved by FDA in August 2011) and demonstrated that targeting can significantly 
shorten development time and cost.12,13 Zelboraf® is used to target melanoma patients together 
with its companion diagnostic (BRAF gene mutation test) and reached the market within 4.5 
years including a regulatory approval time of 3.6 months through an expedited process. 
Xalkori®, was developed for the treatment of patients with non-small cell lung cancer (NSCLC) 
with a specific alteration in the ALK gene. The drug together with its ALK FISH probe 
companion diagnostic reached the market within 5 years from start of Phase I trials. Here, Pfizer 
used a stratified approach to establish the clinical outcomes (i.e., safety and effectiveness) for 
the target populations involving only 255 patients. The approval process for the drug and its 
associated test took only 4.9 months, well ahead of standard review times for priority drugs.14  
2.3 Therapeutic effects and biomarker features  
Prospective stratification is difficult and may also not always be feasible as scientific and 
clinical factors place some limits on the pace of development. In certain therapeutic areas, 
understanding of the molecular basis of diseases is insufficient to select biomarkers at early 
stage of development.15 Also, common disease conditions are often influenced by multiple 
genes/biomarkers in ways not always well understood in early development stages. In other 
therapeutic areas, there is no immediate medical need for diagnostic-based therapies. Gaining 
knowledge about the molecular mechanism of diseases and the underlying common molecular 
pathways on how a drug interferes with next-generation genomic technologies is crucial for 
drug development before clinical symptoms and outcomes are studied in clinical trials.16  
Hence, predictive biomarkers often can be applied rather late in the clinical development 
program, when clinical data show that an optimal benefit-risk profile is only achieved in a 
subpopulation of patients.8 All these considerations and more will influence industry decisions 
to engage in companion diagnostics development although ideally such decisions should be 
made no later than at the end of Phase II17 to allow for more efficient trial designs with smaller 
patient populations. Trusheim et al18 see three key factors when assessing therapeutic areas and 
biomarker features to drive economic value for stratified medicines compared to empirical 
medicines: the therapeutic effect with the selected population, the prevalence of the predictive 
biomarker and the clinical performance of the companion diagnostics (ability to distinguish 
treatment responders from non-responders). Eventually, the value of investment in SM 
approaches is a function of both supply (scientific opportunities) and demand (market 
attractiveness) factors and will require systematic evaluations for each potential therapeutic area 
and its biomarker features. While oncology has been at the forefront of SM approaches for 
many pharmaceutical and biopharmaceutical companies up to now, other therapeutic areas such 
as immunology/transplant, CNS, infectious diseases and cardiovascular may hold great 
potentials for the next 10 years.19 
Given these challenges, many of the pharmaceutical and biopharmaceutical industries still use 
biomarker as an add-on and not as an integral part of the strategy.5 They are employing 
biomarker in the R&D process to keep an option for the full market potential rather than limit 
itself to a prospective stratification with a smaller population (“wait-and-watch” strategy). In 
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fact, many stratified therapeutic on the market today were developed as the results of ‘rescue’ 
strategies to increase efficacy (KRAS/EGFR - Erbitux® and Vectibix® in oncology) or to avoid 
side effects (HLA-5701/Ziagen® in HIV) as kind of salvage option. Consequently, from an 
investor perspective there is a clear need to understand the potential for stratification and to 
assess the value of having the option to stratify either prospectively or as fall back/ project 
salvage option in case.  
2.4 Downstream (post approval) economic considerations 
The differential profile of a SM approach may positively affect commercial factors such as 
‘time to market access’ and market uptake to increase products´ net present value. Several 
publications and economic analyses have assessed the economic potential of SM interventions 
outlining key drivers shifting the sales and adoptions curve and enabling faster return on 
investment (ROI).20,18,21 It has become increasingly clear that early market penetration is 
important and can compensate for loss of size of market. Higher and earlier market penetration, 
combined with attracting new patients and better compliance within a smaller market, can result 
in substantially different post-launch cash-flow profiles compared to empirical medicines and 
corresponding potential health gains for selected populations. However, the interdependency 
between drug and test will only be enhancing ROI where the related diagnostic testing has been 
effectively diffused into the market requiring appropriate commercialization effort.22 In 
addition, and adding to these complexities, gaining market shares will be only feasible if 
reimbursement authorities likewise acknowledge the need for such diagnostics, for example, as 
companion diagnostics of “expensive” biologicals in oncology and if diagnostics are optimally 
aligned with patients’ needs.  
2.5 Reimbursement and clinical adoption challenges  
The uptake of SM in healthcare depends much on appropriate value assessment and the 
economic viability of such approaches in the healthcare setting. In an era of cost containment 
and limited health care resource there is a clear need to consider opportunity cost of decisions 
on which health care intervention to use by demonstrating the potential added value of SM 
technologies bring to the healthcare system. While pricing and reimbursement (P&R) of 
pharmaceuticals in many EU countries and the US can be characterized as somewhat “value-
based”, the reimbursement of diagnostics is often resource or cost-based, with potentially 
relatively low reimbursement rates.23 Especially in Europe,  market access of higher priced 
molecular diagnostics tests is highly influenced by the existing reimbursement schemes. 
Moreover, in certain EU countries, market access for diagnostic-based therapies has been 
achieved only through subsidizations for the diagnostic test by pharmaceutical manufactures.2 
Many analysts have emphasized the need for more flexible pricing and reimbursement schemes 
to encourage innovation in SM and accelerate its adoption.24 Generating robust clinical and 
health economic evidence may provide the confidence that enables payers more rapidly to adopt 
potentially (cost-) effective tests. Novel payment approaches and risk sharing agreements with 
third party payers are increasingly used to overcome the tension between funding new but 
expensive technologies and obtaining value for money where traditional reimbursement is not 
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deemed appropriate. Such forms of market access schemes may be more appropriate to align 
the adequate incentives for various stakeholders involved in P&R decisions with long-term 
patient benefits, including associated funding schemes.  
Driving diagnostic testing adoption is critical and associated with ensuring adequate test 
availability in clinical practice and by influencing health care provider competence in using 
these technologies. Efforts to educate physicians, other clinicians and patients on the use of new 
diagnostic is essential for a proper use of these technologies and may help increasing awareness 
and generating realistic expectations for SM interventions. Also, there is the need for an 
adequate health information infrastructure capable of accommodate and share complex medical 
information in a secure environment.25  
3.  Strategic options for manufactures: Framing the Decision 
 
Decisions to pursue an SM-approach versus conventional “treat-all” approaches are complex, 
and depend on several factors including patient population size, development cost (and patent 
status) and volume trade-offs, the potential for value differentiation and the payers (customers) 
‘willingness to pay’ of the target population. Several examples of approved targeted therapies 
demonstrated the clinical and commercial value that SM can generate under specific 
conditions.18 These examples also expose a diversity of development options outlining certain 
development and commercial challenges.26 A company can follow 
a) an proactive approach, where a biomarker-positive strategy is applied of enrolling only 
those patients in phase IIb/III clinical trials, who were selected by the predictive 
biomarker/clinical useful diagnostic test and the drug is exclusively marketed for the targeted 
sub-population. Such an approach can shorten development time and costs if an improved 
targeted clinical profile meet qualifying criteria by FDA/EMA to leverage policy incentive tools 
such as fast track routes, accelerated approval, or breakthrough therapy. It may also hold high 
potential for demonstrating value to third party payers and prescribing physicians. However, a 
key variable here involves ensuring that biomarker-driven work is initiated early enough to 
optimize a proactive approach by coordinating the timing of drug-diagnostic development in an 
effective way. Imatinib (Glivec®) is a specific example for a proactive SM development which 
has enhanced its clinical and commercial success. Despite a very small proportion of the patient 
population, Glivec® could leverage several offsetting factors such as shorter clinical trials, a 
premium price for the marketed drug, better compliance and high shares within the target 
population. Hence, Glivec® has been able to generate very high revenues ($ 4.7 billion in 2014) 
and health gains given a high response rate among stratified patients and excellent curing 
capabilities for a serious disease like Chronic Myeloid Leukemia (CML). Also, this example 
shows that through the specific defining of the target populations, the premium pricing could 
still go hand-in-hand with acceptable cost-effectiveness ratios.27 Furthermore, the product was 
able to expand initial indication to other diseases such as Gastrointestinal Stromal Tumors 
(GIST). This principle to enlarge the patient population for targeted therapeutics has been 
demonstrated throughout the industry.28  
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b) a re-active strategy with late adoption of a stratified approach. Prospective stratification 
may not always possible because of a lack of predictive biomarkers in early development stages. 
Rather in many cases potential biomarkers are one possible outcome of clinical trials that 
combine hypothetical stratifying biomarkers. Also, there is the case that safety and /or efficacy 
issues may arise during phase III clinical trials which then drives the decision to adopt a patient 
stratification approach provided that a differential response in a pre-defined subgroup can be 
identified by a predictive biomarker/diagnostic test. While late adoption of SM approaches 
limits economic efficiency in drug development it may provide a nice, where economic value 
can be demonstrated for a company. However, an upward pricing option for post-approval 
stratification is limited because the reimbursement environment in many markets is inflexible 
with regard to price increases in such situations. Specific examples are panitumumab and 
cetuximab (in colorectal cancer) that revived once a target population (patients with EGFR-
expressing metastatic colorectal carcinoma with a non-mutated wild-type KRAS genotype) was 
identified for which the drugs would be most valuable. Before the genetic marker was 
discovered, European regulators were reluctant to approve cetuximab (Erbitux®) based on its 
questionable benefit risk profile.29  
3.1 Economic attractiveness of SM options 
A decision-tree model (see figure 1 –attachment) was constructed to assess the economic 
attractiveness of different development options based on various factors including development 
costs, the time of development and product approval, time-to peak sales (comprise time to 
market access & adoption rate), and peak sales prices, affecting the economic potential of a SM 
approach. The aim of this model is to explore the key value drivers and conditions affecting 
profitability of different SM scenarios. For this purpose, a hypothetical business case in the 
oncology market has been developed addressing 4 feasible scenarios. The discounted cash-flow 
model specifically investigated a new drug´s Minimum Viable Market Share (MVMS),30 i.e. 
the market share needed to break even in a risk-adjusted expected net present value (eNPV) 
sense. Our analysis is assuming a cost-effectiveness framework for the different development 
options in order to address third party payer considerations regarding reimbursement and 
affordability. While a cost-effectiveness analysis (CEA) allows payers´ to have a formal method 
for determining value for a new technology; it also allows companies to determine their 
customer’s maximum willingness to pay.31 With this in mind, Table 1 shows the results from 












Table 1. A economic model defining feasible development options in oncology 













types (brain etc) 








(e.g. Erbitux)  
Cost of development  (US$ 
million) 
500 500 500 550 
Years of development &  
approval (´time to market´) 
8 8 8 9 
Net patent life (years) 12 12 12 11 
# of eligible patient /year 
(US+EU) 
500,000 125,000 25,000 375,000 
Price/revenue per patient 
Based on C/E ratio (Box 1) 
30,000 40,000 40,000 30,000 
Years to reach peak 6 6 6 6 
Cost of revenue (%) 40 40 40 40 
Market shares at peak of 
eligible patients where NPV 
is zero (MVMS in %) 
6.9 20.7  103 10.6 
Peak patient treated at 
MVMS 
34,560 25,875 25,750 39,750 
Discount rate (%) 
 















Box 1. Methods and input sources 
 The decision tree analysis (DT) employs sequential decision making to see how the options to implement 
SM potentially demonstrate added value (eNPV). As such the DT incorporates dynamic decision-making 
considering new information throughout the development process. DT analysis incorporates average 
phase transition probabilities received from various sources40 (i.e. phase I-II 0.70; phase II-III 0.39; phase 
III-approval 0.69) to risk-adjust the financial NPVs to expected NPVs (eNPV) for the scenarios. 
 
 For all cases S1-S3 in Table1, it is assumed that the development time (inclusive approval time) of an 
oncology drug requires 8 years and involves clinical out-of-pocket costs (direct costs) of US$500 
million. For S4, the re-active scenario, a 1-year longer time to market owing to the delay in the 
development of a companion diagnostic and additional costs of US$ 50 million15 for performing a 
retrospective biomarker/diagnostics validation after phase III are assumed. There are estimates of 
US$1.2 - 1.8 billion as fully capitalized costs of the development of a new NCE comprising direct cash 
outlays of research and development10, as well as the financing opportunity costs based on an 10 % 
discount rate (cost of capital).41 The model explicitly incorporated this 10% cost of capital in its net 
present value (NPV) calculations for each scenario, thus, it is inappropriate to use the fully capitalized 
cost of US$ 1.2 - 1.8 billion but rather only the out-of-pocket costs (direct cost).   
 
 Stratified medicines, i.e. scenarios 2-4 also require the development of a companion diagnostic 
associated with additional costs and the cost per patients (including diagnostic assessments) will be 
higher on the one hand. While on the other hand, the number of patients for targeted treatments may be 
lower compared to empiric therapy, we assumed equal development cost for empiric versus SM options 
in the base case. 
 
 Price/revenue per patient is related to favourable relative cost-effectiveness ratio (e.g. threshold of 
$50,000 per QALY or Life saved) accepted by payers. Although we see market price levels of $50,000-
60,000 for certain large cancer segments and even higher prices for certain small cancer segments in 
some cases, we assumed prices of $30,000 to 40,000 reflecting revenues per patient per year. These 
assumed prices should mirror increased therapeutic effects according to incremental cost-effectiveness 
ratio (ICER). Our price/revenue assumption took into consideration different treatment durations and 
potential discount/rebate requests certainly expected in some markets to achieve market access.  
 
 The commercial time to reach peak sales is assumed to be the industry average of 6 years.42 An analysis 
of financial reports of small, mid-size and large biopharmaceutical companies indicates an average cost 




According to Trusheim et al the oncology market in US and EU can be segmented into multiple 
organ types,32 ranging from markets of approximately 500,000 new patients per year (i.e. 
200,000 US and 300,000 EU-27) for the largest organ types (i.e. lung, breast, prostate and 
colorectal) to approximately 130,000 patients annually in second-tier organ types (e.g. 
pancreas, Non-Hodgkin’s) or to only 30,000-60,000 patients for most cancer organ –types, such 
as brain, multiple myeloma, Hodgkin lymphoma etc.33,34  
S1 illustrates a business case for the development of empiric medicine for a large oncology such 
as breast or lung. The large cancer segment represents a highly competitive market environment 
with many therapeutics available. Hence, we assume that a new empiric treatment must at least 
achieve benchmark clinical outcomes to ensure adequate market access and uptake and to 
justify certain price assumptions (US$ 30,000), i.e. prove an acceptable cost-effectiveness to 
payers. S1 needs at least 6.9 % of market shares at time of peak sales in this segment to be break 
even (34,560 patient treated). This could be challenging as empiric therapies in this segment 
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often start with a late stage positioning (stage III/IV); i.e. few patients to ensure patient access 
in an increasingly cost-conscious healthcare environment. 
 
S2 illustrates a SM approach in large cancer (e.g. breast). The number of eligible patients is 
assumed to be at 125,000, when targeting 25% of eligible patient population (as analogue to 
Herceptin®) via appropriate diagnostic. Improved clinical outcomes through stratification may 
allow an upward pricing ($40,000) within a C/E framework. In this case, S2 needs at least 
20.7% of market shares in this segment to be break even (with 25,875 patient treated). If we 
assume a 60% market share like in the Herceptin® example (“ideal situation “ at that time) in 
this segment, eNPV would be at 271 mil $, however more follow-up compounds have been 
developed in the meantime in this segments which makes the market situation currently more 
challenging. 
 
S3 illustrates a SM approach with a very low number of targeted patient population (e.g. 5% 
like Xalkori ® in lung cancer), i.e. 25,000 patients or addressing a rather small cancer segment 
(e.g. brain) via stratification. A differentiated therapeutic profile may capture disproportionate 
value through stratification while justifying a premium price (40,000$) within a C/E framework. 
S3 needs at least 103% of market shares in this segment to be break-even (with 25,750 patient 
treated). This means S3 is never economically feasible under these conditions and will have to 
reduce development time and costs as well as to accelerate time to peak sales to become 
economic viable. 
 
S4 illustrates a re-active SM business case in a large cancer (e.g. colorectal as analogue to 
Erbitux® and Vectibix®). Improved clinical outcomes may capture additional value within the 
target sub-population, however upward price flexibility is limited in this case. We assumed a 
65% targeted population similar to KRAS testing in colorectal cancer (i.e. 375,000 patients). 
S4 needs at least 10.6% of market shares in this segment to be break-even (with 39,750 of 
patient treated).  
 
3.2 Key economic drivers for SM options 
The simulation scenario analysis for two proactive SM options (S2 and S3) outlined that 
changes of development time (e.g., from 8 to 5-years) and the time to peak sales (from 6 to 4-
years) have the strongest impact on incremental eNPV´s and MVMS for a company, while 
changes in development cost and transition probability will result in a lower impact on 








  * MVMS = Minimum Viable Market Share where eNPV =0  
The development of SM approach S3 for a very small sub-population (orphan-drug-model) will 
be economic viable when all economic drivers including reduced development time and cost, 
together with an accelerated time to peak sales will be realized (52.2% MVMS or even 45% if 
we assume an increased transition probability in phase III from 0.69 to 0.80).35 This may be 
attainable in settings where there is no comparable alternative or currently available treatments 
are unsatisfactory. Xalkori®, for example needed 29 months in the US market to achieve 77% 
peak market shares within the targeted population.36 A slower market penetration with 8 years 
to reach peak will negatively influence the MVMS and ∆ eNPV for both S2 and S3.  
3.3 Discussion of Key Insights  
Based on a straightforward model, our simulation analysis outlines the effects of development 
time and time to peak sales as key economic value divers. Substantial increases in eNPV occur 
when the proactive SM cases S2 and S3 as described in our hypothetical business case can 
shorten the development program and shift cash inflows to earlier time periods through faster 
commercialization. Also, the acceleration of early market penetration has a substantial effect 
on future cash flows provided that the differential therapeutic profile will positively affect 
commercial factors, such as reimbursement and market uptake. However this case study showed 
that SM approaches for a very small sub-population (orphan-drug model) are only economic 
viable if several economic drivers including reduced development time and costs together with 
an accelerated market penetration can be leveraged.  
There are several ways for the industry to achieve early commercialization provided an 
improved targeted clinical profile meet qualifying criteria by FDA/EMA to leverage policy 
incentive tools such as fast track routes, accelerated approval, or breakthrough therapy. 
Adaptive clinical trials in cooperation with regulatory bodies will play a pivotal role in this 
process to reduce ´ time to market´. There is also the need for an enhanced collaboration between 
Table 2: Simulation 
 
 SM approach S2           SM approach S3 
Model parameter 
 
MVMS* in %  
     at peak 
∆ eNPV 
(US$) 
MVMS in %  
at peak 
      ∆ eNPV 
        (US$) 











5-years ´time to market´ +  









+ 100$mil less 









+ increase to 0.80 transition 








       29,8mil 
     
8-years to reach peak  
 
25     -33,1mil         112.5       -16,2mil 
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the pharmaceutical and diagnostics development teams to ensure alignment on clinical trial 
timelines and regulatory filing procedures.37   
This analysis assumed a cost-effectiveness framework for the different development options in 
order to address payer-based considerations regarding reimbursement and affordability. This 
put some limits for a premium pricing strategy in this hypothetical business case. However, the 
analysis showed that leveraging the identified key economic value drivers can make SM 
approaches potentially economic viable even with a rather “moderate“ upward pricing 
assumption. Globally, third party payers are increasingly conscious of the total budget impact 
of high-priced targeted therapies. As a number of new targeted therapies will reach the markets 
in the next years, it is very likely that more restrictive caps on reimbursable prices for targeted 
therapies will be put in place in many healthcare systems.11 While Xalkori® and Zerboraf® 
were able to realize substantial reduction of development time, their premium price strategies 
have induced market access delays (e.g. negative HTA recommendations from NICE) in many 
EU health care systems resulting in reduced profitability. Identifying optimal prices for test-
treatment combinations reflecting SM value propositions that can lead to “win-win” scenarios 
for patients, individual payers, and the healthcare system overall will facilitate timely market 
access and uptake.  
Late adoption of an SM approach (S4) will limit economic efficiency in drug development, but 
may provide a niche wherein optimal value is demonstrated. The economic incentives are rather 
limited without an earlier commercialization opportunity and the lack of an upward pricing 
option and may need to be weighed with potential additional market shares gains based on 
improved therapeutic performance. In fact, reflecting the actual situation for Erbitux® in EU in 
the years 2007-2009 showed an increase from 6,671 patients treated for 16 weeks as 3rd line 
treatment in 2007 to 62,719 patients with KRAS wild-type  as 1st-line treatment with 28 weeks 
treatment duration treated in the year 2009 driven by improved clinical benefits for the 
patients.38 
 
4.  Conclusion and future perspective 
 
This article has outlined key R&D-related and commercial-related value drivers which could 
explain the favourable economics for SM interventions under specific conditions. Decreasing 
development time and enhancing early market penetration would most directly improve the 
economic attractiveness of SM investments. In this analysis, we argue that factors such as 
reduced time to market due to accelerated approval or other expedited FDA/EMA programs, 
and faster market uptake can substantially improve the economic viability of SM approaches in 
certain cases. However, the decision to pursue a proactive stratified approach depend much on 
the level of prior confidence in the predicted biomarker and a clear understanding about high 
value targets among pharmaceutical/diagnostic manufacturers and regulatory bodies. Offering 
a better targeted and hence ultimately more cost-effective therapy at reimbursable prices will 
facilitate time to market access and allow increasing market share gains within the targeted 
populations. Oncology and orphan diseases are areas where the science has advanced most, and 
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has triggered an increasing number of proactive stratified approaches which are currently under 
development. Yet, the development of an SM approach for a very small sub-population is 
unlikely to be economic feasible unless several economic drivers including reduced 
development time and costs together with an accelerated market penetration can be leveraged 
by a pharmaceutical company. 
 
The analysis suggest to perform early opportunity assessments to understand how the 
therapeutic effect of the treatment, characteristics of the identified patient population, and test 
performance interact and affect commercial value of stratification. This should support a 
company´s ability to generate a highly differential therapeutic profile for a subgroup of patients 
enhancing the value proposition of SM interventions for third party payers and prescribing 
physicians.17 Understanding of certain scenarios is critical and should help manufacturers to 
prioritize investment decisions including whether or not to generate more evidence. Effective 
partnering approaches are needed to share risk and reward to realize efficiency gains in the 
R&D process and to ensure incentives for biomarker/diagnostic companies. This may evolve 
new business models with a further focus on co-operation between different industry sectors, 
and with academia including public-private partnerships. 
  
The conceptual attractiveness of targeting may also reduce development costs if failure rates of 
R&D projects and associated sunk costs can be avoided, especially of late phase clinical trials. 
Hence, on the long-term, a higher % of SM projects into R&D portfolio may enhance overall 
R&D productivity as more promising drug candidates (assets) with better benefit-risk profiles 
will reduce risk and cost of attrition. This should improve company´s future ROI and may 
further stimulate private sector investments in SM interventions. The recent benchmark report 
by the Diaceutics group `Pharma Readiness for Personalized Medicine 2016´ estimated that 
almost 75% of assets currently in late stage development could potentially benefit from a 
targeted approach.39 
 
Industry alone will be unable to successfully leverage the key economic drivers for SM 
interventions outlined in this research. New regulatory approaches including adaptive clinical 
trial design must be forward looking and prepared for the introduction of new 
biomarker/diagnostic technologies to support for their timely access to targeted medicines. 
Also, creative reimbursement models, using managed entry agreements and value-based pricing 
for drugs and diagnostics should provide incentives for appropriate evidence generation and 
alignment between various stakeholders to ensure patient access for SM interventions. Another 
factor influencing development and diffusion of SM interventions relates to an adequate 
information technology infrastructure capable of storing and sharing complex medical 
information in a secure environment.25 Developing standard in electronic medical record and 
tissue storage (for example bio-banking) as well as dealing with the privacy and ethical issues 




Adopting SM approaches into clinical practice continues to provide challenges for 
manufacturer, regulators, payers and providers which must be addressed in a collaborative and 
synergistically way to enhance patient outcomes. Because the economic challenges and 
opportunities of SM are intimately linked by many factors both internal and external to the 
development and clinical adoption process unprecedented alignment of incentives will be 
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Over the past several years Stratified Medicine (SM) has been the focus of substantial interest 
in the pharmaceutical research community due to improved diagnostic technologies and a better 
understanding of diseases’ heterogeneity. The decade since the completion of the human 
genome sequencing project has witnessed significant advances in science, enabling meaningful 
genome sequencing and molecular profiling in biology at increasingly affordable levels.1 The 
ability to target patient subpopulations has the potential to improve treatment efficacy and 
minimize side effects enabling physician to more selectively deploy therapeutics in those 
patient groups.  Several SM interventions have proven beneficial in a number of cancers and 
genetic diseases and researchers are working to identify more and more biomarkers that could 
be used to refine treatments in the future. A 75% increase in investments by the pharmaceutical 
industry in biomarker research over the last 5 years have stimulated interest in targeted therapies 
and further investments are predicted in the near future.2 
Despite these advances, a general sense of dissatisfaction on the progress of SM in terms of 
creating efficiencies in drug development and health care delivery remains. So far, absence 
exists to demonstrate the positive impact on public health (clinical utility and cost-
effectiveness) and to promote the acceptance and uptake of SM in clinical care pathways.[3-6] 
Besides scientific and operational challenges associated with the implementation of this 
“disruptive innovation”, the process of ´stratification´ of patients has raised economic questions 
for payers, the healthcare system and for the manufacturer. The aim of this thesis was to 
investigate these economic issues and opportunities in adapting SM approach to enhance patient 
access, population health, cost effectiveness and return on investment. For that purpose, part I 
of this thesis examined the fundamental economic issues of SM interventions in the context of 
HTA, reimbursement and access decisions. In part II we described two economic assessments 
in which the potential added value of SM interventions in clinical practice has been addressed. 
Subsequently, in part III of this thesis the economic viability of SM interventions from 
manufactures/investors perspectives has been considered. In the current chapter the main 
findings of our studies are presented and discussed. Furthermore, recommendations for practice 
and future research will be provided. 
 
2.  Main findings of this thesis 
2.1 Economic viability of SM approach in the healthcare settings  
2.1.1 Issues on reimbursement schemes and incentive structures   
The uptake of SM in clinical practices depends much on the assessment process, in particular 
regarding HTA and P&R decisions. In chapter 2 we addressed pricing and reimbursement 
issues of SM approaches within EU countries and beyond. This investigation showed that 
pricing and reimbursement schemes in many markets do not currently reflect the specific 
benefits arising from the use of SM approaches, and thus remain a barrier to their development 
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and adoption, especially for the diagnostic component. Third party payers in public and private 
health care systems in EU and the US have adopted different pricing & reimbursement policies 
for drugs and diagnostics. While pricing & reimbursement of pharmaceuticals in many EU 
countries and the US can be characterized as somewhat “value-based”, the reimbursement of 
diagnostics is resource or cost-based7 with potentially relatively low reimbursement rates. 
Diagnostic tests are often covered within the DRG fee schedule in the inpatient (hospital) setting 
and a code-based fee schedule in the outpatient (ambulatory) setting, respectively. This reflects 
a technical procedural cost-based approach which does not consider clinical or economic value. 
Hence, current reimbursement schemes for diagnostics do not reward value creation, which 
may discourage diagnostic companies from investing in such research and evidence 
development. 
Furthermore, limitations of intellectual property protection pose a barrier to market entry in the 
diagnostic arena. Value-based prices will be competed down if test entrants can copy the 
innovators´ approach without having to make the same investment. Low prices and poor 
intellectual property may hamper diagnostic manufactures to invest in “ideal” studies to 
demonstrate clinical utility. Potentially, strategies should be developed to adequately provide 
the relevant incentives for innovations in this area. 
 
The analysis in chapter 2 underscores the clear need for more flexible pricing & reimbursement 
schemes which stimulate investments in evidence generation so that cost-effective technologies 
can provide and demonstrate their value to patients and to the health care system, enabling 
returns that commensurate with that value. In fact, lack of sufficient evidence linking test use 
to patient management and health outcomes remains a fundamental challenge for 
reimbursement of personalized strategies in many markets. The regulatory requirements of 
evidence generation for diagnostic products are quite different to therapeutics with so far 
limited demands on diagnostics to demonstrate clinical utility. This has created uncertainty for 
third-party payers and healthcare providers who are faced with decisions involving costs and 
relative effectiveness. Clarity may still lack and is then needed from regulators and payers 
laying down their expectations for data to ensure a consistent evidentiary framework for stand-
alone diagnostics and test-treatment combination, enhancing evolution of improved economic 
assessment for SM interventions. This definitely involves the need for more comparative-
effectiveness evaluation built into a SM development program, as the opportunity cost of adding 
new technologies is becoming a major factor in HTA assessment and coverage 
recommendations, potentially involving exchange of products in the reimbursed package rather 
than additions only. However, realistic expectations around standards of evidence are needed 
as randomized clinical trials might not always be feasible because of ethical reasons, shift to 
multi-therapeutic regimes, and lack of resources or small patient populations. The use of 
coverage-with-evidence agreements and real-world evidence collection may provide new 
incentives for collaborative approaches between stakeholders. Also, new incentive structures 
and models, such as public-private partnerships for sharing cost of new treatment strategies, 
should further be explored to increase the efficiency of evidence collection. 
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Generating robust clinical and health economic evidence may provide the confidence that 
enables payers more rapidly to adopt potentially (cost-) effective tests. Novel payment 
approaches and risk sharing agreements with third party payers are increasingly used to 
overcome the tension between funding new but expensive technologies and obtaining value for 
money where traditional reimbursement is not deemed appropriate. Such arrangements between 
a manufacturer and payer/provider may be appropriate to align incentives between various 
stakeholders to enable certain market access on a case-by-case basis. Fostering potential 
broader coverage within the healthcare systems will require the coordinated effort of national 
P&R authorities to realize a more synchronized reimbursement system for both drugs and 
diagnostics. This may involve a more holistic approach to health care funding as highlighted in 
chapter 2. Because of budgetary silo mentality in many healthcare systems, national authorities 
may need to develop more centralized and integrated funding models to ensure timely patient 
access of SM applications. This will be especially relevant with the move to multiple 
biomarkers /platform testing as one test could service multiple therapeutic decisions for patients 
and test costs can potentially be attributed to multiple targets. 
While DRG-type systems, fee-schedules and annual budget systems for diagnostics cannot be 
changed immediately, health care systems may enhance implementing temporary 
reimbursement/funding pathways that guarantee realistic funding of companion testing at the 
time of pharmaceutical drug launch. This would bridge reimbursement gaps and will ensure 
that time consuming standard code /fee schedule updating will not delay patient access. The 
French Institute of Cancer (INCa) provides an example of companion diagnostic test promotion 
in the field of oncology reflecting a temporary funding mechanism in this sense.8  
2.1.2 Methodological issues in assessing the HE value for SM interventions 
During our research for this thesis it became evident that consistency in performing economic 
evaluation for SM interventions is lacking notwithstanding the existence of guidelines for 
economic evaluation.9 However, these guidelines have initially been developed for traditional 
pharmaceuticals and not for complex interventions with multiple components. Chapter 3 
describes specific issues relevant to the evaluation of diagnostic-based SM and assessed 
whether current guidance for economic evaluations is sufficient to support decision making for 
SM intervention. It was concluded that current health economics methodology can be applied 
for SM, although various aspects of the guidelines require specific attention for SM 
approaches.These aspects comprise considerations on the choice of comparator, measuring 
effectiveness and outcomes, appropriate modelling structure and the scope of sensitivity 
analyses. Many of these aspects refer to a lack of evidence on testing heterogeneity and the 
quality of effectiveness data. Notably, the level of economic evidence for SM interventions may 
differ from what is generally experienced with traditional pharmaceuticals, thus stressing the 
need to identify best practice for economic modeling including approaches which address 
evidence gaps in a manner that is both acceptable for payers and feasible for test manufactures. 
This may involve increasingly real-life data generation, perhaps via prospective cohort studies 
or chart review, as payers might seek additional post-market evidence for clinical utility. In this 
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context it is also important to understand patients’ and providers’ preferences, since these 
preferences will influence the adoption of new technologies. Accounting for compliance and 
adherence will provide insight into variability of findings and should be incorporated into 
sensitivity analyses.  
 
Incorporating complex genetic or genomic data into cost-effectiveness analyses is a challenge 
that will grow as next generation sequencing technologies enter clinical practice. This may 
require further methodology development to address the increased complexity and the need for 
additional analyses especially when addressing `multiple testing´ considerations.  
These findings highlight areas of future work in this field. It may be desirable to reach consensus 
on observational research methods to generate effectiveness evidence for SM tests to improve 
the quality of economic evaluations and avoid ´wait and see´ policy conclusions with delayed 
patient access. ISPOR Personalized Medicine Special Interest Group and others[10-13] are 
working on the development of adaptive HEOR approaches and standards to help address best 
practice relevant to the rapidly evolving filed of SM. Recognizing the limitations of commonly 
used outcomes measures (e.g., QALYs) further research is needed to justify alternative 
approaches appropriate to measuring values for SM interventions. Examining the adequacy of 
the recently published Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) for reporting evaluations of SM may be another avenue of research.14 
2.1.3 Addressing HTA challenges for SM  
Adding a testing element to pharmaceutical technologies will increase treatment complexity 
and complicates value assessment. As mentioned, diagnostics and pharmaceuticals are 
considered under separate appraisal and payment processes in many healthcare systems. For 
instance, pharmaceutical drugs and the associated companion diagnostics are evaluated 
separately in France, Germany, Italy and Spain, with the evaluation processes being neither 
coordinated nor synchronized.8 Only NICE (UK) has so far established a Diagnostic 
Assessment Program (DAP) which carries out cost-effectiveness assessments of selected 
diagnostics. The investigations in chapters 2 and 4 highlighted the inconsistencies in the value 
assessment for SM approaches in many health care markets which lead to highly viable patient 
access decisions. Commonly accepted standards on how to evaluate diagnostics and test-
treatment combinations have not yet been transparently established or agreed upon by leading 
HTA organizations and payers. Without this, both industry and HTA agencies struggle to 
sufficiently demonstrate the accuracy of the test and thereby their effectiveness. There is a need 
for more integrated HTAs for pharmaceutical drugs and companion diagnostics which requires 
coordination and synchronization between the committees who are engaged in the country-
specific evaluation process. This could be challenging in countries with decentralized 
evaluation processes for companion diagnostics and may require regional or local alignment. 
HTA processes within one and the same country coordinated in a way that results in one single 
HTA report for the SM combined test-treat intervention will avoid inconsistent reimbursement 
recommendations and could facilitate timely patient access. An additional argument in a 
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synchronized assessment lies in the importance of diagnostics as ´gatekeeper´ to patients’ 
treatments. 
 
The research in chapter 4 underscores the need for a broad (holistic) value definition including 
societal, patients and provider perspectives, helping to reap the full potential of using the SM 
approach on the whole treatment pathway of patients. The overall effectiveness of SM 
interventions does not only rely on the development of new treatment modalities, but also on 
providers and patients behaviour as well as the development of a wide range of supporting 
services (e.g. laboratories) that patients need to effectively manage their health. Also, SM raises 
new ethical issues in the market access evaluations, which does not exist for traditional 
pharmaceuticals. Behavioural aspects and the weight of ethical issues related to test 
characteristics (sensitivity/specificity) make the value assessment of SM much more a multi-
criteria decision than traditional pharmaceuticals.  
HTA methodologies will have to evolve to address the multiple components of value that a 
diagnostic and therapy can provide. It is likely that different mechanisms of evaluation will be 
developed that are appropriate to each scenario (i.e., test-treatment combinations vs stand-
alone diagnostic). Organizations and working groups such as The European Personalized 
Medicine Association15 or the US Personalized Medicine Coalition16 have been established to 
focus on producing recommendations for the key evidence requirements and strategic 
approaches reimbursement agencies /payers need to consider and ensure an effective, safe, 
and cost-effective market access for effective and safe targeted therapies in Europe and 
across. Also, cross-industry forums have been organized on this matter by the Academy of 
Medical Sciences (London, UK)17 and the Institute of Medicine workshop (Washington, DC, 
USA)18 in 2013. 
2.1.4 Enhanced HE-data relevance for decision making and market access  
Different health economic data are relevant to different stakeholders in various stages of the 
development and clinical adoption process of targeted therapies. The research in chapter 4 
shows that a rather broad range of information on new technologies is required in order to 
promote informed coverage and adoption decisions. A determining part in health care decision 
making regards the ever more important cost-effectiveness evidence requested by several HTA 
agencies in Europe and across. However, as these health economics data is still relatively scarce 
for diagnostic testing, third party payers are requesting cost-offsets and budget impact 
information to address affordability issues in various health care systems. The focus on budget 
impact for SM interventions by third party payers has been confirmed by several payer 
researches.19,20 
SM also underscores the need for additional information such as patient and physician 
responses to diagnosis, which are not readily available from clinical trials or administrative data 
sets. Health economist may need to take new accountabilities when using observational 
research methods to perform additional value from utilization data to payers. In general, 
improved medication adherence is an area of common interest among all health care 
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stakeholders. Improvements in adherence to medication regimes may lead to better use of a 
therapy and generating a better expected benefit–risk balance for the stratified patients. Darkow 
et al provided an illustration how adherence data have been utilized to improve imatinib 
(Glivec®) treatment and outcomes resulting in substantial reduction of total health care costs 
for patients.21 This imatinib example illustrated that this can be the case even when treatment 
itself is associated with significant health care expenditure. 
Eventually, findings in chapter 4 indicated that HEOR may increasingly be faced with early 
value assessments of potential SM intervention to inform prioritization of further clinical 
research. In this context, early–stage cost-effectiveness analyses models and value of 
information analyses may be particularly useful in SM. These approaches can help 
manufactures to prioritize investment decisions, including whether or not to combine a test and 
a drug and to generate more evidence. These analyses can project the impact of testing on 
overall efficacy and safety and can also suggest the commercial impact in terms of price, 
reimbursement, and budget impact- as well as the societal benefits.10   
 
2.2 Economic assessments for SM interventions 
The second part of this thesis consists of two case studies in which the potential added value of 
diagnostic testing was examined for two different therapeutic areas. Both of these economic 
evaluations in this thesis are analyses using modelling techniques. In chapter 5 we addressed 
specific modelling issues associated with SM interventions and used depression to scrutinize 
the modelling approach with SM in particular. A SM model was constructed using decision 
analytical techniques to perform a cost-effectiveness analysis for a cohort of depressive patients 
using diagnostic testing in the Dutch health care setting. The analysis outlined the importance 
of addressing input parameters such as test sensitivity and specificity and especially false 
negative and false positive considerations of the diagnostic test. This will require additional 
structural model complexity to establish the link between the test results and the consecutive 
treatment changes and outcomes and lead to a higher degree of uncertainty in economic models 
for SM compared with traditional ones. The findings indicated that to some extent, scenario 
analyses may be more appropriate to address increased level of uncertainties in this case and 
should be used in addition to standard structural sensitivity analyses. 
The study confirms, that CYP450 genotype testing (e.g., cytochrome P450/CYP2D6) in 
depression can aid the decision maker (e.g. GP) in dose adjustment of antidepressant treatments, 
thereby potentially reducing disease management costs. Yet, further research is needed in this 
area to generate high-quality evidence that proves the clinical utility of CYP450 testing22 or 
other appropriate diagnostic tests to predict antidepressant efficacy helpful to make appropriate 
drug selection.  
In chapter 6 we developed an economic framework and a novel cost-effectiveness model in 
fertility that allows for assessing the costs and outcomes of new embryo diagnostics and how 
they influence the average “cost per live birth”. The prototype model (Embryo-Dx) is based on 
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costs and outcomes for the Netherlands and takes into consideration how new technologies 
influence live birth costs as well as cost-savings associated with reducing multiple pregnancies. 
The cost-effectiveness analysis in fertility clearly outlined a potential added value of embryo 
diagnostics to improve treatment effectiveness of various “in- vitro fertilization” (IVF) 
treatment strategies considering value-based pricing aspects of the associated diagnostic 
technology. The findings of this study indicate that the introduction of a validated embryo 
technology may further support a move towards increased single embryo transfer procedures in 
IVF clinical practice and vice versa. As improved diagnostics represent a new frontier in 
fertility and reproductive medicine more high-quality detailed cost-effectiveness studies 
involving new invasive and non-invasive embryo technologies, preferable from a societal 
perspective are recommended for demonstrating the economic value in this area. 
The prototype model (Embryo-Dx) and other upcoming cost-effectiveness analyses in this area 
may also trigger healthcare coverage and reimbursement policies addressing appropriate 
DRG´s and value-based diagnostics for assisted reproductive technologies (ART). 
 
2.3 Economic viability of SM approach from a manufacturers/ investors perspective  
Part III of this thesis considers the economic opportunities and challenges of SM concepts from 
a manufactures/investors perspective. SM holds great promise for creating efficiencies in drug 
development and health care delivery. Development can be streamlined by targeting certain 
genetic mutations or molecular pathways, increasing the probability of demonstrating 
significant beneficial treatment response among targeted patient groups. At the same time, SM 
involves a number of changes in the conventional way of drug development and health care 
delivery which impacts on the economics of developing SM. In addition, SM, almost by 
definition is likely to target a treatment to a smaller set of eligible patients and thus limit the 
market size. In this case, evidenced added value may be captured only in terms of premium 
prices, faster adoption or longer effective patent life to offset the reduction in potential revenues 
from market stratification. The economics of developing SM is significantly different from 
developing an empiric medicine and has triggered ongoing discussions by industry, analysts 
and academia.[23-25] It became evident, that investigating and understanding of certain scenarios 
is critical for the industry as a unique set of factors from development to reimbursement and 
market adoption will influence the expected returns of SM interventions and, hence, the 
incentive to invest in new R&D in tandem with diagnostic development. In this context, 
research in chapter 7 highlights on key economic drivers and conditions that favor using a 
stratified approach to create economic viable products and to justify the investment in SM as a 
strategic option. Specifically, a decision tree model was created to address the economic 
attractiveness of different SM development options in a cost-contained healthcare environment. 
For this purpose, a hypothetical business case in the oncology market has been developed 
considering 4 feasible development scenarios. 
The findings of the analysis outlined the effects of decreasing development time and enhancing 
early market penetration as key economic value drivers for SM interventions. A proactive 
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stratified approach can shorten development time and costs if an improved targeted clinical 
profile meet qualifying criteria by FDA/EMA to leverage policy incentive tools such as fast 
track routes, accelerated regulatory approval, and breakthrough therapy etc. This shows that the 
decision to pursue a proactive stratified approach will depend much on the level of prior 
confidence in the predicted biomarker and a clear understanding about high value targets among 
pharmaceutical/diagnostic manufacturer and regulatory bodies. A further result of this analysis 
indicates that the development of stratified therapeutics for a very small sub-population 
(orphan-drug model) is only economic viable if several economic drivers including reduced 
development time and costs together with an accelerated market penetration can be leveraged. 
Offering a better targeted and hence ultimately more cost-effective therapy at reimbursable 
prices will facilitate time to market access and allow increasing market share gains within the 
targeted populations. 
2.3.1 Towards ´smart´ targeting and payer-oriented value propositions for SM 
          interventions 
The appropriate tailoring of highly differentiated patient subgroups determines the possibility 
to reduce development time and requires a strong view about how to stratify the trial population 
in alignment with regulatory bodies. An integrated collaboration between the pharmaceutical 
and diagnostic developers is needed to identify clinically relevant biomarkers and diagnostic 
tools earlier in development process. Oncology and orphan diseases are areas where the science 
has advanced most, and has triggered an increasing number of proactive stratified approaches, 
which are currently under development. However, it is important to recognize that without the 
existence of a predictive biomarker in certain severe disease areas there is no economic rationale 
to pursue a stratified approach. 
 
The findings in chapter 7 suggest performing early opportunity assessments to understand how 
the therapeutic effect of the treatment, the characteristics of the identified patient population, 
and test performance interact and affect economic value. This may facilitate a company´s 
potential to adequately differentiate a compound and strengthen the value proposition of SM 
interventions for pricing and reimbursement authorities. 
 
The analysis of the hypothetical business case in the oncology market in chapter 7 assumed a 
cost-contained reimbursement environment because globally, third party payers are 
increasingly conscious of the total budget impact of high-priced targeted therapies. With the 
prospect of a wave of novel targeted drugs entering markets in the next decade,26 it is very likely 
that more restrictive caps on reimbursable prices for targeted therapies will be put in place in 
many healthcare systems. While Xalkori® and Zerboraf® were able to realize substantial 
reduction of development time, their premium price strategies have induced market access 
delays (e.g. negative HTA recommendations from NICE) in many EU health care systems 
resulting in reduced revenue generation.27 Identifying optimal prices for test-treatment 
combinations reflecting SM value propositions that can lead to “win-win” scenarios for 
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patients, individual payers, and the healthcare system overall will facilitate timely market access 
and uptake.  
 
The conceptual attractiveness of targeting may also reduce development costs if failure rates of 
R&D projects and associated sunk costs can be avoided, especially of late phase clinical trials. 
Hence, on the long-term, a higher % of SM projects into R&D portfolio may enhance overall 
R&D productivity as more promising drug candidates (assets) with better benefit-risk profiles 
will reduce risk and cost of attrition. This should improve a company´s future ROI and may 
further stimulate private sector investments in SM interventions.  
 
2.3.2 Addressing coordination and implementation challenges 
A collaboration approach between drug and diagnostic development is recognized as essential 
for the success of SM. However, such a collaboration raises considerable challenges between 
the involved parties including the timing and alignment of the development strategies of the 
two products, the design of the trial itself as well the regulatory reviews of co-developed 
products. Effective partnering approaches are needed to share risk and reward to realize 
efficiency gains in the R&D process and to ensure incentives for biomarker/diagnostic 
companies, inclusive value sharing. This may evolve new business models with a further focus 
on co-operation between different industry sectors, and with academia including public-private 
partnerships. Alternatively, an integrated approach might be the preferred option if in-house 
diagnostic expertise can be used to align drug and diagnostic development (e.g. Roche). 
 
Our analysis in chapter 7 underscored the importance of effective diffusion of diagnostic 
testing into clinical practices as also shown in other research work.[24,28,29] Driving diagnostic 
testing adoption is critical and associated with ensuring adequate access to the test, maximizing 
physician awareness and demand, to guarantee high quality of testing and optimally enhance 
patient benefits. By providing physicians with clear, concise and specific evidence 
demonstrating the value proposition of a targeted therapy, more physicians will become ‘early 
adopters’. Also, improved long-term patient compliance through diagnostic feedback and 
improved tolerability can further increase market size. Thus, an adequate and focused 
commercialization effort is imperative to properly prepare the market to be receptive to new 
targeted therapy. This may require the development of new capabilities within pharmaceutical 
and diagnostic companies to ensure how diagnostic-based healthcare is delivered to the market.  
Industry alone will be unable to successfully leverage the key economic drivers for SM 
interventions outlined in this research. Adaptive regulatory pathways and creative 
reimbursement models are needed – as discussed in the chapter 2-4 and may enable the 
fulfilment of reduced clinical development times and costs. Another factor influencing 
development and diffusion of SM interventions relates to an adequate information technology 
infrastructure capable of storing and sharing complex medical information in a secure 
environment.30 Developing standards in electronic medical records and tissue storage (for 
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example bio-banking) as well as dealing with the privacy and ethical issues on DNA collection 
are key challenges which need to be addressed by various stakeholders and health policy.  
Efforts to overcome these challenges represent an opportunity for industry, patient groups, 
clinicians and regulators to collaborate synergistically to enhance patient outcomes. Because 
the economic challenges and opportunities of SM are intimately linked by many factors both 
internal and external to the development and clinical adoption process unprecedented alignment 


























1.  McCarthy J, McLeod H, Ginsburg G. Genomic medicine: a decade of successes, challenges, and 
     opportunities. Sci Transl Med 2013; 5: 189sr4. 
 
2.  Tufts Center for the Study of Drug Development. Personalized medicine is playing a growing role 
     In development pipelines. Tufts CSDD Impact Report, 12(6), 2010 available through: 
     http://csdd.tufts.edu/news/complete_story/pr_ir_no-dec_2010 
3.  Miller I, Ashton-Chess J, Spolders H, et al. Market access challenges in the EU for high medical 
     value diagnostic tests. Personalized Medicine (2011) 8(2), 137-148 
 
4.  Oosterhoff M, van der Maas M, Steuten L. A systematic review of health economic evaluations of  
     diagnostic biomarkers. Applied Health Econ Health Policy, Febr. 2016, 14(1), 51-65  
 
5.  Meadows A, Morrison A, Brindley D et al. An evaluation of regulatory and commercial barriers to  
     stratified medicine development and adoption. The Pharmacogenomics Journal (2015) 15, 6-12 
 
6.  Cohen J. Overcoming regulatory and economic challenges facing pharmacogenomics, New 
     Biotechnology 2012; 29: 751-756 
 
7.  Garrison L and Austin F. Linking PGx-based Diagnostics and Drugs. Health Affairs 25. 1281-1290 
     (2006) 
 
8.  Bücheler M, Brüggenjürgen B, Willich S. Personalised Medicine in Europe- enhancing patient  
     access to pharmaceutical drug-diagnostic companion products, Patient Access Study Nov. 2014,  
     EPEMED white paper 
 
9.  NICE, The guidelines manual: assessing cost-effectiveness, Nov 2012. https://www.nice.org.uk 
10. Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of  
      personalized medicine- payer and manufacturer perspectives and implications for health 
      economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest 
      Group. Value Health 2012; 15: 1162-1171 
 
11. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the a economic evaluation of genomic  
      technologies. Pharmacogenomics (2013), 14(15), 1833-1847   
 
12. Phillips K, Sakowski J, Trosman J, Douglas M, Liang S, Neumann P. The economic value of 
      personalized medicine tests: what we know and what we need to know. Genet Med. 2014 March;  
     16(3): 251-257 
 
13. Husereau D, Marshall DA, Levy A, Peacock S, Hoch JS. Health technology assessment and  
      personalized medicine; are economic evaluations guidelines sufficient to support decision making? 
      Intl J Technol Assess Health Care. 2014 Apr; 30(2): 179-187   
 
14. Husereau D, Drummond M, Petrou S et al. Consolidated Health Economic Evaluation  
      Reporting Standards (CHEERS) statement.  Int J Technol Assess Health Care. 2013; 29: 117-122 
15. The European Personalised Medicine Association. Available from: http://www.epemed.org/.  
      (Accessed May 7, 2013) 
 
16. The Personalized Medicine Coalition. Available from: www.personlizedmedicinecoalition.org 





17. The Academy of Medical Sciences. Report on ´Realizing the potential of stratified medicine. July 
      2013 
  
18. McCormack R, Armstrong J, Leonard D. Co-development of genome-based therapeutics and  
      companion diagnostics: insights from an Institute of Medicine roundtable. JAMA 2014; 311: 1395- 
      1396 
 
19. Canestaro W, Pritchard D, Garrison L, Dubois R, Veenstra D. Improving the efficiency and quality 
      of the value  assessment process for companion diagnostic tests: The companion test assessment  
      tool (CAT). Journal of Managed Care & Specialty Pharmacy, August 2015, Vol 21, No. 8 
 
20. Fugel HJ. Payer research for biomedical technology - working paper-. April 2011 
 
21. Darkow T, Henk H, Thomas S et al. Treatment interruptions and non-adherence with imatinib and  
      associated healthcare costs: a retrospective analysis among managed care patients with chronic 
      myelogenous leukaemia. Pharmacoeconomics 2007; 25:481-496 
 
22. National Institute for Health Research (NIHR).The clinical effectiveness and cost-effectiveness of 
testing for cytochrome P450 polymorphisms in patient with schizophrenia treated with 
antipsychotics: a systematic review and economic evaluation. Health Technology Assess. 2010 Jan; 
14(3).1-157, http://www.hta.ac.uk/execsumm/summ1403.shtml 
 
23. Trusheim M, Burgess B, Hu S, Long T et al. Quantifying factors for the success of stratified  
      medicine. Nature Reviews/Drug Discovery Volume 10, Nov 2011 
 
24. Roth M, Keeling P, Smart D. Driving personalized medicine: capturing maximum net present  
      value and optimal return on investment. Personalized Medicine (2010) 7(1), 103-114 
 
25. Trusheim M, Berndt E. Economic challenges and possible policy actions to advance stratified 
      medicine. Personalized Medicine (2012), 9(4), 413-427 
 
26. Koelsch C, Przewrocka J, Keeling P. Towards a balanced value business model for personalized 
      medicine: an outlook. Pharmacogenomics (2013) 14(1), 89-102 
 
27. Blair ED, Stratton E, Kaufmann M. Aligning the Economic Value of Companion Diagnostics and  
      Stratified Medicines. Journal of Personalized Medicine, 2012, 2,257-266  
 
28. Davis J, Ma P, Sutaria S. The microeconomics of personalized medicine. Nat. Rev. Drug Discov. 
      8(4) 279-286, 2009 
  
29. Keeling P, Roth M, Zietlow T. The economics of personalized medicine: commercialization as a  
      driver of return on investment. New Biotechnology, volume 29 (6), Sept. 2012 
       
30. Deverka P, Doksum T, Carlson R. Integrating molecular medicine into the US health care system:  
















Stratified medicine (SM) is an innovative treatment concept which has drawn major attention 
in the pharmaceutical research community due to improved diagnostic technologies and a better 
understanding of diseases´ heterogeneity. The ability to target patient subpopulations has the 
potential to improve treatment efficacy and minimize side effects, enabling physician to more 
selectively deploy therapeutics in those patient groups. Several SM interventions have proven 
beneficial in a number of cancers and genetic diseases and researchers are working to identify 
more and more biomarkers that could be used to refine treatments in the future. At the same 
time, the process of stratification of patients and the implementation of this “disruptive 
innovation” has raised economic questions for payers, the healthcare system and for the 
manufacturer. Decision makers at all levels want value for money and require economic 
evaluations on the opportunity costs before implementing such approaches into clinical 
practice. This thesis investigates these economic challenges and opportunities in adapting SM 
approaches to enhance patient access, population health, cost effectiveness and return on 
investment. 
The first part of the thesis (chapters 2 to 4) considered the new challenges SM is providing for 
the value assessment process, in particular HTA and pricing & reimbursement (P&R) decisions. 
Specifically, in chapter 2 reimbursement issues of SM approaches in several EU countries and 
the US were addressed. This investigation showed that P&R schemes in many markets do not 
currently reflect the specific benefits arising from the use of SM approaches, and thus remain a 
barrier to their development and adoption, especially for the diagnostic component. The 
analysis underscores the clear need for more flexible P&R schemes which stimulate 
investments in evidence generation so that cost-effective technologies can provide and 
demonstrate their value to patients and to the health care system, enabling returns that 
commensurate with that value. Furthermore, fostering potential broader coverage within the 
healthcare systems will require the coordinated effort of national P&R authorities to realize a 
more synchronized reimbursement system for both drugs and diagnostics. Chapter 3 described 
specific methodological issues and challenges relevant to the evaluation of diagnostic-based 
SM and assessed whether current guidance for economic evaluations is sufficient to support 
decision making for SM intervention. It was concluded that current health economics 
methodology can be applied for SM, although various aspects of the guidelines require specific 
attention for SM approaches in order to ensure consistent SM evaluations.These aspects 
comprise considerations on the choice of comparator, measuring effectiveness and outcomes, 
appropriate modelling structure and the scope of sensitivity analyses. Many of these aspects 
refer to a lack of evidence on testing heterogeneity and the quality of effectiveness data. 
Chapter 4 reported on findings of an international expert meeting outlining key challenges 
130 
 
affecting various stakeholders when applying health economic (HE) data in the healthcare 
decision-making process for SM interventions. The results highlighted the inconsistencies in 
the value assessment for SM approaches in many health care markets which lead to highly 
viable patient access decisions. The research underscores the need for a broad (holistic) value 
definition including societal, patients and provider perspectives, helping to reap the full 
potential of using the SM approach on the whole treatment pathway of patients. HTA 
methodology will have to evolve to address the multiple components of value that a diagnostic 
and therapy can provide. Also, findings indicated, that HE and outcomes research work may 
increasingly be faced with early value assessments of potential SM interventions to inform 
prioritization of future clinical research. 
The second part of the thesis (chapters 5 and 6) addressed two economic assessments in which 
the potential added value of SM interventions in clinical practice was examined for two 
different therapeutic areas. Specifically, chapter 5 addressed specific modelling issues 
associated with SM interventions and used depression to scrutinize the modelling approach with 
SM in particular. The analysis outlined the importance of addressing input parameters such as 
test sensitivity and specificity and especially false negative and false positive considerations of 
the diagnostic test. This will require additional structural model complexity to establish the link 
between the test results and the consecutive treatment changes and outcomes and lead to a 
higher degree of uncertainty in economic models for SM compared with traditional ones. In 
chapter 6 an economic framework and a novel cost-effectiveness model in fertility was 
developed that allows for assessing the costs and outcomes of new embryo diagnostics and how 
they influence the average “cost per live birth”. The prototype model (Embryo-Dx) was based 
on costs and outcomes for the Netherlands and takes into consideration how new technologies 
influence live birth costs as well as cost-savings associated with reducing multiple pregnancies. 
This work goes beyond traditional economic evaluation studies and considers value-based 
pricing aspects when introducing non-invasive embryo diagnostics into in-vitro fertilization 
(IVF) standard treatment practices. The findings of this study indicate that the introduction of 
a validated embryo technology may further support a move towards increased single embryo 
transfer procedures in IVF clinical practice and vice versa.  
The third part of this thesis considered the economic opportunities and challenges of SM 
concepts from a manufactures/investors perspective. Because SM involves a number of changes 
in the conventional way of drug development and health care delivery, the economics of 
developing SM is significantly different from developing an empiric medicine. Investigating 
and understanding of certain scenarios is critical for the industry as a unique set of factors from 
development to reimbursement and market adoption will influence the expected returns of SM 
interventions and, hence, the incentive to invest in new R&D in tandem with diagnostic 
development. In chapter 7 a decision tree model was introduced as a specific approach to 
address the economic attractiveness of different SM development options in a cost-contained 
healthcare environment. The illustrative case study in the oncology market outlined key R&D-
related and commercial-related value drivers which could explain a favourable economics for 
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SM interventions under specific conditions. Decreasing development time and enhancing early 
market penetration would most likely improve the economic attractiveness of SM investments. 
However, the decision to pursue a proactive stratified approach depends much on the level of 
prior confidence in the predicted biomarker and a clear understanding about high value targets 
among pharmaceutical/diagnostic manufacturers and regulatory bodies. Offering a better 
targeted and hence ultimately more cost-effective therapy at reimbursable prices may facilitate 
time to market access and allow increasing market share gains within the targeted populations. 
Furthermore, the analysis suggest to perform early opportunity assessments to understand how 
the therapeutic effect of the treatment, characteristics of the identified patient population, and 
test performance interact and affect commercial value of stratification. 
The general discussion in chapter 8 summarized and discussed the main findings of this thesis, 
and provided recommendations for practice and future research in this area. To conclude, this 
thesis tackled some important economic questions that are central to various decision-makers 
when embracing SM into clinical practice and research. Addressing the economic challenges 
and opportunities of adopting SM approaches into clinical practice in a comprehensive way can 
aid stakeholders to guide improvement of efficiency and effectiveness in health care and 























“Stratified medicine” (SM) is een innovatief concept dat tegenwoordig ruim aandacht krijgt in 
de farmaceutische onderzoekswereld,  met name door verbeterde diagnostische technologieën 
en beter begrip van heterogeniteit van ziekten. Doelgericht subpopulaties definiëren geeft de 
potentie behandeling te verbeteren en bijwerkingen te minimaliseren, waarbij artsen selectief 
geneesmiddelen voor die relevante subgroepen kunnen inzetten. Diverse SM interventies 
hebben aagetoond van waarde te zijn binnen de oncologie en genetische aandoeningen en 
onderzoek is erop gericht telkens meer biomarkers te detecteren om behandelingen in de 
toekomst een verdere geheel nieuwe dimensie te geven. Tegelijkertijd heeft dit process van 
stratificeren van patiënten, binnen deze toch wel revolutionaire innovatie, economische 
consequenties voor betalers, het gezondheidszorgsysteem en voor fabrikanten. Op al deze 
niveau’s wordt “value for money” vereist en moeten economische evaluaties de waarde en 
opportuniteitskosten helder maken voordat toepassing in de praktijk grootschalig plaats vindt. 
Dit proefschrift analyseert deze economische uitdagingen en kansen om SM zodanig in te 
richten dat toegang tot SM voor patiënten gegarandeerd is, de publieke gezondheidszorg er wel 
bij vaart, gunstige kosten-effectiviteit geborgd is en voor de fabrikanten “return on investment” 
mogelijk is. 
Het eesrte deel van dit proefschrift (chapters 2 to 4) analyseert de nieuwe uitdagingen waar 
SM ons voor plaatst inzake toegevoegde waarde binnen HTAs en “Pricing & Reimbursement” 
(P&R). In chapter 2 worden diverse issues van SM approaches binnen de EU context en de US 
besproken. Hieruit komt naar voren dat P&R schema’s vaak niet adequaat de waard een baten 
van dergelijke SM benaderingen reflecteren en dat barrieres voor vergoeding en gebruik bestaan 
met name voor de diagnostica. Dit benadrukt de noodzaak voor flexibele en toegesneden P&R, 
hetgeen investering in “evidence” ontwikkeling stimuleert waarin kosten-effectieve 
interventies hun waarde kunnen tonen voor patiënten en het zorgsysteem en het mogelijk maakt 
dat opbrengsten in de pas lopen met de werkelijke waarde van de technologie. Daarbij is ook 
een geïntegreerde inzet nodig van nationale P&R autoriteiten om gesynchroniseerde 
beoordeling en vergoeding te bereiken van geneesmiddelen en diagnostica ter verbreding van 
het gebruik van geneesmiddel-diagnosticum combinaties binnen SM. Chapter 3 beschrijft 
specifieke methodologische issues en uitdagingen bij economische evaluatie van SM en stelt 
de vraag om huidige richtlijnen voor economische evaluatie tevens adequaat zijn voor 
besluitvorming over SM technologieën. De conclusie luidt dat huidige methoden en richtlijnen 
toepasbaar zijn, maar dat voor SM specifieke nadere richtlijnen nodig zijn om consistente 
analyses te kunnen doen. Hierbij gaat het dan met name om de exacte keuze van de 
vergelijkende therapie, hoe precies effectiviteit en uitkomsten te meten, welke modelstructuren 
meest toepasbaar zijn en de reikwijdte van de gevoelighedsanalyses, allemaal gerelateerd aan 
het gebrek aan bewijs over test heterogeniteit en matige kwaliteit van effectiviteitsgegevens. 
Chapter 4 gaat in op de bevindingen van een international expert meeting inzake de 
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uitdagingen voor de diverse partijen bij het toepassen van gezondheidseconomische analyse op 
SM. Er werd gewezen op de inconsistenties in de waardering van nieuwe SM interventies in 
diverse landen waardoor toegang voor patiënten vaak precair en onzeker is. Er werd benadrukt 
dat we eigenlijk niet meer kunnen zonder een brede (holistische) definite van waarde, inclusief 
de perspectieven van de maatschappij, patiënten, aanbieders en verzekeraars waardoor optimaal 
de vruchten geplukt kunnen worden van de nieuwe SM technologieën. HTA methodologieën 
moeten daarbij in de pas lopen en de diverse componenten dekken van die definitie van waarde. 
Tenslotte werd erop gewezen dat gezondheidseconomie en uitkomstenonderzoek steeds meer 
wordt en ook steeds meer zou moeten worden ingezet in vroege fases van technologie 
ontwikkeling zodat verder onderzoek naar geneesmiddel-diagnosticum combinaties verder 
geoptimaliseerd kan worden. 
Het tweede deel van dit proefschrift (chapters 5 and 6) behandelt twee economische analyses 
naar de potentiële toegevoegde waarde van SM interventies in de klinische praktijk van twee 
specifieke therapeutische gebieden. Chapter 5 gaat in op de specifieke issues rond farmaco-
economische modellen bij SM interventies, in het bijzonder voor het ziektebeeld van depressie. 
De bevindingen illustreren het belang van precieze input parameters zoals test gevoeligheid, 
specificiteit, percentage fout negatieven en percentage fouts positieven. Dit impliceert 
additionele en structurele model complexiteit om de link tussen test resultaten en 
vervolgbehandeling adequaat weer te geven en een grotere mate van onzekerheid inherent in 
het model dan we gewend zijn bij de “traditionele” modellen (niet-SM). In chapter 6 betreft 
het een economisch model in fertiliteit, met name inzake de kosten en effecten van embryo 
diagnostiek en hoe dat de “cost per live birth” kan bepalen. Het prototype model (Embryo-Dx) 
werd gebaseerd op kostsen en uitkomsten voor Nederland en neemt zowel de kosten mee van 
levendgeboorten alswel de besparingen. De grenzen van de traditionele gezondheidseconomie 
worden hier ruim overschreden door te kijken naar “value-based pricing” in een controversieel 
gebied als non-invasieve embryo diagnostiek en IVF. De conclusie is dat de introductie van een 
gevalideerde embryo technologie verder gebruik van “single-embryo-transfer” procedures in 
de klinische praktijk van IVF ondersteunen kan en vice versa.  
Het derde deel van het proefschrift behandelt het perspectief van de fabrikant. Omdat SM een 
aantal veranderingen met zich brengt t.o.v. de conventionele manier van 
geneesmiddelontwikkeling en –marketing is de economie van SM heel anders dan voor meer 
empirische geneesmiddelen. Scenario analyse is noodzakelijk voor goed begrip voor de 
fabrikant van de unieke set factoren die een rol spelen bij ontwikkeling, vergoeding, marketing 
en ROI en voor keuzes om te investeren in geneesmiddel-diagnosticum combinaties. In chapter 
7 werd een beslismodel geïntroduceerd als speifieke benadering om de economische 
aantrekkelijkheid van diverse SM strategieën te analyseren binnen een zorgsysteem dat in 
bezuinigingsmodus staat. Een illustratieve “case study” betreft de oncologie, inclusief R&D-
gerelateerde en commercieel-gerelateerde argumenten om de economische aspecten helder te 
krijgen onder specifieke condities. Kortere ontwikkelingstijd en vroege marketing komt het 
economische profiel van SM zeer ten goede. Echter, de uiteindelijke beslissing om voor SM “te 
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gaan” hangt mede af van het vertouwen inde geïdentificeerde biomarker en de waarde die wordt 
gehecht door P&R autoriteiten aan specifieke SM vernieuwingen. Beter toegesneden en kosten-
effectieve SM interventies gaan allicht de toegang tot de markt vergemakkelijken en relevante 
marktaandelen zijn mogelijk voor fabrikanten. Tenslotte, geeft de analyse aan dat evaluaties in 
vroege stadia van geneesmiddelontwikkeling  belangrijk zijn, inclusief goed begrip van 
(omvang van) patient populaties, test karakteristieken en potentiële commerciële waarde van 
SM. 
De algemene discussie in chapter 8 vat de belangrijkste bevindigen nog eens samen en geeft 
relevante aanbevelingen voor de toekomst. Concluderend: dit proefschrift geeft 
aanknopingspunten hoe om te gaan met de cruciale economische vraagstukken die samen 
hangen met SM, zowel in de klinische praktijk als in onderzoek. Door de economische 
aspecten – zowel uitdagingen als kansen – geïntegreerd te analyseren kunnen de diverse 
partijen met belangen beter de efficiëntie en (kosten-)effectiviteit bewaken binnen de nieuwe 
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